SUPPLY OF BLOOD FOR TRANSFUSION IN LATIN AMERICAN AND CARIBBEAN COUNTRIES

2014 and 2015

Pan American Health Organization

World Health Organization
REGIONAL OFFICE FOR THE Americas

SUPPLY OF BLOOD FOR TRANSFUSION IN LATIN AMERICAN AND CARIBBEAN COUNTRIES

2014 and 2015

Pan American Health Organization

World Health Organization
REGIONAL OFFICE FOR THE Americas

Original version in Spanish:

Suministro de sangre para transfusiones en los países de Latinoamérica y del Caribe. 2014 y 2015.

ISBN 978-92-75-31958-1

PAHO HQ Library Cataloguing-in-Publication Data

Pan American Health Organization

Supply of Blood for Transfusion in Latin American and Caribbean Countries, 2014 and 2015.

Washington, D.C. : PAHO; 2017.

1. Blood Banks. 2. Blood Transfusion. 3. Regional Strategies. 4. Latin America. 5. Caribbean Region. I. Title.

ISBN: 978-92-75-11958-7 (NLM Classification: WH 23))

ACKNOWLEDGMENTS

We thank the valuable contribution of the Ministries of Health of the countries, through the National Coordinators of Blood, whose data is presented in this document.

Information compiled and analyzed by: Maria Dolores Pérez-Rosales, with the support of Roberto Carlos Garza Rodríguez, from the Unit of Medicines and Health Technologies (HSS/MT).

TABLE OF CONTENTS

COUNTRY CODES

AIA	Anguilla
ATG	Antigua and Barbuda
ARG	Argentina
ABW	Aruba
BHS	Bahamas
BRB	Barbados
BLZ	Belize
BMU	Bermuda
BOL	Bolivia
BRA	Brazil
VGB	British Virgin Islands
CYM	Cayman Islands
CHL	Chile
COL	Colombia
CRI	Costa Rica
CUB	Cuba
CUW	Curacao
DMA	Dominica
DOM	Dominican Republic
ECU	Ecuador
SLV	El Salvador
GRD	Grenada
GLP	Guadeloupe
GTM	Guatemala
GUY	Guyana
HTI	Haiti
HND	Honduras
JAM	Jamaica
MTQ	Martinique
MEX	Mexico
MSR	Montserrat
NIC	Nicaragua
PAN	Panama
PRY	Paraguay
PER	Peru
KNA	Saint Kitts and Nevis
LCA	Saint Lucia
VCT	Saint Vincent and The Grenadines
SUR	Suriname
TCA	Turks and Caicos Islands
TTO	Trinidad and Tobago
URY	Uruguay
VEN	Venezuela

ABBREVIATIONS

CRYO	Cryoprecipitate
FFP	Fresh Frozen Plasma
FP	Frozen Plasma
HBsAg	Hepatitis B Virus Surface Antigen
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus
HTLV	Human T Cell Lymphotropic Virus
PL	Platelets
RBC	Red Blood Cells
WB	Whole Blood
NR	Not Reported
NA	Not Applicable
APH-PL	Platelets by Apheresis
APH-RBC	Red Blood Cells by Apheresis

INTRODUCTION

This document follows up the publication *"Supply of Blood for Transfusion in Latin American and Caribbean Countries 2012 and 2013"* and presents indicators on the availability, safety, and use of blood and blood components, as well as the organization of national blood systems.

It is based on data provided by the health authorities for years 2014 and 2015. In the Caribbean, 18 countries/territories responded for both 2014 and 2015 and in Latin America, 17 for 2014 and 18 for 2015.

Standard Excel reporting forms were sent to the countries for the collection of statistical data, which on receipt, were analyzed and consolidated for this publication. In 2013, the Pan American Health Organization (PAHO) and World Health Organization (WHO) jointly made changes to the form to coordinate the regional indicators collected by PAHO with the global indicators collected by WHO, facilitating reporting by the national authorities through a single form. The new form also requested information on haemovigilance, apheresis procedures, plasma derivatives, disaggregated blood donor data, transfused patients, and the discarding of blood units.

Some of the additional data are used to monitor and periodically report to the Governing Bodies on progress and challenges in implementing the PLAN OF ACTION FOR UNIVERSAL ACCESS TO SAFE BLOOD 2014-2019, approved by the 53rd Directing Council in October 2014 (CD53/6). The plan has four strategic lines of action:

- Effective and sustainable integration of national blood programs and services into the national health system to achieve blood self-sufficiency, safety, efficiency, availability, and universal access to blood and blood components;
- Self-sufficiency in safe blood and blood components through 100% voluntary non-remunerated donations;
- Quality management in the national blood system and screening for transfusion transmitted infections;
- Health surveillance, haemovigilance, risk management, monitoring, and evaluation.

We hope that this publication will continue to serve as a reference for national authorities, professionals working in this field, and other individuals and institutions interested in developing and organizing the blood systems of countries/territories in the Region of the Americas.

Comparing certain factors that influenced the availability, timeliness, and safety of blood supply for the period examined with the data reported for 2012-2013, we see that the percentage of voluntary blood donors in both the Caribbean and Latin America rose slightly, from 38.53% in 2013 to 44.17% in 2015 (54.89% in the Caribbean and 43.28% in Latin America, respectively). Latin America saw an increase in the number of units processed annually per blood bank, which could be interpreted as an improvement in the concentration of the processes, since there was a simultaneous reduction in the number of processing centers. In this regard, no trend was observed in the Caribbean. With respect to screening coverage, in 2014, only two Latin American and one Caribbean country did not achieve PAHO/WHO-recommended universal screening for transfusion transmitted infections (TTIs) (HIV, HBV, HCV, syphilis, and *T. cruzi*), while in 2015, one Latin American country (which screened 99.94% of all blood units for *T. cruzi*) and one Caribbean country (which screened 98.56% of all units) did not achieve 100% screening. With respect to national external performance evaluation programs, in 2015, 29 countries (13 in Latin America and 16 in the Caribbean) had such programs in serology—a substantial increase over 2011, when 22 countries had one.

In addition, in 2015, 17 countries (7 in Latin America and 10 in the Caribbean) had national external performance evaluation programs in immunohematology—again, representing an increase over 2011, when only 12 countries had such programs.

PROGRESS IN PLAN IMPLEMENTATION

The data for 2015 show some changes in Latin America and the Caribbean. Regarding the national blood coordinations, 27 countries (17 in Latin America and 10 in the Caribbean) have a specific dedicated entity in the Ministry of Health responsible for planning, monitoring, and evaluating the national blood system—figures that show no change with respect to 2011, underscoring the importance of strengthening leadership and governance capacity in national blood systems.

A total of 23 countries have a national blood policy (14 in Latin America and 9 in the Caribbean), which represents progress over 2011 (18 countries). It should be noted that implementing and monitoring these policies requires dedicated entities in the Ministries of Health. Furthermore, in 2015, 15 countries (10 in Latin America and 5 in the Caribbean) reported having national strategic blood plans and specific budgets—a slight increase compared to 2011, when 13 countries had plans and an allocated budget. Furthermore, in 2015, 16 countries had an intersectoral national blood commission (eight in Latin America and eight in the Caribbean); this represents progress over 2011, when only 14 countries had one. These findings come as no surprise, since they tend to reflect the weakness of the dedicated units in the Ministries of Health.

With regard to the reorganization of blood services networks, progress has been reported in terms of the number of blood units processed per year per blood bank and the number of processing centers. Eighteen countries process more than 5,000 blood units per year/blood bank (nine in Latin America and nine in the Caribbean)—a substantial increase compared to 2011, when only 12 countries did so (however, given the geo-demographic characteristics of some Caribbean countries, we recognize that reorganization requires different blood service models). Moreover, in 2015, 2,116 processing centers were reported in Latin America, representing a 9% reduction compared to 2011, when there were 2,321. The consolidation and reorganization of blood services into networks significantly improves quality and safety, while substantially lowering financial costs.

In 2015, 14 countries (six in Latin America and eight in the Caribbean) estimated their national blood requirements, representing an improvement over 2011, when only six countries did so.

In 2015, 10 countries achieved 100% non-remunerated voluntary blood donations (two in Latin America and eight in the Caribbean), revealing little progress compared to 2011 (eight countries). We observe that more countries know their national blood needs, which facilitates the planning of blood drives to increase the availability and accessibility of blood and blood components. However, there remains the challenge of achieving regular non-remunerated voluntary donation as the first pillar of blood safety—a problem accentuated by epidemiological changes in the countries that affect transfusion safety.

With respect to the rational use of blood and blood components, progress has been made in the availability of national guidelines for clinical use and the existence of hospital transfusion committees. However, we still have no information or monitoring in the countries to determine how users/prescribers apply these national guidelines to ensure the appropriate use of blood and blood components. Nevertheless, 19 countries reported having transfusion committees in 2015 (10 in Latin America and nine in the Caribbean); this represents substantial progress over 2011, when only seven countries had such committees. Furthermore, in 2015, 23 countries (14 in Latin America and 9 in the Caribbean) reported having national guidelines for proper blood use—a slight increase compared to 2011, when 20 countries had guidelines.

With respect to the discarding of red blood cells due to expiration, data disaggregated by expiration and other causes were unavailable when the Regional Plan was drafted; therefore, the indicator reported was based on red blood cells discarded for both reasons. We are currently able to report exclusively on discards due to expiration; thus, the percentage of discards has substantially declined. In 2015, the percentage of discards in Latin America and the Caribbean due to red blood cell expiration was 2.99% of total fractionated red blood cells. In 2011, the figure was 10.3%, recalling again that this was due to both expiration and other causes. The reduction in discards of red blood cells due to expiration may in part be a result of the progress made in reorganizing blood services into networks and of knowledge about the estimation of national blood needs.

Furthermore, in 2015, 25 countries (15 in Latin America and 10 in the Caribbean) had established a national inspection, surveillance, and control model in blood services. This represents progress compared to 2011 (20 countries). Moreover, in 2015, nine countries reported having set up a national haemovigilance system (five in Latin America and four in the Caribbean), again representing progress compared to 2011, when only two countries had done so. This underscores the importance of improving surveillance, monitoring, and evaluation systems to obtain information for the identification and implementation of timely and appropriate interventions that ensure the sufficiency, safety, and availability of blood and blood components and universal access to them.

The information on national external performance evaluation programs in serology and immunohematology and on the countries that annually report the indicators of the plan can be found at the beginning of the Introduction to this report.

ADDITIONAL DATA

Since the new form collects more information than the previous one, additional data are presented to shed greater light on the development and expansion of blood services in our Region, especially with respect to blood donors, and to motivate national health authorities, national program directors, and other colleagues working in the countries to make the necessary efforts and adjustments to the procedures for collecting and ensuring the availability of information.

Donor characterization

Gender of blood donors: The data for 2014 correspond to 13 Caribbean and five Latin American countries, and the data for 2015, to 18 Caribbean and six Latin American countries.

Based on the data received from the Region of the Americas, it appears that the majority of donors in the Caribbean are men. The same holds true for Latin America; however, here, the data may not be representative, since very few countries reported this information (Figures 1 and 2).

Figure 1. Gender of blood donors, Caribbean 2014 and 2015



Figure 2. Gender of blood donors, Latin America 2014 and 2015



Age of blood donors: The data for 2014 correspond to six Caribbean and three Latin American countries, and the data for 2015, to 12 Caribbean and six Latin American countries.

The majority of blood donors in the Caribbean appear to be in the 24-44 age group, for both 2014 and 2015. This could be useful for targeting strategies to promote non remunerated, altruistic voluntary blood donation through information, education, and communication among this age group. In Latin America, the 18-24 age group is reported to provide the most

donations. However, it is important to bear in mind how few countries provided this indicator; thus, the data are unlikely to be representative (Figures 3 and 4).

Figure 3. Age of blood donors, Caribbean 2014 and 2015



Figure 4. Age of blood donors, Latin America 2014 and 2015



Characterization of the discarding of blood units and components

Reasons for discarding blood units: The analysis for 2014 is based on the data received from 16 Caribbean and 16 Latin American countries, and for 2015, from 17 Caribbean and 17 Latin American countries.

As in 2012 2013, the main reason for discarding red blood cells in the Caribbean countries in 2014-2015 was reactivity to markers for transfusion-transmitted infections, which may reflect the need to improve pre-donation processes—in other words, motivating people to donate and informing and educating the community about transfusion-transmitted infections,

stressing the shared responsibility of individuals who donate and the adoption of confidential self exclusion mechanisms. It would also be useful to review donor motivation and selection processes, including the competence and training of the interviewers who decide whether to accept people as blood donors, ascertaining what guidance and assistance they receive. The main reason for discarding platelets was expiration, which suggests the need to review blood and blood component supply management, which would include working in networks and better planning based on use.

In terms of discards of red blood cells and platelets in Latin America in 2014-2015, the most representative discard rate (which has fallen in recent years) is associated with the expiration of blood units, followed by reactivity to markers for transfusion-transmitted infections. It is therefore recommended that, as in the Caribbean, donor motivation and selection processes and supply distribution management be reviewed and processes and procedures put in place to guarantee the cold chain.

All causes of expiration reported by the countries are controllable; hence, the imperative to determine their point of origin, so that the necessary corrective action can be taken to increase the availability and safety of blood and blood components and the efficiency of the system (Figures 5, 6, 7, and 8).

Figure 5. Reasons for discarding red blood cells, Caribbean 2014 and 2015



Figure 6. Reasons for discarding platelets, Caribbean 2014 and 2015



Figure 7. Reasons for discarding red blood cells, Latin America 2014 and 2015



Figure 8. Reasons for discarding platelets, Latin America 2014 and 2015



Characterization of use

Age of transfused patients: The data for 2014 correspond to six Caribbean and three Latin American countries, and for 2015, to 11 countries in the Caribbean and one in Latin America. This confirms the lack of available data in transfusion services; thus, the figures below are not representative of the region, but do give some idea of potential trends, as information since 2011 is available.

In the Caribbean countries, the majority of transfused patients in 2014 were also in the 15-44 and 45-60 age groups. In 2015, the majority of transfused patients were in the >60 age group, followed by the 15-44 and 45-60 age groups, respectively. This suggests a trend toward greater population aging, which is associated with more cardiovascular issues, chronic diseases, orthopedic surgeries, etc. The low representativeness of the data for Latin America makes any deductive analysis impossible (Figures 9 and 10).

Figure 9. Age group of transfused patients, Caribbean 2014 and 2015



Figure 10. Age range of transfused patients, Latin America 2014 and 2015



Percentage of the population that received transfusions: The data for 2014 correspond to nine Caribbean and 10 Latin American countries, and for 2015, to 13 Caribbean and eight Latin American countries.

In 2014, approximately 1.19% of the population in both the Caribbean and Latin America received transfusions. In 2015, the figure for the Caribbean was approximately 0.82% and for Latin America, 1.11%. This indicator could serve as a guide for planning blood drives and foster debate to optimize the appropriate use of blood and blood components (Figures 11 and 12).

Figure 11. Percentage of the population that received transfusions, Caribbean 2014 and 2015



Figure 12. Percentage of the population that received transfusions, Latin America 2014 and 2015




LATIN AMERICAN
COUNTRIES
2014

TABLE 1. BLOOD COLLECTION, 2014

COUNTRY	TOTAL UNITS COLLECTED	NUMBER OF DONORS				BLOOD DONATION RATE PER 1000 PEOPLE*
		AUTOLOGOUS	ALLOGENEIC			
			VOLUNTARY	REPLACEMENT	REMUNERATED	
ARG	859,233	5,400	417,368	436,465	0	20.55
BOL	101,166	62	40,435	60,669	0	9.33
BRA *2012	3,335,035	2,056	1,983,857	1,349,122	0	16.51
CHL	240,911	0	59,722	181,189	0	13.55
COL	756,370	23,246	647,269	85,855	0	15.46
CRI	73,057	6	46,188	26,863	0	14.79
CUB	415,902	0	415,902	0	0	36.94
ECU	232,215	78	139,571	92,566	0	14.53
SLV	98,090	2	14,665	83,423	0	15.36
GTM	114,404	16	7,622	106,766	0	7.21
HND	58,612	1	10,111	48,107	393	7.09
MEX	1,939,060	0	49,794	1,889,266	0	15.66
NIC	75,035	0	75,035	0	0	12.16
PAN	37,833	22	3,017	27,551	7,243	9.64
PRY	87,888	0	8,022	79,866	0	12.70
PER *2013	204,871	118	9,340	195,403	10	6.66
DOM	93,949	58	9,379	84,177	335	8.92
URY	96,563	305	47,927	48,331	0	28.24
VEN	312,048	0	16,455	295,593	0	10.11

* Demographic data is obtained from: Pan American Health Organization/World Health Organization, Communicable Diseases and Health Analysis/ Health Information and Analysis. Health Situation in the Americas: Basic Indicators 2014. Washington, D.C., United States of America, 2014.

TABLE 2. BLOOD COLLECTION FROM ALLOGENEIC DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	TYPE OF ALLOGENEIC DONOR (PERCENTAGE)		
		VOLUNTARY	REPLACEMENT	REMUNERATED
ARG	853,833	48.88	51.12	0
BOL	101,104	39.99	60.01	0
BRA *2012	3,332,979	59.52	40.48	0
CHL	240,911	24.79	75.21	0
COL	733,124	88.29	11.71	0
CRI	73,051	63.23	36.77	0
CUB	415,902	100	0	0
ECU	232,137	60.12	39.88	0
SLV	98,088	14.95	85.05	0
GTM	114,388	6.66	93.34	0
HND	58,611	17.25	82.08	0.67
MEX	1,939,060	2.57	97.43	0
NIC	75,035	100	0	0
PAN	37,811	7.98	72.87	19.15
PRY	87,888	9.13	90.87	0
PER *2013	204,753	4.56	95.43	0.01
DOM	93,891	9.99	89.65	0.36
URY	96,258	49.79	50.21	0
VEN	312,048	5.27	94.73	0

Figure 1. Percentage of blood collection ranked from greatest to least by voluntary donations, Latin America 2014



TABLE 2.1. BLOOD COLLECTION ACCORDING TO THE SITE, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
ARG	853,833	83,474	333,894	436,465	0	0	0
BOL	101,104	19,266	21,169	60,669	0	0	0
BRA *2012	3,332,979	NR	NR	NR	NR	NR	NR
CHL	240,911	39,179	20,543	181,189	0	0	0
COL	733,124	0	647,269	85,855	0	0	0
CRI	73,051	44,477	1,711	26,863	0	0	0
CUB	415,902	415,902	0	0	0	0	0
ECU	232,137	38,291	101,280	91,673	893	0	0
SLV	98,088	0	14,665	83,423	0	0	0
GTM	114,338	1,351	6,271	104,056	2,710	0	0
HND	58,611	3,229	6,882	47,840	267	393	0
MEX	1,939,060	47,492	2,302	1,889,266	0	0	0
NIC	75,035	14,652	60,383	0	0	0	0
PAN	37,811	1,037	1,980	26,373	1,178	6,958	285
PRY	87,888	2,923	5,099	79,823	43	0	0
PER *2013	204,753	1	9,339	195,403	0	10	0
DOM	93,891	9,358	21	83,832	345	335	0
URY	96,258	34,156	13,771	48,331	0	0	0
VEN	312,048	NR	NR	NR	NR	NR	NR

EM: Extramural.
NR: Not Reported.

TABLE 2.2. BLOOD COLLECTION ACCORDING TO THE SITE, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	PERCENTAGE OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
ARG	853,833	9.78	39.1	51.12	0	0	0
BOL	101,104	19.05	20.94	60.01	0	0	0
BRA *2012	3,332,979	NR	NR	NR	NR	NR	NR
CHL	240,911	16.26	8.53	75.21	0	0	
COL	733,124	0	88.29	11.71	0	0	0
CRI	73,051	60.89	2.34	36.77	0	0	0
CUB	415,902	100	0	0	0	0	0
ECU	232,137	16.5	43.63	39.49	0.38	0	0
SLV	98,088	0	14.95	85.05	0	0	0
GTM	114,338	1.18	5.48	91.01	2.37	0	0
HND	58,611	5.51	11.74	81.62	0.46	0.67	0
MEX	1,939,060	2.45	0.12	97.43	0	0	0
NIC	75,035	19.53	80.47	0	0	0	0
PAN	37,811	2.74	5.24	69.75	3.12	18.40	0.75
PRY	87,888	3.33	5.8	90.82	0.05	0	0
PER *2013	204,753	0	4.56	95.43	0	0.01	0
DOM	93,891	9.97	0.02	89.29	0.37	0.35	0
URY	96,258	35.48	14.31	50.21	0	0	0
VEN	312,048	NR	NR	NR	NR	NR	NR

EM: Extramural.
NR: Not Reported.

TABLE 3. SELECTION OF ALLOGENEIC DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS								
		VOLUNTARY			REPLACEMENT			REMUNERATED		
		INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE
ARG	853,833	431,846	14,478	0	542,052	105,587	0	NA	NA	NA
BOL	101,104	56,493	13,778	2,280	93,074	32,405	0	NA	NA	NA
BRA *2012	3,332,979	2,438,665	454,808	0	1,668,832	319,710	0	NA	NA	NA
CHL	240,911	73,977	14,255	0	233,325	52,136	0	NA	NA	NA
COL	733,124	816,241	168,972	0	85,855	0	0	NA	NA	NA
CRI	73,051	66,484	20,263	33	27,923	1,060	0	NA	NA	NA
CUB	415,902	431,647	15,745	0	NA	NA	NA	NA	NA	NA
ECU	232,137	167,084	27,416	97	117,528	24,506	456	NA	NA	NA
SLV	98,088	14,665	0	0	117,617	33,623	571	NA	NA	NA
GTM	114,388	9,468	1,817	29	148,130	39,884	1,480	NA	NA	NA
HND	58,611	10,116	2	3	53,988	5,813	68	393	NR	0
MEX	1,939,060	49,794	0	NR	2,445,533	556,267	NR	NA	NA	NA
NIC	75,035	81,670	6,635	0	NA	NA	NA	NA	NA	NA
PAN	37,811	3,017	NR	NR	27,551	NR	NR	7,243	NR	NR
PRY	87,888	8,561	539	NR	87,770	7,904	NR	NA	NA	NA
PER *2013	204,753	13,347	3,972	35	278,452	82,579	470	47	37	0
DOM	93,891	12,454	3,072	3	108,920	24,739	4	338	3	0
URY	96,258	60,663	12,736	0	64,136	15,805	0	NA	NA	NA
VEN	312,048	NR	NR	NR	NR	NR	NR	NA	NA	NA

Incomplete: It refers to people selected as donors, but for whom the extraction/collection could not be performed or was performed incompletely (problems that may be encountered in accessing a vein, insufficient or exceeded volume, among others).
NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

TABLE 4. DEFERRAL OF ALLOGENEIC DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	VOLUNTARY		REPLACEMENT		REMUNERATED	
		NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED
ARG	853,833	431,846	3.35	542,052	19.48	NA	NA
BOL	101,104	56,493	24.39	93,074	34.82	NA	NA
BRA *2012	3,332,979	2,438,665	18.65	1,668,832	19.16	NA	NA
CHL	240,911	73,977	19.27	233,325	22.34	NA	NA
COL	733,124	816,241	20.7	85,855	NR	NA	NA
CRI	73,051	66,484	30.48	27,923	3.80	NA	NA
CUB	415,902	431,647	3.65	NA	NA	NA	NA
ECU	232,137	167,084	16.41	117,528	20.85	NA	NA
SLV	98,088	14,665	0	117,617	28.59	NA	NA
GTM	114,388	9,468	19.19	148,130	26.92	NA	NA
HND	58,611	10,116	0.02	53,988	10.77	393	NR
MEX	1,939,060	49,794	0	2,445,533	22.75	NA	NA
NIC	75,035	81,670	8.12	NA	NA	NA	NA
PAN	37,811	3,017	NR	27,551	NR	7,243	NR
PRY	87,888	8,561	6.3	87,770	9.01	NA	NA
PER *2013	204,753	13,347	29.76	278,452	29.66	47	78.72
DOM	93,891	12,454	24.66	108,920	22.71	338	0.89
URY	96,258	60,663	20.99	64,136	24.64	NA	NA
VEN	312,048	NR	NR	NR	NR	NA	NA

NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

Figure 2. Percentage of deferred donors by allogeneic donor type, Latin America 2014



TABLE 4.1. VOLUNTARY NON-REMUNERATED DONATIONS FROM FIRST-TIME AND REPEAT DONORS, 2014

COUNTRY	TOTAL OF VOLUNTARY NON-REMUNERATED BLOOD DONATIONS	FIRST-TIME		REPEAT	
		NUMBER	%	NUMBER	%
ARG	417,368	166,947	40	250,421	60
BOL	40,435	29,351	72.59	11,084	27.41
BRA *2012	1,983,857	NR	NR	NR	NR
CHL	59,722	38,958	65.23	20,764	34.77
COL	647,269	382,132	59.04	265,137	40.96
CRI	46,188	NR	NR	NR	NR
CUB	415,902	33,272	8	382,630	92
ECU	139,571	NR	NR	NR	NR
SLV	14,665	10,345	70.54	4,320	29.46
GTM	7,622	NR	NR	NR	NR
HND	10,111	NR	NR	NR	NR
MEX	49,794	49,502	99.41	292	0.59
NIC	75,035	30,764	41	44,271	59
PAN	3,017	NR	NR	NR	NR
PRY	8,022	NR	NR	NR	NR
PER *2013	9,340	NR	NR	NR	NR
DOM	9,379	NR	NR	NR	NR
URY	47,927	NR	NR	NR	NR
VEN	16,455	NR	NR	NR	NR

NR: Not Reported.

TABLE 4.2. APHERESIS, 2014

COUNTRY	NUMBER OF BLOOD DONATIONS COLLECTED THROUGH APHERESIS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST-TIME	REPEAT		
ARG	NR	NR	NR	NA
BOL	NR	NR	NR	NA
BRA *2012	NR	NR	NR	NA
CHL	NR	NR	NR	NA
COL	11,256	21,588	4,502	NA
CRI	NR	NR	NR	NA
CUB	NR	NR	NA	NA
ECU	4,905			NA
SLV	267		921	NA
GTM	NR	NR	1,996	NA
HND	NR	NR	NR	NR
MEX	0	0	67,949	NA
NIC	0	0	NA	NA
PAN	3,620			NR
PRY	NR	NR	NR	NA
PER *2013	9,055			NR
DOM	NR	NR	NR	NR
URY	NR	NR	NR	NA
VEN	12,663	NR	NR	NA

NR: Not Reported.

TABLE 4.3. NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL), 2014

COUNTRY	NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL)				
	LOW WEIGHT	LOW HAEMOGLOBIN	HIGH-RISK BEHAVIOR	TRAVEL HISTORY	OTHER
ARG	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR
CHL	NR	NR	NR	NR	NR
COL	NR	NR	NR	NR	NR
CRI	NR	NR	NR	NR	NR
CUB	NR	NR	NR	NR	NR
ECU	NR	NR	NR	NR	NR
SLV	NR	NR	NR	NR	NR
GTM	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR
MEX	NR	NR	NR	NR	NR
NIC	NR	NR	NR	NR	NR
PAN	NR	5,545	2,735	NR	16,633*
PRY	NR	NR	NR	NR	NR
PER *2013	NR	NR	32,187	NR	NR
DOM	NR	NR	NR	NR	NR
URY	NR	777	NR	NR	NR
VEN	NR	NR	NR	NR	NR

PAN: Includes low blood pressure, dental caries, medicines.
NR: Not Reported.

TABLE 4.4. NUMBER OF UNITS COLLECTED BY AGE GROUPS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED BY AGE GROUPS				
	UNDER 18 YEARS	18 TO 24 YEARS	25 TO 44 YEARS	45 TO 64 YEARS	65 YEARS OR OLDER
ARG	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR
CHL*	0	140,610	51,567	48,734	0
COL*	0	390,825	170,166	195,081	298
CRI	NR	NR	NR	NR	NR
CUB	NR	NR	NR	NR	NR
ECU	NR	NR	NR	NR	NR
SLV*	0	21,625	96,495	13,392	742
GTM	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR
MEX	NR	NR	NR	NR	NR
NIC	NR	NR	NR	NR	NR
PAN	NR	NR	NR	NR	NR
PRY	NR	NR	NR	NR	NR
PER *2013	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR
URY	NR	NR	NR	NR	NR
VEN	NR	NR	NR	NR	NR

CHL: Age groups: 18-34, 35-44, 45-64 years old.
COL: age groups: 18-30, 31-40, 41-65 years old.
SLV: Age groups: 17-24, 25-45, 46-59, and older than 60 years old.
These numbers refer to donors interviewed and not only effective donations.
NR: Not Reported.

TABLE 4.5. NUMBER OF UNITS COLLECTED BY MALE AND FEMALE DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	
	MALE DONORS	FEMALE DONORS
ARG	NR	NR
BOL	NR	NR
BRA *2012	NR	NR
CHL	127,996	112,915
COL	421,372	334,998
CRI	NR	NR
CUB	338,629	84,658
ECU	NR	NR
SLV*	94,091	38,163
GTM	NR	NR
HND	NR	NR
MEX	NR	NR
NIC	45,771	29,264
PAN	NR	NR
PRY	NR	NR
PER *2013	NR	NR
DOM	NR	NR
URY	NR	NR
VEN	NR	NR

SLV: These numbers refer to donors interviewed and not only effective donations.
NR: Not Reported.

TABLE 5. EFFICIENCY OF BLOOD PROCESSING, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF COLLECTING CENTERS	NUMBER OF PROCESSING CENTERS	ANNUAL PROCESSING PER BANK	DAILY PROCESSING PER BANK (260 DAYS)
ARG	859,233	280	254	3,383	13.01
BOL	101,166	18	18	5,620	21.62
BRA *2012	3,335,035	544	530	6,293	24.20
CHL	240,911	47	17	14,171	54.50
COL	756,370	83	83	9,113	35.05
CRI	73,057	34	32	2,283	8.78
CUB	415,902	46	46	9,041	34.77
ECU	232,215	21	21	11,058	42.53
SLV	98,090	28	13	7,545	29.02
GTM	114,404	60	60	1,907	7.33
HND	58,612	29	17	3,448	13.26
MEX	1,939,060	556	556	3,488	13.41
NIC	75,035	5	2	37,518	144.3
PAN	37,833	28	27	1,401	5.39
PRY	87,888	11	6	14,648	56.34
PER *2013	204,871	89	89	2,302	8.85
DOM	93,949	71	71	1,323	5.09
URY	96,563	61	56	1,724	6.63
VEN	312,048	337	206	1,515	5.83

TABLE 6. COVERAGE (%) OF SCREENING FOR INFECTIOUS MARKERS, 2014

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	Anti-HBc
ARG	100	100	100	100	100	100	100
BOL	100	100	100	100	100	0	0
BRA *2012	100	100	100	100	100	100	100
CHL	100	100	100	100	100	100	NR
COL	100	100	100	100	100	93.11	95.5
CRI	100	100	100	100	100	100	100
CUB	100	100	100	100	NR	NR	NR
ECU	100	100	100	100	100	6.61	28.46
SLV	100	100	100	100	100	NR	NR
GTM	100	100	100	100	100	NR	82.91
HND*	99.14	99.17	99.24	99.21	99.25	98.65	98.68
MEX	100	100	100	100	96.45	NR	NR
NIC	100	100	100	100	100	NR	NR
PAN	100	100	100	100	100	100	100
PRY	100	100	100	100	100	100	100
PER *2013	100	100	100	100	100	100	100
DOM	100	100	100	100	NR	100	11.77
URY	100	100	100	100	100	100	100
VEN	100	100	100	100	100	100	100

HND: Blood units that are not screened are discarded.
NR: Not Reported.

TABLE 7. PERCENTAGE OF UNITS NOT SCREENED FOR INFECTIOUS MARKERS, 2014

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*
HND	0.86	0.83	0.76	0.79	0.75
MEX					3.55

TABLE 8. PROPORTION (%) OF REACTIVE/POSITIVE UNITS, 2014

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	Anti-HBc
ARG	0.20	0.22	0.45	1.12	2.46	0.18	1.54
BOL	0.25	0.25	0.36	0.75	3.90	NR	NR
BRA *2012	0.42	0.16	0.30	0.82	0.31	0.19	1.62
CHL	0.12	0.01	0.01	0.94	0.12	0.10	NR
COL	0.23	0.14	0.39	1.51	0.41	0.30	1.80
CRI	0.08	0.41	0.21	0.62	0.15	0.08	0.74
CUB	0.02	0.41	0.92	0.51	NR	NR	NR
ECU	0.30	0.23	0.25	1.25	0.25	0.01	0.1
SLV	0.09	0.12	0.22	1.19	2.30	NR	NR
GTM	0.15	0.45	0.57	1.56	1.04	NR	3.40
HND	0.28	0.26	0.45	0.80	0.96	0.18	1.96
MEX	0.26	0.16	0.6	0.58	0.48	NR	NR
NIC	0.07	0.21	0.30	0.30	0.31	NR	NR
PAN	0.11	0.20	0.34	1.04	0.37	0.32	1.67
PRY	0.34	0.34	0.37	6.57	2.33	0.21	2.90
PER *2013	0.23	0.38	0.56	1.19	0.50	0.88	4.19
DOM	0.28	1.02	0.21	0.71	NR	0.16	4.7
URY	0.09	0.10	0.32	0.51	0.21	0.10	0.88
VEN	0.25	0.37	0.28	1.67	0.35	0.14	2.74

NR: Not Reported.

Figure 3. Proportion (%) of reactive/positive units for markers, Latin America 2014



TABLE 8.1. PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS, 2014

COUNTRY	PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST-TIME	REPEAT		
ARG	NR	NR	NR	NA
BOL	NR	NR	NR	NA
BRA *2012	NR	NR	NR	NA
CHL	0.16	0.12	0.10	NA
COL	0.30	0.15	0.21	NA
CRI	NR	NR	NR	NA
CUB	0.02		NA	NA
ECU	NR	NR	NR	NA
SLV	NR	NR	NR	NA
GTM	NR	NR	NR	NA
HND	NR	NR	NR	NR
MEX	NR	NR	NR	NA
NIC	0.04	0.03	NA	NA
PAN	NR	NR	NR	NR
PRY	NR	NR	NR	NA
PER *2013	NR	NR	NR	NR
DOM	NR	NR	NR	NR
URY	NR	NR	NR	NA
VEN	NR	NR	NR	NA

NR: Not Reported.

TABLE 9. SEPARATION INTO COMPONENTS (NUMBER), 2014

COUNTRY	UNITS RECEIVED	RBC	FFP	FP	CRYO	PL
ARG	959,233	868,645	373,822	495,823	13,084	521,187
BOL	101,166	98,397	82,483	11,907	7,008	41,342
BRA *2012	3,335,035	3,231,788	2,689,156	477,826	215,615	2,031,891
CHL	240,911	233,389	201,099	33,347	15,106	153,273
COL	756,370	739,420	586,234	126,761	68,626	315,498
CRI	73,057	71,412	71,006	387	15,257	53,622
CUB	415,902	404,207	53,807	33,068	20,738	69,031
ECU	232,215	223,962	174,105	28,709	7,447	107,256
SLV	98,090	86,141	64,607	NR	14,239	74,150
GTM	114,404	100,329	55,035	2,646	2,941	43,722
HND	58,612	35,494	28,676	NR	3,087	23,586
MEX	1,939,060	1,815,839	1,340,336	285,176	101,196	737,999
NIC	75,035	73,236	67,328	6,296	7,260	43,420
PAN	55,801	50,729	25,396	NR	7,708	28,952
PRY	87,888	79,754	59,752	12,022	6,979	43,000
PER *2013	204,871	185,717	138,344	29,142	18,071	105,145
DOM	93,600	49,155	4,111	5,121	NR	5,363
URY	96,563	NR	NR	NR	NR	NR
VEN	312,048	298,394	240,981	NR	15,249	174,699

NR: Not Reported.

TABLE 9.1. BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER), 2014

COUNTRY	WB	RBC	FFP	FP	CRYO	PL
ARG	9,918	137,645	62,550	83,850	2,943	135,787
BOL	3,191	6,506	30,683	10,340	1,943	14,462
BRA *2012	8,840	308,229	964,329	44,729	3,051	279,635
CHL	NR	22,554	41,915	NR	1,501	60,421
COL	7,870	62,891	354,161	109,521	18,634	102,719
CRI	2	9,081	55,257	NR	2,948	28,238
CUB	NR	6,541	1,278	2,097	1,274	12,491
ECU	5,067	12,213	55,604	15,196	699	34,082
SLV	662	5,662	12,562	NR	7,693	638
GTM	1,966	15,480	16,571	337	359	11,561
HND	3,524	2,385	15,025	NR	83	2,843
MEX	58,128	116,672	535,306	340,689	15,858	231,040
NIC	1,799	1,339	34,285	5,645	166	1,023
PAN	101	8,570	6,478	NR	292	11,865
PRY	1,467	11,306	15,166	13,273*	677	26,589
PER *2013	2,170	25,413	42,774	26,944	1,405	28,143
DOM	10,694	5,080	1,230	570	NR	511
URY	6	13,816	7,354	219	7	18,919
VEN	34,576	NR	NR	NR	NR	NR

PRY: Due to the storage period of the frozen plasma, many of the discarded units were produced in 2013, meaning that the number of units discarded in 2014 exceeds those produced in that year.
NR: Not Reported.

TABLE 10. AVAILABILITY OF BLOOD COMPONENTS (%), 2014

COUNTRY	% SEPARATED INTO COMPONENTS					% BLOOD AND BLOOD COMPONENTS DISCARDED					
	RBC	FFP	FP	CRYO	PL	WB	RBC	FFP	FP	CRYO	PL
ARG	90.56	38.97	51.69	1.36	54.33	1.03	15.85	16.73	16.91	22.49	26.05
BOL	97.26	81.53	11.77	6.93	40.87	3.15	6.61	37.2	86.84	27.73	34.98
BRA *2012	96.9	80.63	14.33	6.47	60.93	8.56	9.54	35.86	9.36	1.42	13.76
CHL	96.88	83.47	13.84	6.27	63.62	0	9.66	20.84	NR	9.94	39.42
COL	97.76	77.51	16.76	9.07	41.71	1.04	8.50	60.40	86.40	27.15	32.56
CRI	97.75	97.19	0.53	20.88	73.40	0.003	12.72	77.82	NR	19.32	52.66
CUB	97.19	12.94	7.95	4.99	16.60	NR	1.62	2.37	6.34	6.14	18.09
ECU	96.45	74.98	12.36	3.21	46.19	2.18	5.45	31.94	52.93	9.39	31.78
SLV	87.81	65.87	NR	14.52	75.60	0.68	6.57	19.44	NR	54.03	0.86
GTM	87.7	48.1	2.31	2.57	38.22	1.72	15.43	30.11	12.74	12.21	26.44
HND	60.56	48.93	NR	5.27	40.24	7.11	6.72	52.40	NR	2.69	12.05
MEX	93.65	69.12	14.71	5.22	38.07	3	6.42	39.94	*	15.67	31.31
NIC	97.6	89.73	8.39	9.68	57.87	1.09	1.83	50.92	89.66	2.29	2.36
PAN	90.91	45.51	NR	13.81	51.88	0.18	16.89	25.51	NR	3.79	40.98
PRY	90.75	67.99	13.68	7.94	48.93	1.67	14.18	25.38	*	9.7	61.83
PER *2013	90.65	67.53	14.22	8.82	51.32	11.33	13.68	30.92	92.46	7.78	26.77
DOM	52.52	4.39	5.47	NR	5.73	11.42	10.33	29.92	11.13	NR	9.53
URY	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
VEN	95.62	77.23	NR	4.89	55.98	NR	NR	NR	NR	NR	NR

MEX: Based on Mexican regulations, the allowed time for the storage of plasma is 36 months, so blood banks can report the discarding of units of plasma of previous years and not necessarily of the units obtained in the current year.
PRY: Due to the storage period of the frozen plasma, many of the discarded units were produced in 2013, meaning that the number of units discarded in 2014 exceeds those produced in that year.
NR: Not Reported.

Figure 4. Percentage of blood and blood components discarded, Latin America 2014



TABLE 10.1. BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES, 2014

COUNTRY	BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES		
	RBC	PLATELETS	PLASMA
ARG	NR	NR	NR
BOL	NR	NR	NR
BRA *2012	NR	NR	NR
CHL	0	NR	0
COL	29,473	153,669	4,542
CRI	NR	NR	NR
CUB	0	1,754	40,044
ECU	0	4,905	0
SLV	331	5,865	96
GTM	33	1,946	NR
HND	0	1,164	0
MEX	NR	67,719	230
NIC	0	0	0
PAN	207	3,546	0
PRY	NR	NR	NR
PER *2013	NR	9,611	NR
DOM	NR	NR	NR
URY	NR	1,467	NR
VEN	0	12,663	

NR: Not Reported.

TABLE 10.2. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER), 2014

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER)																	
	WB			RBC			FFP			FP			CRYO			PLA		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
ARG	8,800	908	210	88,025	48,550	1,070	39,560	20,100	2,890	51,200	28,450	4,200	2,800	NR	143	84,287	46,300	5,200
BOL	18	190	2,983	816	3,868	1,822	1,283	2,949	26,451	2,679	289	7,372	361	203	1,379	9,336	1,220	3,906
BRA *2012	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CHL	NR	NR	NR	10,748	5,289	6,517	1,205	5,056	35,654	NR	NR	NR	519	81	901	44,316	2,693	13,412
COL	78	830	6,962	16,059	31,618	15,214	901	26,481	326,779	3,084	2,002	104,435	141	1,156	17,337	30,823	12,501	59,395
CRI	0	0	2	7,411	1,670	0	53,450	1,668	139	NR	NR	NR	2,948	0	0	26,570	1,668	0
CUB	NR	NR	NR	1,293	0	5,248	108	0	1,170	313	0	1,784	635	0	639	4,390	0	8,101
ECU	NR	NR	5,067	NR	NR	12,213	NR	NR	55,604	NR	NR	15,196	NR	NR	699	NR	NR	34,082
SLV	327	194	141	707	4,346	609	198	3,244	9,120	NR	NR	NR	3,121	2,772	1,800	63	298	277
GTM	127	1,634	205	4,874	7,630	2,976	678	3,030	12,863	230	90	17	176	72	111	8,790	2,020	751
HND	714	1,762	1,048	1,873	5	507	333	NR	14,692	NR	NR	NR	19	NR	64	2,457	NR	386
MEX	1,769	12,329	44,030	51,264	28,536	36,872	64,760	21,606	448,940	59,559	5,040	276,090	3,514	1,676	10,669	156,585	13,078	61,377
NIC	0	0	821	0	825	514	0	564	33,721	0	121	5,524	0	62	104	0	53	970
PAN	49	29	23	5,549	1,888	1,133	509	1,053	4,916	NR	NR	NR	31	21	240	7,197	1,580	3,088
PRY	138	503	826	1,745	8,751	810	3,133	5,614	6,419	698	1,021	11,554	9	306	362	9,490	4,936	12,163
PER *2013	120	1,222	828	5,744	13,642	6,027	26,262	10,699	5,813	18,565	250	8,129	751	8	646	19,398	7,587	1,158
DOM	2,240	3,497	4,957	850	0	4,230	59	0	1,171	0	0	570	0	0	0	409	0	102
URY	6	0	0	6,688	2,856	4,272	0	2,702	4,652	2	154	63	2	0	5	12,171	2,702	4,046
VEN	8,183	17,988	8,405	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 10.3. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE), 2014

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE)																	
	WB			RBC			FFP			FP			CRYO			PLA		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
ARG	88.73	9.15	2.12	63.95	35.27	0.78	63.25	32.13	4.62	61.06	33.93	5.01	95.14	0	4.86	62.07	34.1	3.83
BOL	0.57	5.95	93.48	12.54	59.45	28.01	4.18	9.61	86.21	25.91	2.8	71.29	18.58	10.45	70.97	64.55	8.44	27.01
BRA *2012	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CHL	NR	NR	NR	47.65	23.45	28.90	2.88	12.06	85.06	NR	NR	NR	34.58	5.40	60.02	73.34	4.46	22.2
COL	0.99	10.55	88.46	26.62	48.16	25.22	0.25	7.48	92.27	2.81	1.83	95.36	0.76	6.20	93.04	30.01	12.17	57.82
CRI	0	0	100	81.61	18.39	0	96.73	3.02	0.25	NR	NR	NR	100	0	0	94.09	5.91	0
CUB	NR	NR	NR	24.64	NR	80.23	8.45	NR	91.55	14.93	NR	85.07	49.84	NR	50.16	35.14	NR	64.86
ECU	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
SLV	49.40	29.30	21.30	12.49	76.76	10.75	1.58	25.82	72.60	NR	NR	NR	40.57	36.03	23.40	9.87	46.71	43.42
GTM	6.46	83.11	10.43	31.49	49.29	19.22	4.09	18.29	77.62	68.25	26.71	5.04	49.02	20.06	30.92	76.03	17.47	6.50
HND	20.26	50	29.74	78.53	0.21	21.26	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
MEX	3.04	21.21	75.75	43.94	24.46	31.60	12.1	4.03	83.87	17.48	1.48	81.04	22.16	10.56	67.28	67.77	5.66	26.57
NIC	0	0	100	0	61.61	38.39	0	1.64	98.36	0	2.14	97.86	0	37.35	62.65	0	5.18	94.82
PAN	48.52	28.71	22.77	64.75	22.03	13.22	7.86	16.25	75.89	NR	NR	NR	10.62	7.19	82.19	60.66	13.31	26.03
PRY	9.41	34.29	56.30	15.43	77.40	7.17	20.66	37.02	42.32	5.26	7.69	87.05	1.33	45.20	53.47	35.69	18.56	45.75
PER *2013	5.53	56.31	38.16	22.60	53.68	23.72	61.40	25.01	13.59	68.9	0.93	30.17	53.45	0.57	45.98	68.93	26.96	4.11
DOM	20.95	32.70	46.35	16.73	NR	83.27	4.80	NR	95.20	NR	NR	NR	NR	NR	NR	80.04	NR	19.96
URY	100	0	0	48.41	20.67	30.92	0	36.74	63.26	0.91	70.32	28.77	28.57	0	71.43	64.33	14.28	21.39
VEN	23.67	52.02	24.31	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 11. TRANSFUSION, 2014

COUNTRY	NUMBER OF COMPONENTS TRANSFUSED							
	WB	RBC	FFP	FP	CRYO	PL	APH-PL	APH-RBC
ARG	12,000	731,000	84,000	110,000	24,168	385,400	36,000	NR
BOL	NR	NR	NR	NR	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR	NR	NR	NR
CHL	NR	230,488	82,854	NR	12,355	93,081	NR	NR
COL	8,250	664,457	201,360	NR	44,396	162,495	128,445	NR
CRI	NR	NR	NR	NR	NR	NR	NR	NR
CUB	NR	337,788	37,190	4,259	20,481	43,844	NR	NR
ECU	NR	65,595	24,370	2,679	1,468	18,150	149	NR
SLV	3,195	65,877	24,550	NR	14,842	25,890	NR	NR
GTM	1,069	114,637	32,901	521	3,186	24,369	3,155	38
HND	2,227	26,817	9,410	34	1,619	6,826	491	32
MEX	13,538	1,336,350	582,413	22,183	84,503	309,752	NR	NR
NIC	0	61,864	20,013	41,034	2,386	NR	NR	NR
PAN	64	42,969	19,873	1,450	3,441	36,369	5,066	NR
PRY	448	60,866	31,138	533	9,771	18,040	NR	NR
PER *2013	1,746	162,809	65,296	936	15,400	80,431	10,256	NR
DOM	19,969	33,824	300	NR	20	1,400	495	24
URY	2,589	79,047	22,487	324	2,265	37,357	2,184	0
VEN	NR	NR	NR	NR	NR	NR	NR	NR

APH-PL: Platelets by apheresis.
APH-RBC: Red Blood Cells by apheresis.
NR: Not Reported.

TABLE 11.1 HOSPITALS AND TRANSFUSIONS, 2014

COUNTRY	# OF TRANSFUSION SERVICES	# OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS	NUMBER OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS AND PARTICIPATE/HAVE:					
			TRANSFUSION COMMITTEE		CLINICAL AUDIT		SYSTEM FOR REPORTING ADVERSE REACTIONS	
			#	%	#	%	#	%
ARG	419	2,723	364*	27*	364*	27*	NR	NR
BOL	NR	NR	NR	NR	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR	NR	NR	NR
CHL	60	60	60	100	NR	NR	60	100
COL	441	441	441	100	441	100	441	100
CRI	32	32	NR	NR	NR	NR	NR	NR
CUB	152	152	152	100	152	100	152	100
ECU	150	75	75	100	NR	NR	75	100
SLV	48	45	10	18	NR	NR	45	100
GTM	9	48	NR	NR	NR	NR	NR	NR
HND	62	62	0	0	0	0	0	0
MEX	4,522	5,000	164*	3	0	0	0	0
NIC	66	42*	10	23.81	21	50	10	23.81
PAN	2	30	6	20	12	40	30	100
PRY	61	52	0	0	0	0	52	100
PER *2013	198	289	55	19.03	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR	NR	NR	NR
URY	74	73	NR	NR	NR	NR	73	100
VEN	337	337	NR	NR	NR	NR	NR	NR

ARG: Only 1323 hospitals from the public sector that perform transfusions are considered. The private sector is not included.
MEX: It represents only 30% of the data collected in the country.
NIC: Only information from public hospitals is reported.
NR: Not Reported.

TABLE 11.2. NUMBER OF PATIENTS TRANSFUSED BY AGE, 2014

COUNTRY	# OF PATIENTS TRANSFUSED IN THE COUNTRY	NUMBER OF PATIENTS TRANSFUSED BY AGE				
		<5	05-14	15 - 44	45 - 59	>60
ARG	400,000	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR	NR
CHL	421,403	53,820		367,583		
COL	311,024	14,964	16,821	0	279,239	0
CRI	37,341	NR	NR	NR	NR	NR
CUB	143,893	NR	NR	NR	NR	NR
ECU	112,411*	NR	NR	NR	NR	NR
SLV	86,140*	0	13,108*	13,984*	43,625*	15,423*
GTM	NR	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR	NR
MEX	NR	NR	NR	NR	NR	NR
NIC	NR	NR	NR	NR	NR	NR
PAN	NR	NR	NR	NR	NR	NR
PRY	120,796*	NR	NR	NR	NR	NR
PER *2013	NR	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR	NR
URY	34,407	1,530	NR	NR	NR	32,877
VEN	565,399	NR	NR	NR	NR	NR

ECU, PRY: This figure represents the number of blood components transfused, but not the number of transfused patients.
SLV: The number of patients transfused corresponds only to the hospitals of the Ministry of Health. The age groups used are: under 10 years, 10-19 years, 20-59 years, and over 60 years.
NR: Not Reported.

TABLE 11.3. ADVERSE TRANSFUSION REACTIONS, 2014

COUNTRY	ADVERSE TRANSFUSION REACTIONS															
	Haemolysis due to ABO incompatibility	Haemolysis due to other allo-antibody	Non-immunological haemolysis	Post-transfusion purpura	Anaphylaxis-hypersensitivity	TRALI	Graft versus host disease	Transfusion-associated HIV infection	Transfusion-associated HBV infection	Transfusion-associated HCV infection	Other transfusion-associated viral infection	Sepsis due to bacterial contamination	Transfusion-associated malaria infection	Other parasitical infection	Transfusion-associated circulatory overload	Other serious adverse transfusion reaction
ARG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CHL	5	NR	NR	NR	370	2	NR	NR	NR	NR	NR	0	NR	NR	16	2
COL	NR	NR	NR	NR	NR	NR	NR	NR	NR	3	NR	NR	NR	NR	NR	287
CRI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CUB	NR	14	989	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ECU	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
SLV	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GTM	NR	2	NR	NR	28	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	46
HND	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
MEX	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
NIC	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
PAN	NR	NR	NR	NR	79	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
PRY	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
PER *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
URY	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
VEN	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 12. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: LAW, POLICY AND COORDINATION, 2014

COUNTRY	SPECIFIC LAW	RESPONSIBLE UNIT	SPECIFIC BUDGET	NATIONAL POLICY	NATIONAL COMMISSION
ARG	YES	YES	YES	YES	YES
BOL	YES	YES	YES	YES	YES
BRA *2012	YES	YES	YES	YES	YES
CHL	PARTIAL*	YES	YES	YES	YES
COL	YES	YES	YES	YES	NO
CRI	NO	YES	NO	NO	NO
CUB	YES	YES	NO	YES	YES
ECU	YES	YES	YES	YES	YES
SLV	NO	YES	NO	YES	NO
GTM	YES	YES	YES	YES	NO
HND	NO	NO	YES	PARTIAL*	NO
MEX	YES	YES	YES	YES	NO
NIC	YES	YES	YES	YES	YES
PAN	YES	YES	NO	YES	NO
PRY	YES	YES	YES	YES	NO
PER *2013	YES	YES	YES	YES	NO
DOM	NO	YES	NO	YES	NO
URY	YES	NO	NO	NO	NO
VEN	YES	YES	YES	NO	NO

CHL: In process of revision and approval.
HND: In process of elaboration and approval.

TABLE 13. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: GUIDELINES, NORMS AND INFORMATION SYSTEM, 2014

COUNTRY	REFERENCE CENTER	NATIONAL PLAN	DONOR NORMS	OPERATION NORMS	CLINICAL GUIDELINES	SERVICE REGISTRATION	INFORMATION SYSTEM
ARG	YES	YES	YES	YES	YES	YES	YES
BOL	YES	YES	YES	YES	YES	YES	YES
BRA *2012	NO	YES	YES	YES	YES	YES	YES
CHL	YES	YES	YES	YES	YES	YES	NO
COL	YES	YES	YES	YES	YES	YES	NO
CRI	PARTIAL*	NO	NO	YES	NO	YES	YES
CUB	YES	YES	YES	YES	YES	YES	YES
ECU	YES	PARTIAL*	PARTIAL*	YES	YES	YES	NO
SLV	YES	YES	YES	YES	YES	YES	NO
GTM	YES	YES	YES	YES	YES	YES	YES
HND	PARTIAL*	NO	YES	YES	NO	NO	NO
MEX	YES	YES	YES	YES	YES	YES	NO
NIC	YES	YES	YES	YES	YES	YES	YES
PAN	YES	YES	YES	YES	YES	YES	YES
PRY	YES	YES	YES	YES	YES	YES	YES
PER *2013	YES	NO	YES	YES	YES	YES	NO
DOM	NO	YES	YES	YES	YES	YES	NO
URY	YES	NO	YES	YES	NO	YES	YES
VEN	YES	NO	YES	YES	NO	YES	YES

CRI: The reference center for HIV is San Juan de Dios Hospital, and for Chagas it is the INCIENSA.
ECU: The National Blood Plan and the blood donation norm are being developed.
HND: The Network of Clinical Laboratories of the country has a reference center in Tegucigalpa (called the National Surveillance Laboratory), which also serves as reference in screening tests to blood units when requested.

TABLE 14. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: QUALITY, 2014

COUNTRY	QUALITY ASSURANCE POLICY	NATIONAL QUALITY MANAGEMENT PROGRAM	NATIONAL PROGRAM OF EXTERNAL EVALUATION SEROLOGY-TTI	NATIONAL PROGRAM OF EXTERNAL EVALUATION IMMUNOHEMATOLOGY	INSPECTION PROGRAM	CONTINUED EDUCATION
ARG	YES	YES	YES	NO	YES	YES
BOL	YES	YES	YES	NO	YES	YES
BRA *2012	YES	YES	YES	YES	YES	YES
CHL	YES	YES	YES	YES	YES	YES
COL	YES	YES	YES	YES	YES	YES
CRI	NO	NO	YES*	YES*	YES	NO
CUB	YES	YES	YES	YES	YES	YES
ECU	PARTIAL*	YES	YES	NO	YES	YES
SLV	NO	YES	YES	NO	PARTIAL*	YES
GTM	NO	NO	NO	NO	YES	YES
HND	NO	NO	NO	NO	NO	NO
MEX	YES	YES	YES	YES	YES	YES
NIC	YES	YES	YES	YES	YES	YES
PAN	YES	NO	NO	NO	NO	NO
PRY	YES	YES	YES	NO	YES	YES
PER *2013	YES	NO	YES	NO	YES	NO
DOM	NO	NO	YES	NO	YES	NO
URY	NO	NO	NO	NO	YES	NO
VEN	YES	NO	NO	NO	NO	YES

CRI: The Caja Costarricense del Seguro Social has its own program for both serology and immunohematology.
ECU: Blood services are subject to the activities undertaken by the Dirección Nacional de Calidad.
SLV: In process of formalization and projected to start in 2015.

TABLE 15. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: CERTIFICATION AND ACCREDITATION, 2014

COUNTRY	STAFF CERTIFICATION	SERVICE ACCREDITATION
ARG	YES	YES
BOL	YES	YES
BRA *2012	YES	YES
CHL	YES	YES
COL	YES	NO
CRI	YES	NO
CUB	YES	YES
ECU	NO	YES
SLV	NO	NO
GTM	YES	NO
HND	NO	NO
MEX	YES	NO
NIC	YES	NR
PAN	NO	NO
PRY	NO	NO
PER *2013	NO	NO
DOM	NO	NO
URY	NO	YES
VEN	NO	NO

NR: Not Reported.

TABLE 16. ORGANIZATION OF THE TRANSFUSION SERVICES AND HAEMOVIGILANCE, 2014

COUNTRY	NATIONAL TRANSFUSION COMMITTEE	INTRAHOSPITAL TRANSFUSION COMMITTEE	NATIONAL HAEMOVIGILANCE PROGRAM	BLOOD UNITS NEEDED TO COVER THE NATIONAL REQUIREMENTS
ARG	NO	PARTIAL*	YES	YES
BOL	NO	YES	NO	NR
BRA *2012	NR	YES	YES	NR
CHL	NO	YES	YES*	YES
COL	NO	YES	YES	PARTIAL*
CRI	PARTIAL*	PARTIAL*	NO	NO
CUB	YES	YES	YES	YES
ECU	NO	YES	NO	YES
SLV	NO	YES	NO	YES
GTM	NO	PARTIAL*	NO*	YES
HND	NO	NO	NO	NO
MEX	NO	YES	PARTIAL*	YES
NIC	NR	YES	NO	YES
PAN	NO	PARTIAL*	NO	NO
PRY	NO	YES	NO	YES
PER *2013	NO	NO	NO	YES
DOM	NO	NO	NO	NO
URY	NO	NO	NO	NO
VEN	NO	NO	PARTIAL*	YES

ARG: Jurisdictions that represent approximately 50% of transfusions.
CHL: Program executed by Epidemiología MINSAL.
COL: In progress of establishing blood needs according to the protocol developed by PAHO.
CRI: It has the National Commission on Transfusion Safety, which is not currently active. It also has intra-hospital transfusion committees in some hospitals.
GTM: 9 hospital transfusion committees are being developed. Since February 2014 the Hemovigilance program began.
MEX: In process of authorization of the registration documents.
PAN: Only 4 blood services have transfusion committees.
VEN: The Program is awaiting approval by the MPPS. There is currently a pilot test with the Society of Hematology.
NR: Not Reported.

TABLE 17. FINANCING AND COSTS OF BLOOD SERVICES, 2014

COUNTRY	ANNUAL REPORT ON ACTIVITIES	SYSTEM OF COST-RECOVERY	FINANCIAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	TECHNICAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	ESTIMATED TOTAL FUNDING (IN US DOLLARS)				APPROXIMATE COST (IN US DOLLARS) OF PRODUCING:	
					TOTAL	FROM THE NATIONAL GOVERNMENT	FROM FEES AND COST RECOVERY	FROM EXTERNAL DONORS	WHOLE BLOOD	RED BLOOD CELLS
ARG	NO	YES	YES	YES	34,000,000	20,000,000	NR	NR	100	50
BOL	NO	NO	NO	NO	86,206.90	86,206.90		0	35.90	28.70
BRA *2012	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CHL	NO	NO	NO	YES	13,760,000	13,760,000	0	0	20.80	69.83
COL	YES	YES	NO	YES	NR	NR	NR	NR	NR	NR
CRI	NO	NO	NO	NO	NR	NR	NR	NR	NR	40
CUB	YES	NO	NO	NO	NR	NR	NR	NR	NR	NR
ECU	YES	YES	NO	YES	2,970,930.09	2,970,930.09	0	0	NR	52.53
SLV	YES	NO	NO	YES	NR	NR	NR	NR	65	75
GTM	YES	NO	NO	YES	NR	NR	NO	NO	NR	NR
HND	NO	YES	NR	YES	NR	1,728,991.45	NR	NR	NR	NR
MEX	YES	YES	NO	NO	5,272,730.67	5,272,730.67	0	0	NR	156
NIC	YES	YES	NO	YES	5,000,000	90%	10%	0	16	16
PAN	YES	NO	YES	YES	40,000	37,000	NR	3,000	NR	NR
PRY	YES	YES	YES	YES	3,959,624	3,890,023	69,601	400,000*	NR	39
PER *2013	YES	YES	NO	YES	300,000	NR	NR	0	70	90
DOM	YES	YES	YES	YES	NR	NR	NR	NR	NR	NR
URY	YES	NO	YES	NO	NR	NR	NR	NR	NR	NR
VEN	YES	NO	NO	NO	NR	NR	NR	NR	NR	NR

PRY: The funds from external donors are not reflected in the "Total of the financing", since these contributions are not annual but by project.
NR: Not Reported.

TABLE 18. STOCKS OF CONSUMABLES, 2014

COUNTRY	DID STOCKS OF ANY OF THE FOLLOWING CONSUMABLES RUN OUT:			
	BLOOD COLLECTION BAGS	TEST KITS FOR TRANSFUSION-TRANSMISSIBLE INFECTIONS	REAGENTS FOR ROUTINE BLOOD GROUPING	OTHERS
ARG	NO	NO	NO	Disposable for Apheresis and Leukocyte Filters
BOL	NO	NO	NO	NO
BRA *2012	NR	NR	NR	NR
CHL	NO	NO	NO	NO
COL	NR	NR	NR	NR
CRI	NO	NO	NO	NO
CUB	NO	NO	NO	NO
ECU	NO	NO	NO	NO
SLV	NO	NO	NO	NO
GTM	YES	YES	YES	NR
HND	NR	YES	NR	NR
MEX	NO	NO	NO	NO
NIC	NO	NO	NO	NO
PAN	NO	NO	NO	NO
PRY	NO	NO	NO	NO
PER *2013	NO	NO	NO	NR
DOM	NO	NO	NO	NO
URY	NO	NO	NO	NO
VEN	NO	NO	NO	NO

NR: Not Reported.

TABLE 19. NOTIFICATION SYSTEM, 2014

COUNTRY	SPECIFIC BUDGET FOR THE BLOOD DONOR PROGRAMME	CELEBRATION OF WORLD BLOOD DONOR DAY	REGISTER-DATABASE FOR BLOOD DONORS	NATIONAL DONOR SELECTION CRITERIA	DONOR NOTIFICATION SYSTEM FOR TEST RESULTS					SYSTEM OF POST-DONATION COUNSELLING AND REFERRAL TO CARE AND TREATMENT
					HIV	HEPATITIS B	HEPATITIS C	SYPHILIS	OTHER	
ARG	YES	YES	YES	YES	YES	YES	YES	YES	Brucellosis and HTLV I-II	YES
BOL	YES	YES	YES	YES	YES	NO	NO	NO	Chagas	NO
BRA *2012	NR	YES	NR	NR	NR	NR	NR	NR	NR	NR
CHL	NO	YES	YES	YES	YES	YES	YES	YES	Irregular Antibodies and Red Blood Cell sensitization reactions	YES
COL	NO	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
CRI	NO	YES	YES	NO	NO	NO	NO	NO	NO	NO
CUB	NO	YES	YES	YES	YES	YES	YES	YES	NO	YES
ECU	YES	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
SLV	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
GTM	NO	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
HND	NO	YES	NO	YES	NO	YES	NO	NO	NO	NO
MEX	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
NIC	YES	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
PAN	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
PRY	YES	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
PER *2013	NO	YES	YES	YES	YES	YES	YES	YES	HTLV I-II, Chagas	YES
DOM	NO	YES	NO	NO	NO	NO	NO	NO	NO	YES
URY	NO	YES	YES	YES	YES	YES	YES	YES	HTLV I-II, Chagas, CMV	YES
VEN	YES	YES	YES	YES	YES	YES	YES	YES	YES	PARTIAL*

VEN: Not all blood services have staff to conduct counseling.
NR: Not Reported.

TABLE 20. ORGANIZATION OF THE BLOOD SERVICES, 2014

COUNTRY	# OF BLOOD SERVICES IN THE COUNTRY			# OF BLOOD SERVICES COVERED BY THIS REPORT			PERCENTAGE OF BLOOD DONATIONS COVERED BY THIS REPORT
	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	
ARG	45	209	254	38	175	213	95
BOL	11	7	18	11	7	18	100
BRA *2012	NR	NR	NR	NR	NR	NR	NR
CHL	5	60	65	5	57	62	80
COL	24	59	83	24	59	83	98.3
CRI	2	32	34	2	31	33	100
CUB	16	21	37	NR	NR	NR	100
ECU	7	14	21	7	14	21	100
SLV	1	28	29	1	28	29	100
GTM	13	48	61	13	48	61	89
HND	2	16	18	2	8	10	91
MEX	NR	NR	556	NR	NR	556	100
NIC	2	0	2	2	0	2	100
PAN	0	31	31	0	31	31	100
PRY	1	7	8	1	7	8	100
PER *2013	1	288	289	1	288	289	100
DOM	37	34	71	25	17	42	NR
URY	3	71	74	3	71	74	97
VEN	4	333	337	4	333	337	79.93

NR: Not Reported.

TABLE 21. COUNTRIES WITH 100% SCREENING FOR INFECTIOUS MARKERS, 2014

HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	FIVE MARKERS	HTLV I-II	Anti-HBc
ARG	ARG	ARG	ARG	ARG	ARG	ARG	ARG
BOL	BOL	BOL	BOL	BOL	BOL		
BRA	BRA	BRA	BRA	BRA	BRA	BRA	BRA
CHL	CHL	CHL	CHL	CHL	CHL	CHL	
COL	COL	COL	COL	COL	COL		
CRI	CRI	CRI	CRI	CRI	CRI	CRI	CRI
CUB	CUB	CUB	CUB				
ECU	ECU	ECU	ECU	ECU	ECU		
SLV	SLV	SLV	SLV	SLV	SLV		
GTM	GTM	GTM	GTM	GTM	GTM		
MEX	MEX	MEX	MEX				
NIC	NIC	NIC	NIC	NIC	NIC		
PAN	PAN	PAN	PAN	PAN	PAN	PAN	PAN
PRY	PRY	PRY	PRY	PRY	PRY	PRY	PRY
PER	PER	PER	PER	PER	PER	PER	PER
DOM	DOM	DOM	DOM			DOM	
URY	URY	URY	URY	URY	URY	URY	URY
VEN	VEN	VEN	VEN	VEN	VEN	VEN	VEN
18	**18**	**18**	**18**	**15**	**14**	**10**	**8**

TABLE 22. PLASMA DERIVED MEDICAL PRODUCTS (PDMP), 2014

COUNTRY	THE ESSENTIAL MEDICINES LIST INCLUDES THE FOLLOWING PDMP:					PROVISION OF PDMP FOR THE COVERAGE OF THE COUNTRY NEEDS:		
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS	FRACTIONATION (DOMESTIC OR/ AND CONTRACT) OF PLASMA COLLECTED IN THE COUNTRY	PLASMA COLLECTED IN THE COUNTRY WAS SOLD TO THE MANUFACTURERS OF PDMP, AND PRODUCTS ARE PURCHASED FROM PDMP SUPPLIERS	NO PLASMA COLLECTED IN THE COUNTRY ARE USED FOR FRACTIONATION AND ALL PDMP PRODUCTS ARE IMPORTED FROM ABROAD
ARG	YES	YES	YES	YES	Prothrombin complex	YES	NO	NO
BOL	NR	NR	YES	YES	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR	NR	NR	NR
CHL	YES	YES	YES	NO	NO	YES	NO	NO
COL	YES	YES	YES	YES	NR	NR	NR	YES
CRI	YES	YES	YES	YES	NR	NO	NO	YES
CUB	YES	YES	NO	NO	Albumin (Human) 20%, normal human immunoglobulin and transfer factor.	YES	NO	NO
ECU	NO	NO	YES	YES	normal human immunoglobulin	NO	NO	YES
SLV	YES	YES	YES	YES	NR	NO	NO	YES
GTM	YES	YES	YES	YES	NR	NO	NO	YES
HND	NR	NR	NR	NR	NR	NR	NR	NR
MEX	YES	YES	YES	YES	NR	YES	NO	PARCIAL*
NIC	NR	NR	NR	NR	NR	NR	NR	NR
PAN	YES	YES	YES	YES	Prothrombin complex concentrate	NO	NO	YES
PRY	NO	NO	NO	NO	NR	NO	NO	YES
PER *2013	YES	NR	YES	NO	NR	NO	NO	YES
DOM	NR	NR	NR	NR	NR	NR	NR	NR
URY	YES	YES	YES	YES	NR	YES	NO	NO
VEN	YES	YES	YES	YES	Anti D (Vial 300 ml) Anti T (Vial 250UI)	YES	YES	NO

MEX: Only a percentage of plasma obtained by fractionation is used for therapeutic purposes.
NR: Not Reported.

TABLE 23. PLASMA FRACTIONATION, 2014

COUNTRY	PLASMA FRACTIONATION		
	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE PUBLIC/NOT FOR PROFIT SECTOR	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE FOR-PROFIT SECTOR	THERE IS AN AGREEMENT WITH ANOTHER COUNTRY FOR THE SHIPPING OF PLASMA TO BE FRACTIONED
ARG	YES	NO	NO
BOL	NR	NR	NR
BRA *2012	NR	NR	NR
CHL	NO	NO	YES*
COL	NR	NR	NR
CRI	NR	NR	NR
CUB	YES	NO	NO
ECU	NO	NO	NO
SLV	NO	NO	NO
GTM	NR	NR	NR
HND	NO	NO	NO
MEX	YES	NO	NO
NIC	NR	NR	NR
PAN	NR	NR	NR
PRY	NO	NO	YES*
PER *2013	NO	NO	NO
DOM	NR	NR	NR
URY	NO	NO	YES*
VEN	YES	NO	NO

CHL: Agreement with Universidad Nacional de Córdoba, Argentina.
PRY: Agreement with Universidad Nacional de Córdoba, Argentina.
URU: Agreement with Universidad Nacional de Córdoba, Argentina.
NR: Not Reported.

TABLE 24. PLASMA MANUFACTURING OF PDMP, 2014

COUNTRY	MANUFACTURING OF PDMP				
	PDMP MANUFACTURED BY FRACTIONATION WITHIN THE COUNTRY OR THROUGH CONTRACT FRACTIONATION				
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS
ARG	YES	YES	YES	YES	Prothrombin complex
BOL	NR	NR	NR	NR	NR
BRA *2012	NR	NR	NR	NR	NR
CHL	YES	YES	YES	NO	NO
COL	NR	NR	NR	NR	NR
CRI	NR	NR	NR	NR	NR
CUB	YES	YES	NR	NR	AntiD Human Immunoglobulin
ECU	NR	NR	NR	NR	NR
SLV	NR	NR	NR	NR	NR
GTM	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR
MEX	NO	NO	NO	NO	NR
NIC	NR	NR	NR	NR	NR
PAN	NR	NR	NR	NR	NR
PRY	NO	NO	NO	NO	NO
PER *2013	NO	NO	NO	NO	NR
DOM	NR	NR	NR	NR	NR
URY	YES	YES	YES	NO	NR
VEN	YES	YES	YES	YES	NR

NR: Not Reported.

2014 NATIONAL STAFF WHO SUBMITTED THE OFFICIAL REPORT TO THE PAN AMERICAN HEALTH ORGANIZATION
LATIN AMERICAN COUNTRIES

COUNTRY	NAME	POSITION	ADDRESS
ARGENTINA	Mabel Maschio	Coordinadora General Plan Nacional de Sangre	Ministerio De Salud de la Nación Av. 9 de Julio 1925, 9no. Piso Ciudad Autónoma de Buenos Aires Tel.: 54 11 4379 9000 INT 4825 e-mail: mmaschio@msal.gov.ar
BOLIVIA	Ericka Lucía Machicao	Coordinadora General del Programa Nacional de Sangre del Ministerio de Salud	Programa Nacional de Sangre del Ministerio de Salud Calle Capitán Ravelo N° 2199, 4° Piso, Escuela Nacional de Salud Tel. 2 2126046 email: elmclpb@gmail.com
BRAZIL	João Paulo Baccara Araujo	Coordenador-Geral de Sangue e Hemoderivados/ CGSH	Departamento de Atenção Especializada e Temática/DAET Secretaria de Atenção à Saúde/SAS Ministério da Saúde/MS SAF SUL - Trecho 2 - Bloco F - Ala B - Torre 2 - 2º Andar - Sala 202 - Ed. Premium Brasília-DF, Brasil. Tel.: (61) 3315-6178/6149 e-mail: sangue@saude.gov.br
CHILE	Ana Jara Rojas	Coordinadora Nacional de Servicios de Sangre	Ministerio de Salud Enrique Mac iver 541, Santiago Centro, Chile Tel.:02-25681911 e-mail: ana.jara@minsal.cl; estefany.morales@minsal.cl
COLOMBIA	Javier Humberto Guzmán Cruz	Director de Medicamentos y Tecnologías en Salud	Ministerio de Salud y Protección Social Carrera 13 No 32 - 76 Tel.: 57 1 3305000 e-mail: jguzman@minsalud.gov.co
COSTA RICA	Gerardo Solano Elizondo	Unidad Servicios de Salud de Atención Directa a las Personas	Ministerio de Salud San José, Distrito Hospital, calle 16, avenidas 6 y 8 Tel.: (506) 2222-9115 e-mail: gerardo.solano@misalud.go.cr
CUBA	Luis Enrique Pérez Ulloa	Jefe del Programa Nacional de Sangre	MINSAP Calle 23 Esquina N.Vedado. La Habana.Cuba Tel.: 8396328 e-mail: luisenriquep@infomed.sld.cu
ECUADOR	Elizabeth Barona	Responsable del Programa Nacional de Sangre	Ministerio de Salud Pública República del Salvador y Suecia Tel.: 3 958 950 EXT. 640 e-mail: florelizabeth.barona@msp.gob.ec
EL SALVADOR	Maryuri Villatoro	Coordinadora de la Red Nacional de Bancos de Sangre	Direccion Nacional de Hospitales, MINSAL Calle Arce, # 827 San Salvador, El Salvador Tel.: (503) 25917628 / (503) 70337235 e-mail: mcvillatoro@salud.gob.sv

COUNTRY	NAME	POSITION	ADDRESS
GUATEMALA	Myriam Juarez	Responsable del Programa Nacional de Medicina Transfusional y Bancos de Sangre	Programa Nacional de Medicina Transfusional y Bancos de Sangre 5 Av. 11-40 zona 11, Ciudad Guatemala, Guatemala Tel.: (502)2471-9540 e-mail: pmtbs.mspas@gmail.com
HONDURAS	Ada Pavon	Coordinadora de Servicios de Sangre	Secretaría de Salud Col. El Jasmin Tegucigalpa, Honduras Tel: 504- 2237-5800 e-mail: adapavon@yahoo.com.mx
MEXICO	Julieta Rojo Medina	Director General	Centro Nacional de la Transfusión Sanguínea Othon de Mendizabal 195 Col. Zacatenco del Gustavo A. Madero, México D.F CP 07360 Tel: (5255)51192832 y 51193963 e-mail: julieta.rojo@salud.gob.mx
NICARAGUA	Alcides González Mairena	Secretario Ejecutivo Comisión Nacional de Sangre / MINSA	Ministerio de Salud Complejo Concepción Palacios, Managua Tel.: (505)-2289-4700 ext. 1195 e-mail: conasa01@minsa.gob.ni
PANAMA	Esmeralda Tuy	Coordinadora Técnica	Programa Nacional de Sangre-Ministerio de Salud Ancón, Calle Gorgas. Edificio 261. Tercer piso. Apdo.0-6812 Panamá 1, Panamá Tel.: (507)5129436 e-mail: sistemanacionaldesangre@hotmail.com
PARAGUAY	Nelson Marquez	Encargado de la Red Nacional de Servicios de Sangre	Programa Nacional de Sangre-Ministerio de Salud Pública y Bienestar Social Rca Argentina 222 entre Mcal. López y Boggiani Asunción – Paraguay Tel.: 595 21 606364 e-mail: pnsangre2004@gmail.com
PERU	Mariela Delgado Burga	Coordinadora Nacional	PRONAHEBAS-MINSA Av. Salaverry Cuadra 8 s/n Tel: 511-315-6600 Anexo 2675 - 2540 e-mail: mdelgado@minsa.gob.pe
DOMINICAN REPUBLIC	Sócrates E. Sosa Peña	Director del Programa Nacional de Bancos de Sangre	Ministerio de Salud Pública Av. Dr. Homero Hernandez Esq. Tiradentes, Ens. La Fé, Santo Domingo Tel: 809 541 3121 Ext. 2473-2474 e-mail: socratessosa@hotmail.com
URUGUAY	Lourdes Viano / Laura Ucar	Directora y Sub Directora	Servicio Nacional de Sangre 8 de Octubre, 2720 Tel. 24872414 int 302 y 318 e-mail: direccion.sns@asse.com.uy
VENEZUELA	Roraima Nuñez	Coordinadora del Programa Nacional de Bancos de Sangre	Ministerio del Poder Popular para la Salud Centro Simón Bolívar Torre Sur Piso 8, Oficina 824, Caracas Tel: 212 408 0576 / 4080543 e-mail: psbancodesangre@mpps.gob.ve / adbasaca@gmail.com

CARIBBEAN COUNTRIES 2014

TABLE 1. BLOOD COLLECTION, 2014

COUNTRY	TOTAL UNITS COLLECTED	NUMBER OF DONORS				BLOOD DONATION RATE PER 1000 PEOPLE*
		AUTOLOGOUS	ALLOGENEIC			
			VOLUNTARY	REPLACEMENT	REMUNERATED	
AIA	121	0	21	100	0	7.56
ATG	NR	NR	NR	NR	NR	NR
ABW	2,829	0	2,829	0	0	25.49
BHS	4,563	5	1,859	2,699	0	11.91
BRB	4,638	57	529	4,052	0	15.99
BLZ	4,329	0	1,116	3,213	0	12.73
BMU	1,602	0	1,602	0	0	22.89
VGB	350	NR	NR	NR	NR	10.61
CYM	1,071	0	1,071	0	0	19.47
CUW	6,628	0	6,628	0	0	44.78
DMA	1,006	0	66	940	0	13.78
GRD	1,267	1	509	757	0	11.52
GUY *2013	11,148	0	10,679	469	0	13.87
HTI	28,867	0	15,505	13,362	0	2.76
JAM	29,390	112	6,412	22,866	0	10.50
MSR	NR	NR	NR	NR	NR	NR
KNA *2013	331	0	71	260	0	6.37
LCA	2,448	8	1,402	1,038	0	15.02
VCT	1,081	17	77	987	0	10.50
SUR	10,521	0	10,521	0	0	19.34
TCA	354	0	135	219	0	7.22
TTO	21,249	77	3,753	17,419	0	15.81

*Demographic data is obtained from: Pan American Health Organization/World Health Organization, Communicable Diseases and Health Analysis/ Health Information and Analysis. Health Situation in the Americas: Basic Indicators 2014. Washington, D.C., United States of America, 2014.
NR: Not Reported.

TABLE 2. BLOOD COLLECTION FROM ALLOGENEIC DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	TYPE OF ALLOGENEIC DONOR (PERCENTAGE)		
		VOLUNTARY	REPLACEMENT	REMUNERATED
AIA	121	17.35	82.65	0
ATG	NR	NR	NR	NR
ABW	2,829	100	0	0
BHS	4,558	40.79	59.21	0
BRB	4,581	11.55	88.45	0
BLZ	4,329	25.78	74.22	0
BMU	1,602	100	0	0
VGB	350	NR	NR	NR
CYM	1,071	100	0	0
CUW	6,628	100	0	0
DMA	1,006	6.56	93.44	0
GRD	1,266	40.20	59.8	0
GUY *2013	11,148	95.79	4.21	0
HTI	28,867	53.71	46.29	0
JAM	29,278	21.90	78.10	0
MSR	NR	NR	NR	NR
KNA *2013	331	21.45	78.55	0
LCA	2,440	57.46	42.54	0
VCT	1,064	7.24	92.76	0
SUR	10,521	100	0	0
TCA	354	38.14	61.86	0
TTO	21,172	17.73	82.27	0

NR: Not Reported.

Figure 1. Percentage of blood collection ranked from greatest to least by voluntary donations, Caribbean 2014



TABLE 2.1. BLOOD COLLECTION ACCORDING TO THE SITE, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
AIA	121	21	0	100	0	0	0
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	2,829	0	2,829	0	0	0	0
BHS	4,558	792	1,067	2,699	0	0	0
BRB	4,581	480	49	4,052	0	0	0
BLZ	4,329	231	885	3,213	0	0	0
BMU	1,602	1,602	0	0	0	0	0
VGB	350	NR	NR	NR	NR	NR	NR
CYM	1,071	1,071	0	0	0	0	0
CUW	6,628	0	6,628	0	0	0	0
DMA	1,006	66	0	940	0	0	0
GRD	1,266	458	51	757	0	0	0
GUY *2013	11,148	NR	NR	NR	NR	NR	NR
HTI	28,867	3,719	11,786	13,362	0	0	0
JAM	29,278	6,412	0	22,866	0	0	0
MSR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	331	NR	NR	NR	NR	NR	NR
LCA	2,440	144	1,258	892	146	0	0
VCT	1,064	77	0	987	0	0	0
SUR	10,521	9,265	1,256	0	0	0	0
TCA	354	115	20	219	0	0	0
TTO	21,172	3,753	0	17,419	0	0	0

EM: Extramural.
NR: Not Reported.

TABLE 2.2. BLOOD COLLECTION ACCORDING TO THE SITE, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	PERCENTAGE OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
AIA	121	17.35	0	82.65	0	0	0
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	2,829	0	100	0	0	0	0
BHS	4,558	17.38	23.41	59.21	0	0	0
BRB	4,581	10.48	1.07	88.45	0	0	0
BLZ	4,329	5.34	20.44	74.22	0	0	0
BMU	1,602	100	0	0	0	0	0
VGB	350	NR	NR	NR	NR	NR	NR
CYM	1,071	100	0	0	0	0	0
CUW	6,628	0	100	0	0	0	0
DMA	1,006	6.56	0	93.44	0	0	0
GRD	1,266	36.18	4.03	59.79	0	0	0
GUY *2013	11,148	NR	NR	NR	NR	NR	NR
HTI	28,867	12.88	40.83	46.29	0	0	0
JAM	29,278	21.90	0	78.10	0	0	0
MSR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	331	NR	NR	NR	NR	NR	NR
LCA	2,440	5.90	51.56	36.56	5.98	0	0
VCT	1,064	7.24	0	92.76	0	0	0
SUR	10,521	88.06	11.94	0	0	0	0
TCA	354	32.49	5.65	61.86	0	0	0
TTO	21,172	17.73	0	82.27	0	0	0

EM: Extramural.
NR: Not Reported.

TABLE 3. SELECTION OF ALLOGENEIC DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS								
		VOLUNTARY			REPLACEMENT			REMUNERATED		
		INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE
AIA	121	33	12	0	251	151	0	NA	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	2,829	2,859	10	20	NA	NA	NA	NA	NA	NA
BHS	4,558	2,197	286	52	3,753	967	87	NA	NA	NA
BRB	4,581	529	0	0	4,819	709	58	NA	NA	NA
BLZ	4,329	1,575	459	0	4,631	1,418	0	NA	NA	NA
BMU	1,602	1,798	168	28	NA	NA	NA	NA	NA	NA
VGB	350	NR	NR	NR	NR	NR	NR	NR	NR	NR
CYM	1,071	1,251	168	12	NA	NA	NA	NA	NA	NA
CUW	6,628	6,656	13	15	NA	NA	NA	NA	NA	NA
DMA	1,006	67	0	1	1,499	550	9	NA	NA	NA
GRD	1,266	530	21	0	846	89	0	NA	NA	NA
GUY *2013	11,148	11,373	694	NR	NR	NR	NR	NR	NR	NR
HTI	28,867	20,768	5,263	0	19,608	6,246	0	NA	NA	NA
JAM	29,278	6,412	NR	NR	22,866	NR	NR	NA	NA	NA
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	331	71	NR	NR	350	90	NR	NR	NR	NR
LCA	2,440	1,556	154	0	1,947	909	0	NA	NA	NA
VCT	1,064	126	49	0	2,017	1,018	12	NA	NA	NA
SUR	10,521	12,044	1,355	168	NA	NA	NA	NA	NA	NA
TCA	354	NR	NR	NR	NR	NR	NR	NR	NR	NR
TTO	21,172	5,198	1,445	0	33,600	16,181	0	NA	NA	NA

Incomplete: It refers to people selected as donors, but for whom the extraction/collection could not be performed or was performed incompletely (problems that may be encountered in accessing a vein, insufficient or exceeded volume, among others).
NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

TABLE 4. DEFERRAL OF ALLOGENEIC DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	VOLUNTARY		REPLACEMENT		REMUNERATED	
		NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED
AIA	121	33	36.36	251	60.16	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	2,829	2,859	0.35	NA	NA	NA	NA
BHS	4,558	2,197	13.02	3,753	25.77	NA	NA
BRB	4,581	529	0	4,819	14.71	NA	NA
BLZ	4,329	1,575	29.14	4,631	30.62	NA	NA
BMU	1,602	1,798	9.34	NA	NA	NA	NA
VGB	350	NR	NR	NR	NR	NR	NR
CYM	1,071	1,251	13.43	NA	NA	NA	NA
CUW	6,628	6,656	0.19	NA	NA	NA	NA
DMA	1,006	67	0	1,499	36.69	NA	NA
GRD	1,266	530	3.96	846	10.52	NA	NA
GUY *2013	11,148	11,373	6.10	NR	NR	NA	NA
HTI	28,867	20,768	25.34	19,608	31.85	NA	NA
JAM	29,278	6,412	NR	22,866	NR	NA	NA
MSR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	331	71	NR	350	25.71	NA	NA
LCA	2,440	1,556	9.90	1,947	46.69	NA	NA
VCT	1,064	126	38.89	2,017	50.47	NA	NA
SUR	10,521	12,044	11.25	NA	NA	NA	NA
TCA	354	NR	NR	NR	NR	NR	NR
TTO	21,172	5,198	27.80	33,600	48.16	NA	NA

NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

Figure 2. Percentage of deferred donors by allogeneic donor type, Caribbean 2014



TABLE 4.1. VOLUNTARY NON-REMUNERATED DONATIONS FROM FIRST-TIME AND REPEAT DONORS, 2014

COUNTRY	TOTAL OF VOLUNTARY NON-REMUNERATED BLOOD DONATIONS	FIRST-TIME		REPEAT	
		NUMBER	%	NUMBER	%
AIA	21	0	0	21	100
ATG	NR	NR	NR	NR	NR
ABW	2,829	303	10.71	2,526	89.29
BHS	1,859	NR	NR	NR	NR
BRB	529	NR	NR	NR	NR
BLZ	1,116	NR	NR	NR	NR
BMU	1,602	130	8.11	1,472	91.89
VGB	NR	NR	NR	NR	NR
CYM	1,071	126	11.76	945	88.24
CUW	6,628	249	3.76	6,379	96.24
DMA	66	NR	NR	NR	NR
GRD	509	55	10.81	454	89.19
GUY *2013	NR	NR	NR	NR	NR
HTI	15,505	NR	NR	NR	NR
JAM	6,412	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR
LCA	1,402	495	35.31	907	64.69
VCT	77	NR	NR	NR	NR
SUR	10,521	0	0	10,521	100
TCA	135	NR	NR	NR	NR
TTO	3,753	564*	32.43*	1,175*	67.57*

TTO: This information is not collected at the National level; data is estimated with the results of the mobile/external collection.
NR: Not Reported.

TABLE 4.2. APHERESIS, 2014

COUNTRY	NUMBER OF BLOOD DONATIONS COLLECTED THROUGH APHERESIS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST-TIME	REPEAT		
AIA	0	0	0	0
ATG	NR	NR	NR	NR
ABW	0	0	0	0
BHS	0	0	0	0
BRB	86			0
BLZ	0	0	0	0
BMU	0	154	0	0
VGB	0	0	0	0
CYM	0	0	0	0
CUW	0	0	0	0
DMA	0	0	0	0
GRD	0	0	0	0
GUY *2013	NR	NR	NR	NR
HTI	NR	NR	NR	NR
JAM	0	0	0	0
MSR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR
LCA	0	0	0	0
VCT	0	0	0	0
SUR	0	0	0	0
TCA	0	0	0	0
TTO	0	0	0	0

NR: Not Reported.

TABLE 4.3. NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL), 2014

COUNTRY	NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL)				
	LOW WEIGHT	LOW HAEMOGLOBIN	HIGH-RISK BEHAVIOR	TRAVEL HISTORY	OTHER
AIA	0	84	0	0	79
ATG	NR	NR	NR	NR	NR
ABW	NR	12	NR	NR	8
BHS*	45	935	54	18	222
BRB	NR	NR	NR	NR	NR
BLZ	NR	NR	NR	NR	NR
BMU	0	88	7	3	70
VGB	NR	NR	NR	NR	NR
CYM	0	110	1	8	35*
CUW	0	5	0	0	8
DMA	0	79	101	27	334*
GRD	0	61	1	0	45*
GUY *2013	NR	NR	NR	NR	NR
HTI	NR	NR	NR	NR	NR
JAM	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR
LCA	7	252	127	0	149
VCT	NR	368	NR	NR	NR
SUR	0	887	123	20	301*
TCA	0	7	0	0	7*
TTO	NR	NR	NR	NR	NR

BHS: Information from Princess Margaret Hospital.
CYM: Gout, Tattoo, slow bleed, antibiotics.
DMA: On medication/ fever.
GRD: Difficult venipuncture, low blood pressure, pregnancy.
SUR: Hypertension and recent vaccination.
TCA: Tatoo and alcohol consumption.
NR: Not Reported.

TABLE 4.4. NUMBER OF UNITS COLLECTED BY AGE GROUPS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED BY AGE GROUPS				
	UNDER 18 YEARS	18 TO 24 YEARS	25 TO 44 YEARS	45 TO 64 YEARS	65 YEARS OR OLDER
AIA	0	11	74	36	0
ATG	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR
BRB	NR	NR	NR	NR	NR
BLZ	NR	NR	NR	NR	NR
BMU	NR	NR	NR	NR	NR
VGB	NR	NR	NR	NR	NR
CYM	3	68	499	452	63
CUW	NR	NR	NR	NR	NR
DMA	0	148	183	681	4
GRD	2	204	736	331	0
GUY *2013	NR	NR	NR	NR	NR
HTI	NR	NR	NR	NR	NR
JAM	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR
LCA	5	341	789	251	6
VCT	NR	NR	NR	NR	NR
SUR	0	882	4,923	4,600	284
TCA	NR	NR	NR	NR	NR
TTO	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 4.5. NUMBER OF UNITS COLLECTED BY MALE AND FEMALE DONORS, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	
	MALE DONORS	FEMALE DONORS
AIA	110	11
ATG	NR	NR
ABW	1,147	573
BHS*	2,723	1,044
BRB	3,093	1,585
BLZ	NR	NR
BMU	615	987
VGB	NR	NR
CYM	616	455
CUW	4,516	2,112
DMA	715	301
GRD	1,008	178
GUY *2013	NR	NR
HTI	NR	NR
JAM	NR	NR
MSR	NR	NR
KNA *2013	NR	NR
LCA	1,534	922
VCT	753	246
SUR	2,750	1,372
TCA	248	106
TTO	NR	NR

BHS: Information from Hospital Princess Margaret.
NR: Not Reported.

TABLE 5. EFFICIENCY OF BLOOD PROCESSING, 2014

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF COLLECTING CENTERS	NUMBER OF PROCESSING CENTERS	ANNUAL PROCESSING PER BANK	DAILY PROCESSING PER BANK (260 DAYS)
AIA	121	1	1	121	0.46
ATG	NR	NR	NR	NR	NR
ABW	2,829	1	1	2,829	10.88
BHS	4,563	3	3	1,521	5.85
BRB	4,638	1	1	4,638	17.84
BLZ	4,329	7	1	4,329	16.65
BMU	1,602	1	1	1,602	6.16
VGB	350	1	1	350	1.35
CYM	1,071	2	2	536	2.06
CUW	6,628	1	1	6,628	25.49
DMA	1,006	NR	NR	NR	NR
GRD	1,267	1	1	1,267	4.87
GUY *2013	11,148	5	1	11,148	42.87
HTI	28,867	14	1	28,867	111.03
JAM	29,390	10	3	9,797	37.68
MSR	NR	NR	NR	NR	NR
KNA *2013	331	2	2	166	0.64
LCA	2,448	2	1	2,448	9.41
VCT	1,081	1	1	1,081	4.16
SUR	10,521	5	1	10,521	40.47
TCA	354	1	1	354	1.36
TTO	21,249	7	2	10,625	40.86

NR: Not Reported.

TABLE 6. COVERAGE (%) OF SCREENING FOR INFECTIOUS MARKERS, 2014

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	T. cruzi	HTLV I-II	Anti-HBc
AIA	100	100	100	100	NR	0	NR
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	100	100	100	100	NR	100	NR
BHS	100	100	100	100	0	100	0
BRB	100	100	100	100	0	100	0
BLZ	100	100	100	100	100	NR	NR
BMU	100	100	100	100	0.39	100	100
VGB	100	100	100	100	0	100	63.43
CYM	100	100	100	100	0	100	0
CUW	100	100	100	100	0	100	0
DMA	100	100	NR	100	NR	100	NR
GRD	100	100	100	100	0	100	0
GUY *2013	100	100	100	100	100	100	NR
HTI	100	100	100	100	0	100	0
JAM	100	100	100	100	0	100	0
MSR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	100	100	100	100	0	76.13	NR
LCA	100	100	100	100	0	100	0
VCT	85.70	85.70	85.70	85.70	0	85.70	0
SUR	100	100	100	100	100	100	0
TCA	100	100	100	100	0	100	100
TTO	NR	NR	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 7. PERCENTAGE OF UNITS NOT SCREENED FOR INFECTIOUS MARKERS, 2014

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	HTLV I-II
VCT	14.30	14.30	14.30	14.30	14.30
KNA *2013					23.87

TABLE 8. PROPORTION (%) OF REACTIVE/POSITIVE UNITS, 2014

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	Anti-HBc
AIA	NR	NR	NR	NR	NA	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	0	0	0	0	NA	0.035	NA
BHS	0	0.13	0.04	0.35	NA	0.09	NA
BRB	0.15	0.32	0.51	1.22	NA	0.43	NA
BLZ	0.16	0.51	0.23	0.67	0.19	NA	NA
BMU	0	0	0	0	0	0	0
VGB	0	0	0.57	0.86	NA	0.57	4.05
CYM	0	0.37	0	0.28	NA	1.21	NA
CUW	0	0	0	0	NA	0.015	NA
DMA	0	0.20	NR	1.89	NA	0.80	NA
GRD	0.32	0.71	0.24	0.24	NA	0	NA
GUY *2013	0.34	0.88	0.46	0.57	NR	0.83	NR
HTI	0.98	3.42	0.86	2.57	NA	0.69	NA
JAM	0.44	0.75	0.27	1.73	NA	1.51	NA
MSR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	0	3.63	0	0	NR	0	NR
LCA	0.08	1.26	0.12	1.75	NA	0.61	NA
VCT	0.10	0.80	0.30	2.70	NA	2.21	NA
SUR	0.01	0.09	0.03	0.03	0.01	0.02	NA
TCA	0.28	0.85	0	0.85	NA	0.28	5.65
TTO	NR	NR	NR	NR	NR	NR	NR

NA: Not Applicable. It is used in those countries that do not report prevalence of infectious markers because they do not perform those screening tests.
NR: Not Reported.

Figure 3. Proportion (%) of reactive/positive units, Caribbean 2014



TABLE 8.1. PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS, 2014

COUNTRY	PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST-TIME	REPEAT		
AIA	NR	NR	NR	NA
ATG	NR	NR	NR	NR
ABW	NR	NR	NA	NA
BHS	NR	NR	NR	NA
BRB	NR	NR	NR	NA
BLZ	NR	NR	NR	NA
BMU	NR	NR	NA	NA
VGB	NR	NR	NR	NR
CYM	0	0	NA	NA
CUW	0	0	NA	NA
DMA	0	0	0	NA
GRD	NR	NR	NR	NA
GUY *2013	NR	NR	NR	NA
HTI	NR	NR	NR	NA
JAM	NR	NR	NR	NA
MSR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NA
LCA	0	0.04	0.04	NA
VCT	0	0	0.10	NA
SUR	0.01		NA	NA
TCA	NR	NR	NR	NA
TTO	NR	NR	NR	NA

NR: Not Reported.

TABLE 9. SEPARATION INTO COMPONENTS (NUMBER), 2014

COUNTRY	UNITS RECEIVED	RBC	FFP	FP	CRYO	PL
AIA	121	79	0	0	0	0
ATG	NR	NR	NR	NR	NR	NR
ABW	2,829	2,829	416	0	0	2,327
BHS	3,767	3,767	1,416	0	0	1,350
BRB	4,588	1,023	1,023	0	14	945
BLZ	4,329	1,546	528	1,018	30	502
BMU	1,602	1,602*	358	NR	NR	153*
VGB	350	350	84	266	0	0
CYM	1,071	973	417	NR	NR	NR
CUW	6,628	6,628	5,100	0	0	1,200
DMA	1,006	510	510	0	0	475
GRD	1,267	1,255	50	20	0	142
GUY *2013	11,148	11,016	6,596	NR	670	3,531
HTI	28,867	18,037	18,037	0	0	497
JAM	29,390	20,077	14,649	1,971	2,047	6,316
MSR	NR	NR	NR	NR	NR	NR
KNA *2013	331	30	30	NR	NR	NR
LCA	2,456	2,450	813	0	0	1,080
VCT	999	982	191	0	0	191
SUR	10,689	10,517	2,190	0	0	2,634
TCA	354	227	219	2	0	6
TTO	NR	NR	NR	NR	NR	NR

BMU:Platelets were obtained through apheresis. 137 units of RBC, that were obtained through apheresis, are not included.
NR: Not Reported.

TABLE 9.1. BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER), 2014

COUNTRY	WB	RBC	FFP	FP	CRYO	PL
AIA	10	0	NA	NA	NA	NA
ATG	NR	NR	NR	NR	NR	NR
ABW	0	41	41	0	0	NR
BHS	0	234	253	0	0	341
BRB	313	135	NR	NR	NR	NR
BLZ	774	116	83	131	NR	272
BMU	28	66	49	NR	NR	101*
VGB	0	41	14	0	0	0
CYM	44	131	113	0	5	68
CUW	0	61	61	0	0	0
DMA	49	53	138	0	0	289
GRD	12	124	1	1,186	0	0
GUY *2013	153	1,102	98	NR	5	266
HTI	2,327	NR	NR	NR	NR	NR
JAM	0	1,247	527	11	62	278
MSR	NR	NR	NR	NR	NR	NR
KNA *2013	63	7	7	NR	NR	NR
LCA	116	89	0	0	0	560
VCT	3	112	11	0	0	125
SUR	0	76	26	0	0	476
TCA	28	182	0	0	0	0
TTO	NR	NR	NR	NR	NR	NR

BMU: The units of platelets discarded were obtained through apheresis.
NR: Not Reported.

TABLE 10. AVAILABILITY OF BLOOD COMPONENTS (%), 2014

COUNTRY	% SEPARATED INTO COMPONENTS					% BLOOD AND BLOOD COMPONENTS DISCARDED					
	RBC	FFP	FP	CRYO	PL	WB	RBC	FFP	FP	CRYO	PL
AIA	65.29	0	0	0	0	8.26	0	NA	NA	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	100	14.70	0	0	82.25	0	1.45	9.86	NA	NA	NR
BHS	100	37.59	0	0	35.84	0	6.21	17.87	NA	NA	25.26
BRB	22.30	22.30	0	0.31	20.60	6.82	13.20	0	NA	0	0
BLZ	35.71	12.20	23.52	0.69	11.60	17.88	7.50	15.72	12.87	0	54.18
BMU	100	22.35	0	0	9.55*	2.19	4.12	13.69	NA	NA	66.01
VGB	100	24	76	0	0	0	11.71	16.67	0	NA	NA
CYM	90.85	38.94	0	0	0	4.11	13.46	27.10	NA	NA	NA
CUW	100	76.95	0	0	18.11	0	0.92	1.20	NA	NA	0
DMA	50.70	50.70	0	0	47.22	4.87	10.39	27.06	NA	NA	60.84
GRD	99.05	3.95	1.58	0	11.21	0.95	9.88	2	NA*	NA	0
GUY *2013	98.82	59.17	NR	6.01	31.67	NR	10	1.49	NR	0.75	7.53
HTI	62.48	62.48	0	0	1.72	8.06	NR	NR	NA	NA	NR
JAM	68.31	49.84	6.71	6.96	21.49	0	6.21	3.60	0.56	3.03	4.40
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	9.10	9.10	NR	NR	NR	NR	23.33	23.33	NR	NR	NR
LCA	99.76	33.10	0	0	43.97	4.72	3.63	0	NA	NA	51.85
VCT	98.30	19.12	0	0	19.12	0.30	11.41	5.76	NA	NA	65.45
SUR	98.39	20.49	0	0	24.64	0	0.72	1.19	NA	NA	18.07
TCA	64.12	61.86	0.57	0	1.70	7.91	80.18	0	0	NA	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

BMU:Platelets were obtained through apheresis.
GRD: The units of FP discarded include units that were separated/prepared in previous years.
*NA: Used in those cases where there are no blood components discarded because those components were not separated/prepared. NA is also used in those cases were discarded units include units that were separated/prepared in previous years.
NR: Not Reported.

Figure 4. Percentage of blood and blood components discarded, Caribbean 2014



TABLE 10.1. BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES, 2014

COUNTRY	BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES		
	RBC	PLATELETS	PLASMA
AIA	0	0	0
ATG	NR	NR	NR
ABW	0	0	0
BHS	0	0	0
BRB	0	86	0
BLZ	0	0	0
BMU	137	153	150
VGB	0	0	0
CYM	0	0	0
CUW	0	0	0
DMA	0	0	0
GRD	0	0	0
GUY *2013	NR	NR	NR
HTI	0	0	0
JAM	0	0	0
MSR	NR	NR	NR
KNA *2013	NR	NR	NR
LCA	0	0	0
VCT	0	0	0
SUR	0	0	0
TCA	0	0	0
TTO	0	0	0

NR: Not Reported.

TABLE 10.2. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER), 2014

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER)																	
	WB			RBC			FFP			FP			CRYO			PL		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
AIA	9	0	1	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	0	0	0	40	1	0	40	1	0	0	0	0	0	0	0	0	0	0
BHS	0	0	0	72	117	45	25	117	111	0	0	0	0	0	0	197	117	27
BRB	186	102	25	81	17	37	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	443	305	26	88	23	5	42	23	18	57	0	74	NR	NR	NR	246	23	3
BMU	0	0	35	53	6	7	15	0	34	NR	NR	NR	NR	NR	NR	101	0	0
VGB	0	0	0	27	14	0	0	14	0	0	0	0	0	0	0	0	0	0
CYM	30	14	0	122	9	0	102	9	2	0	0	0	5	0	0	68	0	0
CUW	0	0	0	60	1	0	60	1	0	0	0	0	0	0	0	0	0	0
DMA	30	18	1	37	13	3	122	13	3	0	0	0	0	0	0	276	10	3
GRD	0	12	0	92	32	0	0	1	0	1	0	1,185	0	0	0	0	0	0
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HTI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
JAM	0	0	0	113	907	227	0	454	73	0	3	8	0	57	5	67	168	43
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	0	116	0	89	0	0	0	0	0	0	0	0	0	0	0	560	0	0
VCT	3	0	0	41	61	10	0	11	0	0	0	0	0	0	0	114	11	0
SUR	0	0	0	15	28	33	0	24	2	0	0	0	0	0	0	451	25	0
TCA	0	28	0	174	0	8	0	0	0	0	0	0	0	0	0	0	0	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 10.3. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE), 2014

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE)																	
	WB			RBC			FFP			FP			CRYO			PL		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
AIA	90	0	10	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	0	0	0	97.56	2.44	0	97.56	2.44	0	0	0	0	0	0	0	0	0	0
BHS	0	0	0	30.77	50	19.23	9.88	46.25	43.87	0	0	0	0	0	0	57.77	34.31	7.92
BRB	59.42	32.59	7.99	60	12.59	27.41	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	57.24	39.40	3.36	75.86	19.83	4.31	50.60	27.71	21.69	43.51	0	56.49	NR	NR	NR	90.44	8.46	1.10
BMU	0	0	100	80.30	9.10	10.6	30.61	0	69.39	NR	NR	NR	NR	NR	NR	100	0	0
VGB	0	0	0	65.85	34.15	0	0	100	0	0	0	0	0	0	0	0	0	0
CYM	68.18	31.82	0	93.13	6.87	0	90.27	7.96	1.77	0	0	0	100	0	0	100	0	0
CUW	0	0	0	98.36	1.64	0	98.36	1.64	0	0	0	0	0	0	0	0	0	0
DMA	61.22	36.73	2.05	69.81	24.53	5.66	88.41	9.42	2.17	0	0	0	0	0	0	95.5	3.46	1.04
GRD	0	100	0	74.19	25.81	0	0	100	0	0.08	0	99.92	0	0	0	0	0	0
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HTI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
JAM	0	0	0	9.06	72.73	18.21	0	86.15	13.85	0	27.27	72.73	0	91.94	8.06	24.10	60.43	15.47
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	0	100	0	100	0	0	0	0	0	0	0	0	0	0	0	100	0	0
VCT	100	0	0	36.61	54.46	8.93	0	100	0	0	0	0	0	0	0	91.20	8.80	0
SUR	0	0	0	19.74	36.84	43.42	0	92.31	7.69	0	0	0	0	0	0	94.75	5.25	0
TCA	0	100	0	95.60	4.40	0	0	0	0	0	0	0	0	0	0	0	0	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 11. TRANSFUSION, 2014

COUNTRY	NUMBER OF COMPONENTS TRANSFUSED							
	WB	RBC	FFP	FP	CRYO	PL	APH-PL	APH-RBC
AIA	30	79	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR	NR	NR	NR
BRB	0	4,293	967	0	0	523	82	0
BLZ	1,978	1,863	651	170	30	222	0	0
BMU	0	1,630	307	0	0	0	52	0
VGB	NR	NR	NR	NR	NR	NR	NR	NR
CYM	11	1,066	350	0	6	0	35	0
CUW	NR	NR	NR	NR	NR	NR	NR	NR
DMA	7	954	86	0	0	186	0	0
GRD	1	520	44	4	0	21	0	0
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR
HTI	6,388	23,459	204	4	0	533	0	0
JAM	9,313	20,077	11,519	633	1,571	3,958	0	0
MSR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR
LCA	0	1,636	762	0	0	321	0	0
VCT	NR	NR	NR	NR	NR	NR	NR	NR
SUR	0	10,205	2,012	0	0	1,794	0	0
TCA	16	91	2	0	0	2	0	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR

APH-PL: Platelets by apheresis.
APH-RBC: Red Blood Cells by apheresis.
NR: Not Reported.

TABLE 11.1 HOSPITALS AND TRANSFUSIONS, 2014

COUNTRY	# OF TRANSFUSION SERVICES	# OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS	NUMBER OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS AND PARTICIPATE/HAVE:					
			TRANSFUSION COMMITTEE		CLINICAL AUDIT		SYSTEM FOR REPORTING ADVERSE REACTIONS	
			#	%	#	%	#	%
AIA	2	1	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR
ABW	1	1	1	100	1	100	1	100
BHS	3	NR	NR	NR	NR	NR	NR	NR
BRB	3	3	1	33.30	1	33.30	3	100
BLZ	13	13	NR	NR	NR	NR	NR	NR
BMU	1	1	1	100	1	100	1	100
VGB	2	2	0	0	0	0	1	50
CYM	4	4	0	0	0	0	0	0
CUW	1	3	3	100	3	100	3	100
DMA	1	1	NR	NR	NR	NR	NR	NR
GRD	NR	NR	NR	NR	NR	NR	NR	NR
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR
HTI	37	90	20	22.22	0	0	0*	0
JAM	1	41	0	0	0	0	NR	NR
MSR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NR	3	NR	NR	NR	NR	NR	NR
VCT	1	3	NR	NR	NR	NR	1	33.33
SUR	5	5	5	100	0	0	5	100
TCA	1	2	2	100	0	0	2	100
TTO	NR	NR	NR	NR	NR	NR	NR	NR

HTI: In process of implementation.
NR: Not Reported.

TABLE 11.2. NUMBER OF PATIENTS TRANSFUSED BY AGE, 2014

COUNTRY	# OF PATIENTS TRANSFUSED IN THE COUNTRY	NUMBER OF PATIENTS TRANSFUSED BY AGE				
		<5	05 - 14	15-44	45-59	>60
AIA	44	0	0	12	11	21
ATG	NR	NR	NR	NR	NR	NR
ABW	1,600	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR	NR
BRB	NR	NR	NR	NR	NR	NR
BLZ	4,408	301	227	1,599	1,741	540
BMU	450	3	2	85	94	266
VGB	NR	NR	NR	NR	NR	NR
CYM	314	10	2	88	50	164
CUW	3,500	NR	NR	NR	NR	NR
DMA	1,233	81	17	343	277	515
GRD	NR	NR	NR	NR	NR	NR
GUY *2013	NR	NR	NR	NR	NR	NR
HTI	NR	NR	NR	NR	NR	NR
JAM	NR	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR
LCA*	559	39	7	203	118	192
VCT	NR	NR	NR	NR	NR	NR
SUR	NR	NR	NR	NR	NR	NR
TCA	111	NR	NR	NR	NR	NR
TTO	NR	NR	NR	NR	NR	NR

LCA: Data from 2 of the 3 hospitals that perform blood transfusions in the country.
NR: Not Reported.

TABLE 11.3. ADVERSE TRANSFUSION REACTIONS, 2014

COUNTRY	ADVERSE TRANSFUSION REACTIONS															
	Haemolysis due to ABO incompatibility	Haemolysis due to other allo-antibody	Non-immunological haemolysis	Post-transfusion purpura	Anaphylaxis-hypersensitivity	TRALI	Graft versus host disease	Transfusion-associated HIV infection	Transfusion-associated HBV infection	Transfusion-associated HCV infection	Other transfusion-associated viral infection	Sepsis due to bacterial contamination	Transfusion-associated malaria infection	Other parasitical infection	Transfusion-associated circulatory overload	Other serious adverse transfusion reaction
AIA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	0	3	0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BRB	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	NR	3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BMU	NR	NR	NR	NR	3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
VGB	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CYM	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CUW	0	3	0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DMA	0	0	0	0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GRD	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HTI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
JAM	0	NR	NR	NR	NR	NR	NR	0	0	0	0	0	0	0	NR	0
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
VCT	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
SUR	NR	NR	NR	NR	NR	NR	0	0	0	0	0	0	0	0	0	0
TCA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 12. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: LAW, POLICY AND COORDINATION, 2014

COUNTRY	SPECIFIC LAW	RESPONSIBLE UNIT	SPECIFIC BUDGET	NATIONAL POLICY	NATIONAL COMMISSION
AIA	NO	NO	NO	NO	NO
ATG	NR	NR	NR	NR	NR
ABW	YES	YES	YES	YES	YES
BHS	NO	NO	NO	NO	YES
BRB	NR	NR	NR	NR	NR
BLZ	NO	YES	NO	NO	NO
BMU	YES	YES	YES	YES	YES
VGB	NO	NO	NO	NO	NO
CYM	NO	NO	NO	NO	NO
CUW	YES	NO	NO	YES	NO
DMA	NR	NR	NR	NR	NR
GRD	NO	NO	NO	NO	NO
GUY *2013	NO	YES	YES	NO	NO
HTI	NO	YES	YES	YES	YES
JAM	NO	YES	YES	YES	NO
MSR	NR	NR	NR	NR	NR
KNA *2013	NO	NO	NO	NO	NO
LCA	NO	NO	NO	NO	NO
VCT	NO	NO	NO	NO	NO
SUR	YES	NO	YES	YES	YES
TCA	NO	YES	YES	NO	NO
TTO	NO	YES	YES	YES	NO

NR: Not Reported.

TABLE 13. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: GUIDELINES, NORMS AND INFORMATION SYSTEM, 2014

COUNTRY	REFERENCE CENTER	NATIONAL PLAN	DONOR NORMS	OPERATION NORMS	CLINICAL GUIDELINES	SERVICE REGISTRATION	INFORMATION SYSTEM
AIA	NO	NO	YES	NO	NO	NO	NO
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	YES	YES	YES	NO	YES	YES	NO
BHS	NO	YES	YES	NO	NO	YES	YES
BRB	NR	NR	NR	NR	NR	NR	NR
BLZ	YES	NO	YES	NO	NO	YES	YES
BMU	NO	YES	YES	YES	YES	YES	YES
VGB	NO	NO	YES	YES	NO	NO	NO
CYM	NO	NO	YES	YES	NO	NO	NO
CUW	YES	YES	YES	NO	YES	YES	NO
DMA	NR	NR	NR	NR	NR	NR	NR
GRD	NO	NO	YES	NO	NO	YES	NO
GUY *2013	NO	NO	YES	NO	NO	NR	NR
HTI	YES	YES	YES	YES	YES	NO	NO
JAM	YES	YES	YES	YES	YES	YES	NO
MSR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	YES	NO	NO	NO	NO	NO	NR
LCA	YES	NO	YES	YES	NO	NO	NR
VCT	NO	NO	NO	NO	NO	NO	NO
SUR	NO	NO	YES	YES	NO	YES	YES
TCA	NO	NO	YES	NO	NO	NO	NO
TTO	YES	NO	NO	YES	YES	YES	NO

NR: Not Reported.

TABLE 14. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: QUALITY, 2014

COUNTRY	QUALITY ASSURANCE POLICY	NATIONAL QUALITY MANAGEMENT PROGRAM	NATIONAL PROGRAM OF EXTERNAL EVALUATION SEROLOGY-TTI	NATIONAL PROGRAM OF EXTERNAL EVALUATION IMMUNOHEMATOLOGY	INSPECTION PROGRAM	CONTINUED EDUCATION
AIA	PARTIAL*	NO	YES	NO	NO	NR
ATG	NR	NR	YES	NR	NR	NR
ABW	YES	YES	NO	YES	YES	YES
BHS	NO	NO	NO	NO	NO	NO
BRB	NR	NR	YES	YES	NR	NR
BLZ	NO	NO	YES	NO	YES	NO
BMU	YES	YES	NO	NO	YES	YES
VGB	NO	NO	NO	NO	NO	NO
CYM	YES	YES	NO	NO	YES	YES
CUW	YES	YES	YES	YES	YES	YES
DMA	NR	NR	YES	NR	NR	NR
GRD	NO	NO	YES	NO	NO	NO
GUY *2013	NO	NR	YES	YES	NO	YES
HTI	NO	NO	YES	YES	NO	YES
JAM	YES	YES	NO	NO	NO	YES
MSR	NR	NR	YES	NR	NR	NR
KNA *2013	NO	NR	NO	NO	NO	NO
LCA	NO	NO	YES	YES	NO	NO
VCT	NO	NO	YES	YES	NO	NO
SUR	NO	YES	YES	YES	NO	YES
TCA	NO	NO	NO	NO	NO	PARTIAL*
TTO	YES	NO	YES	NO	NO	NO

AIA: There is a quality assurance policy for the laboratory.
TCA: In development process.
NR: Not Reported.

TABLE 15. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: CERTIFICATION AND ACCREDITATION, 2014

COUNTRY	STAFF CERTIFICATION	SERVICE ACCREDITATION
AIA	NO	NO
ATG	NR	NR
ABW	NO	NO
BHS	YES	NO
BRB	NR	NR
BLZ	NO	NO
BMU	YES	YES
VGB	NO	NO
CYM	YES	YES
CUW	NO	NO
DMA	NR	NR
GRD	NO	NO
GUY *2013	YES	NO
HTI	NO	NO
JAM	YES	NO
MSR	NR	NR
KNA *2013	NO	NO
LCA	YES	NO
VCT	NO	NO
SUR	YES	NO
TCA	YES	NO
TTO	NO	NO

NR: Not Reported.

TABLE 16. ORGANIZATION OF THE TRANSFUSION SERVICES AND HAEMOVIGILANCE, 2014

COUNTRY	NATIONAL TRANSFUSION COMMITTEE	INTRAHOSPITAL TRANSFUSION COMMITTEE	NATIONAL HAEMOVIGILANCE PROGRAM	BLOOD UNITS NEEDED TO COVER THE NATIONAL REQUIREMENTS
AIA	NO	PARTIAL*	NO	NR
ATG	NR	NR	NR	NR
ABW	NO	NO	YES	YES
BHS	NO	NO	NO	NR
BRB	NR	NR	NR	NR
BLZ	NO	NO	NO	NR
BMU	YES	YES	YES	NO
VGB	NO	NO	NO	NO
CYM	NO	NO	NO	YES
CUW	NO	NO	YES	YES
DMA	NR	NR	NR	NR
GRD	NO	NO	NO	NR
GUY *2013	NR	NR	NR	NR
HTI	NO	YES	NO	YES
JAM	NO	NO	PARTIAL*	YES
MSR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR
LCA	NO	NO	NO	NR
VCT	NO	NO	NO	YES
SUR	YES	YES	NO	YES
TCA	NO	YES	NO	YES
TTO	NO	PARTIAL*	NO	NO

AIA: In process of reactivation of the Intrahospital Transfusion Committee.
JAM: In process of implementation.
TTO: The public facilities have a transfusion committees.
NR: Not Reported.

TABLE 17. FINANCING AND COSTS OF BLOOD SERVICES, 2014

COUNTRY	ANNUAL REPORT ON ACTIVITIES	SYSTEM OF COST-RECOVERY	FINANCIAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	TECHNICAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	ESTIMATED TOTAL FUNDING (IN US DOLLARS)				APPROXIMATE COST (IN US DOLLARS) OF PRODUCING:	
					TOTAL	FROM THE NATIONAL GOVERNMENT	FROM FEES AND COST RECOVERY	FROM EXTERNAL DONORS	WHOLE BLOOD	RED BLOOD CELLS
AIA	NO	YES	NO	YES	NR	NR	NR	NR	350	350
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BHS	NO	NO	NO	NO	NR	NR	NR	NR	185	160
BRB	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	YES	NO	NO	YES	NR	NR	NR	NR	NR	NR
BMU	NO	NO	NO	YES	636,199	NR	NR	NR	262.94	262.94
VGB	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
CYM	NO	YES	NO	YES	NR	NR	NR	NR	300	320
CUW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DMA	NO	NR	NO	NO	NR	NR	NR	NR	NR	NR
GRD	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HTI	YES	NO	YES	YES	2,750,000	150,000	0	2,600,000	95	NR
JAM	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
VCT	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
SUR	NO	YES	YES	YES	1,444,000	229,000	1,215,000	200,000	NR	71
TCA	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
TTO	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 18. STOCKS OF CONSUMABLES, 2014

COUNTRY	DID STOCKS OF ANY OF THE FOLLOWING CONSUMABLES RUN OUT:			
	BLOOD COLLECTION BAGS	TEST KITS FOR TRANSFUSION-TRANSMISSIBLE INFECTIONS	REAGENTS FOR ROUTINE BLOOD GROUPING	OTHERS
AIA	NO	NO	NO	NR
ATG	NR	NR	NR	NR
ABW	NR	NR	NR	NR
BHS	NO	YES	NO	NR
BRB	NR	NR	NR	NR
BLZ	NO	YES	NO	NR
BMU	NO	NO	NO	NO
VGB	NO	NO	NO	NR
CYM	NO	NO	NO	NR
CUW	NR	NR	NR	NR
DMA	NO	NO	NO	NR
GRD	NO	NO	NO	NR
GUY *2013	NR	NR	NR	NR
HTI	NO	YES	YES	NR
JAM	NO	YES	NO	NO
MSR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR
LCA	YES	YES	YES	NO
VCT	YES	YES	NO	YES*
SUR	NO	NO	NO	NO
TCA	NO	NO	NO	NR
TTO	YES	NR	NR	NR

VCT: COOMBS ANTI-IgG CARDS USED FOR X-MATCHING.
NR: Not Reported.

TABLE 19. NOTIFICATION SYSTEM, 2014

COUNTRY	SPECIFIC BUDGET FOR THE BLOOD DONOR PROGRAMME	CELEBRATION OF WORLD BLOOD DONOR DAY	REGISTER-DATABASE FOR BLOOD DONORS	NATIONAL DONOR SELECTION CRITERIA	DONOR NOTIFICATION SYSTEM FOR TEST RESULTS					SYSTEM OF POST-DONATION COUNSELLING AND REFERRAL TO CARE AND TREATMENT
					HIV	HEPATITIS B	HEPATITIS C	SYPHILIS	OTHER	
AIA	NO	YES	YES	YES	NO	NO	NO	NO	NO	YES
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BHS	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
BRB	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	NO	YES	YES	YES	YES	YES	YES	YES	Chagas and Malaria	YES
BMU	YES	YES	YES	YES	YES	YES	YES	YES	HTLV , Chagas and West Nile Virus	YES
VGB	NO	NO	YES	NO	YES	YES	YES	YES	NR	YES
CYM	NO	YES	YES	YES	YES	YES	YES	YES	HTLV	YES
CUW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DMA	NO	YES	YES	YES	YES	YES	NR	YES	HTLV	YES
GRD	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HTI	YES	YES	YES	YES	YES	YES	YES	YES	HTLV I-II	NO
JAM	NO	YES	YES	YES	YES	YES	YES	YES	HTLV	YES
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NO	NO	YES	YES	YES	YES	YES	YES	NR	YES
VCT	NO	YES	NO	NO	NO	NO	NO	NO	NO	YES
SUR	YES	YES	YES	YES	YES	YES	YES	YES	HTLV, Malaria and Chagas	YES
TCA	YES	YES	YES	YES	YES	YES	YES	YES	NR	YES
TTO	NO	YES	YES	YES	YES	YES	YES	NO	HTLV I-II and Chagas	YES

NR: Not Reported.

TABLE 20. ORGANIZATION OF THE BLOOD SERVICES, 2014

COUNTRY	# OF BLOOD SERVICES IN THE COUNTRY			# OF BLOOD SERVICES COVERED BY THIS REPORT			PERCENTAGE OF BLOOD DONATIONS COVERED BY THIS REPORT
	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	
AIA	0	1	1	0	1	1	100
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	1	0	1	1	0	1	100
BHS	0	3	3	0	2	2	70
BRB	0	1	1	0	1	1	NR
BLZ	1	12	13	1	7	8	NR
BMU	0	1	1	0	1	1	100
VGB	0	1	1	0	1	1	NR
CYM	2	2	4	2	2	4	NR
CUW	1	0	1	1	0	1	NR
DMA	0	1	1	0	1	1	NR
GRD	0	1	1	0	1	1	NR
GUY *2013	NR	NR	NR	NR	NR	NR	NR
HTI	9	6	15	9	6	15	95*
JAM	1	9	10	1	9	10	100
MSR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR
LCA	NR	NR	NR	0	2	2	NR
VCT	0	1	1	0	1	1	NR
SUR	1	0	1	1	0	1	100
TCA	1	1	2	1	1	2	NR
TTO	1	5	6	1	5	6	100

HTI: Doctors without borders collected 2000 blood units that represent 5% of the total collection.
NR: Not Reported.

TABLE 21. COUNTRIES WITH 100% SCREENING FOR INFECTIOUS MARKERS, 2014

HIV	HBsAg	HCV	SYPHILIS	HTLV I-II
AIA	AIA	AIA	AIA	
ABW	ABW	ABW	ABW	ABW
BHS	BHS	BHS	BHS	BHS
BRB	BRB	BRB	BRB	BRB
BLZ	BLZ	BLZ	BLZ	
BMU	BMU	BMU	BMU	BMU
VGB	VGB	VGB	VGB	VGB
CYM	CYM	CYM	CYM	CYM
CUW	CUW	CUW	CUW	CUW
DMA	DMA	DMA	DMA	DMA
GRD	GRD	GRD	GRD	GRD
GUY	GUY	GUY	GUY	GUY
HTI	HTI	HTI	HTI	HTI
JAM	JAM	JAM	JAM	JAM
KNA	KNA	KNA	KNA	
LCA	LCA	LCA	LCA	LCA
SUR	SUR	SUR	SUR	SUR
TCA	TCA	TCA	TCA	TCA
18	**18**	**18**	**18**	**15**

TABLE 22. PLASMA DERIVED MEDICAL PRDUCTS (PDMP), 2014

COUNTRY	THE ESSENTIAL MEDICINES LIST INCLUDES THE FOLLOWING PDMP:					PROVISION OF PDMP FOR THE COVERAGE OF THE COUNTRY NEEDS:		
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS	FRACTIONATION (DOMESTIC OR/ AND CONTRACT) OF PLASMA COLLECTED IN THE COUNTRY	PLASMA COLLECTED IN THE COUNTRY WAS SOLD TO THE MANUFACTURERS OF PDMP, AND PRODUCTS ARE PURCHASED FROM PDMP SUPPLIERS	NO PLASMA COLLECTED IN THE COUNTRY ARE USED FOR FRACTIONATION AND ALL PDMP PRODUCTS ARE IMPORTED FROM ABROAD
AIA	NO	NO	NO	NO	NR	NO	NO	YES
ATG	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NO	NO	NO	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR	NR	NR	NR
BRB	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	NR	NR	NR	NR	NR	NR	NR	NR
BMU	YES	YES	YES	YES	Coagulation Factor VIIa (Recombinant), Rh Immunoglobulin, Fibrinogen Concentrate	NO	NO	YES
VGB	NR	NR	NR	NR	NR	NO	NO	YES
CYM	YES	YES	YES	YES	Tissue Plasminogen Activator, Caffeine Citrate	NO	YES	YES
CUW	NR	NO	NO	NO	NR	NR	NR	NR
DMA	NO	NO	NO	NO	NO	NO	NO	YES
GRD	NR	NR	NR	NR	NR	NR	NR	NR
GUY *2013	NR	NR	NR	NR	NR	NR	NR	NR
HTI	NO	NO	NO	NO	NO	NO	NO	NO
JAM	YES	YES	YES	YES	NO	NO	NO	NO
MSR	NR	NR	NR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NO	NO	NO	NO	NR	NO	NO	YES
VCT	NR	NR	NR	NR	NR	NO	NO	YES
SUR	NO	NO	NR	NR	NR	NO	NO	YES
TCA	NO	NO	NO	NO	NO	NO	NO	NR
TTO	NR	NO	NO	NO	NO	NO	NO	NO

NR: Not Reported.

TABLE 23. PLASMA FRACTIONATION, 2014

COUNTRY	PLASMA FRACTIONATION		
	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE PUBLIC/NOT FOR PROFIT SECTOR	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE FOR-PROFIT SECTOR	THERE IS AN AGREEMENT WITH ANOTHER COUNTRY FOR THE SHIPPING OF PLASMA TO BE FRACTIONED
AIA	NR	NR	NR
ATG	NR	NR	NR
ABW	NO	NO	NO
BHS	NR	NR	NR
BRB	NR	NR	NR
BLZ	NO	NO	NO
BMU	NR	NR	NR
VGB	NR	NR	NR
CYM	NR	NR	NR
CUW	NO	NO	NO
DMA	NO	NO	NO
GRD	NR	NR	NR
GUY *2013	NR	NR	NR
HTI	NO	NO	NO
JAM	NR	NR	NR
MSR	NR	NR	NR
KNA *2013	NR	NR	NR
LCA	NR	NR	NR
VCT	NO	NO	NO
SUR	NR	NR	NR
TCA	NR	NR	NR
TTO	NR	NR	NR

NR: Not Reported.

TABLE 24. PLASMA MANUFACTURING OF PDMP, 2014

COUNTRY	MANUFACTURING OF PDMP				
	PDMP MANUFACTURED BY FRACTIONATION WITHIN THE COUNTRY OR THROUGH CONTRACT FRACTIONATION				
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS
AIA	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR
ABW	NO	NO	NO	NO	NO
BHS	NR	NR	NR	NR	NR
BRB	NR	NR	NR	NR	NR
BLZ	NR	NR	NR	NR	NR
BMU	NR	NR	NR	NR	NR
VGB	NR	NR	NR	NR	NR
CYM	NR	NR	NR	NR	NR
CUW	NO	NO	NO	NO	NO
DMA	NR	NR	NR	NR	NR
GRD	NR	NR	NR	NR	NR
GUY *2013	NR	NR	NR	NR	NR
HTI	NO	NO	NO	NO	NO
JAM	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR
KNA *2013	NR	NR	NR	NR	NR
LCA	NR	NR	NR	NR	NR
VCT	NO	NO	NO	NO	NO
SUR	NR	NR	NR	NR	NR
TCA	NR	NR	NR	NR	NR
TTO	NR	NR	NR	NR	NR

NR: Not Reported.

2014 NATIONAL STAFF WHO SUBMITTED THE OFFICIAL REPORT TO THE PAN AMERICAN HEALTH ORGANIZATION
CARIBBEAN COUNTRIES

COUNTRY	NAME	POSITION	ADDRESS
ANGUILLA	Everette Duncan	Coordinator, Laboratory Services	Princess Alexandra Hospital Stoney Ground Tel. 1 264 497 2551 Email: evie@anguillanet.com
ARUBA	A.J. Duits	Director	Aruba Blood Bank Foundation Dr. Horacio Oduber Boulevard #1 Tel. 2975870002 Email: ajduits@gmail.com
BAHAMAS	George Bruney	Director of Pathology and Laboratory Medicine	Princess Margaret Hospital Shirley Street Tel. 1242-322-2861 EXT 1234 Email: gbruney@pmh.phabahamas.org
BARBADOS	Adrian Howard	Senior Laboratory Technologist	Queen Elizabeth Hospital Martindale Road, Bridgetown, Saint Michael Tel. 2468363959 Email: yowardan@hotmail.com
BELIZE	Joy Robateau	Senior Medical Laboratory Technologist	Belize National Blood Transfusion Services Princess Margaret Drive Tel. 501-224-5010 Email: j_robateau@yahoo.com
BERMUDA	Cheryl Peek-Ball	Chief Medical Officer	Ministry of Health, Seniors and Environment Continental Building, 25 Church Street, Hamilton HM12 Tel. (441) 278-4900 Email: cepeekball@gov.bm
BRITISH VIRGIN ISLANDS	Allene Brewley-Roach	Laboratory Director	Peebles Hospital (BVIHSA) # 32 Main Street Tel. 284-852-7500 Email: peebleslab@hotmail.com
CAYMAN ISLANDS	Judith Clarke	Laboratory Manager	Cayman Island Health Services Authority 95 Hospital Road, PO Box 915, Grand Cayman, KY1-1103 Tel. 13452442670 Email: judith.clarke@hsa.ky
CURACAO	A.J. Duits	Director	Red Cross Blood Bank Foundation Pater Euwensweg 36 Tel. 59994618433 Email: ajduits@gmail.com

COUNTRY	NAME	POSITION	ADDRESS
DOMINICA	Richard Anselm	Lab Technologist	PMH Laboratory Federation Drive Roseau Tel. 17672662144 Email: pmhlab@dominica.gov.dm
GRENADA	B. MC Barnette	Haemotologist	General Hospital St. Georges Tel: 473 435 1976 E-mail: bcgmcbarnette@yahoo.com
GUYANA	Nadia Liu	Medical Director	National Blood Transfusion Services Lamaha & East Streets, Georgetown, Guyana Tel. 592 223 7182 Email: nliu@health.gov.gy
HAITI	Ernst NOEL	Directeur	Programme National de Sécurité Transfusionnelle/MSPP 1, Angle Rue Jacques Roumain et Ave Mais Gate, Delmas, Haiti Tel. (509)2227-4137 Email: pnst@mspp.gouv.ht
JAMAICA	Veronica Taylor	Acting Director	National Blood Transfusion Service 21 Slipe Pen Road Tel. (876)922 5181 Email: veronicataylor201@hotmail.com
ST. KITTS AND NEVIS	Candace Gumbs	Laboratory Manager	Pathology Laboratory - Joseph N France General Hospital Buckley's Site, Basseterre, St Kitts Tel. 869-465-2551 Ext 163 Email: pathlab@yahoo.com
SAINT LUCIA	Veronica Lee	Medical Technologist	St Lucia Blood Bank Service Victoria Hospital Tel. (758)452-5430 Email: slubloodbank@gmail.com
ST. VINCENT AND THE GRENADINES	Kamarla Questelles	Medical Technologist	Blood Bank, Mcmh Pathology Laboratory Bentick Square, Kingstown Tel. 784-456-1185 EXT 149 Email: KQUESTELLES@YAHOO.COM
SURINAME	Maria Tjon A Loi	Medical director	National Blood Bank of the Suriname Red Cross Society Rode Kruislaan 24 Tel. 597 499175 Email: Maria.Tjonaloi@redcross.sr
TURKS AND CAICOS	Peggy . P. Samuels	Chief Medical Technologist	National Blood Bank, Turks and Caicos Islands Arch Plaza Tel. 1649- 338-5132 Email: ppsamuels@gov.tc
TRINIDAD AND TOBAGO	Adanna John-Caraballo Young	Nurse Manager	The National Blood Transfusion Service 160 Charlotte Street, Port of Spain Tel. 1 (868) 627-2619 *Email: adana.john-young@health.gov.tt*

LATIN AMERICAN COUNTRIES 2015

TABLE 1. BLOOD COLLECTION, 2015

COUNTRY	TOTAL UNITS COLLECTED	NUMBER OF DONORS				BLOOD DONATION RATE PER 1000 PEOPLE*
		AUTOLOGOUS	ALLOGENEIC			
			VOLUNTARY	REPLACEMENT	REMUNERATED	
ARG	1,026,845	1,166	468,361	557,318	0	24.36
BOL	108,132	60	44,188	63,884	0	9.81
BRA	3,098,338	9,216	1,892,114	1,197,008	0	15.21
CHL	239,549	0	68,176	171,373	0	13.36
COL	795,792	104	725,209	70,479	0	16.07
CRI	75,733	1	45,733	29,999	0	15.14
CUB	416,923	0	416,923	0	0	37.06
ECU	246,887	118	168,464	78,305	0	15.21
SLV	92,882	63	15,810	77,009	0	14.45
GTM	126,244	22	6,870	119,352	0	7.77
HND	71,646	9	13,326	57,624	687	8.50
MEX	2,170,002	2,269	82,365	2,085,368	0	17.33
NIC	74,955	0	74,955	0	0	11.98
PAN	56,313	19	3,970	49,340	2,984	14.12
PRY	86,120	123	8,819	77,178	0	12.24
PER	NR	NR	NR	NR	NR	NR
DOM	78,533	18	9,126	69,330	59	7.37
URY	90,669	198	46,534	43,937	0	26.43
VEN	299,879	NR	17,420	282,459	0	9.58

*Demographic data is obtained from: Pan American Health Organization/World Health Organization, Communicable Diseases and Health Analysis/ Health Information and Analysis. Health Situation in the Americas: Basic Indicators 2014. Washington, D.C., United States of America, 2015.
NR: Not Reported.

TABLE 2. BLOOD COLLECTION FROM ALLOGENEIC DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	TYPE OF ALLOGENEIC DONOR (PERCENTAGE)		
		VOLUNTARY	REPLACEMENT	REMUNERATED
ARG	1,025,679	45.66	54.34	0
BOL	108,072	40.89	59.11	0
BRA	3,089,122	61.25	38.75	0
CHL	239,549	28.46	71.54	0
COL	795,688	91.14	8.86	0
CRI	75,732	60.39	39.61	0
CUB	416,923	100	0	0
ECU	246,769	68.27	31.73	0
SLV	92,819	17.03	82.97	0
GTM	126,222	5.44	94.56	0
HND	71,637	18.60	80.44	0.96
MEX	2,167,733	3.80	96.20	0
NIC	74,955	100	0	0
PAN	56,294	7.05	87.65	5.30
PRY	85,997	10.25	89.75	0
PER	NR	NR	NR	NR
DOM	78,515	11.62	88.30	0.08
URY	90,471	51.44	48.56	0
VEN	299,879	5.81	94.19	0

NR: Not Reported.

Figure 1. Percentage of blood collection ranked from greatest to least by voluntary donations, Latin America 2015



TABLE 2.1. BLOOD COLLECTION ACCORDING TO THE SITE, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
ARG	1,025,679	364,092	104,269	519,190	38,128	0	0
BOL	108,072	22,159	22,029	63,884	0	0	0
BRA	3,089,122	1,892,114	0	1,197,008	0	0	0
CHL	239,549	68,176	0	171,373	0	0	0
COL	795,688	155,429	569,780	70,479	0	0	0
CRI	75,732	13,086	32,647	28,051	1,948	0	0
CUB	416,923	416,923	0	0	0	0	0
ECU	246,769	48,122	120,342	77,156	1,149	0	0
SLV	92,819	9,620	6,190	77,009	0	0	0
GTM	126,222	1,699	5,171	116,344	3,008	0	0
HND	71,637	335	12,991	57,448	176	687	0
MEX	2,167,733	82,365	0	2,085,368	0	0	0
NIC	74,955	11,835	63,120	0	0	0	0
PAN	56,294	1,221	2,749	49,038	302	2,984	0
PRY	85,997	3,320	5,499	77,178	0	0	0
PER	NR	NR	NR	NR	NR	NR	NR
DOM	78,515	9,079	47	69,317	13	59	0
URY	90,471	37,425	9,109	43,031	906	0	0
VEN	299,879	NR	NR	NR	NR	NR	NR

EM: Extramural.
NR: Not Reported.

TABLE 2.2. BLOOD COLLECTION ACCORDING TO THE SITE, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	PERCENTAGE OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
ARG	1,025,679	35.50	10.16	50.62	3.72	0	0
BOL	108,072	20.50	20.39	59.11	0	0	0
BRA	3,089,122	61.25	0	38.75	0	0	0
CHL	239,549	28.46	0	71.54	0	0	0
COL	795,688	19.53	71.61	8.86	0	0	0
CRI	75,732	17.28	43.11	37.04	2.57	0	0
CUB	416,923	100	0	0	0	0	0
ECU	246,769	19.50	48.77	31.27	0.46	0	0
SLV	92,819	10.36	6.67	82.97	0	0	0
GTM	126,222	1.35	4.10	92.17	2.38	0	0
HND	71,637	0.47	18.13	80.19	0.25	0.96	0
MEX	2,167,733	3.80	0	96.20	0	0	0
NIC	74,955	15.79	84.21	0	0	0	0
PAN	56,294	2.17	4.88	87.11	0.54	5.30	0
PRY	85,997	3.86	6.39	89.75	0	0	0
PER	NR	NR	NR	NR	NR	NR	NR
DOM	78,515	11.56	0.06	88.29	0.02	0.07	0
URY	90,471	41.37	10.07	47.56	1	0	0
VEN	299,879	NR	NR	NR	NR	NR	NR

EM: Extramural.
NR: Not Reported.

TABLE 3. SELECTION OF ALLOGENEIC DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS								
		VOLUNTARY			REPLACEMENT			REMUNERATED		
		INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE
ARG	1,025,679	514,510	45,169	980	683,598	124,510	1,770	NA	NA	NA
BOL	108,072	60,335	14,219	1,928	95,366	31,482	0	NA	NA	NA
BRA	3,089,122	2,326,194	434,080	0	1,500,854	303,846	0	NA	NA	NA
CHL	239,549	85,978	17,802	0	222,508	51,135	0	NA	NA	NA
COL	795,688	883,968	158,759	0	86,366	15,887	0	NA	NA	NA
CRI	75,732	53,922	8,055	134	44,688	14,094	595	NA	NA	NA
CUB	416,923	440,098	20,396	2,779	NA	NA	NA	NA	NA	NA
ECU	246,769	193,614	23,449	1,701	102,372	23,519	548	NA	NA	NA
SLV	92,819	18,472	2,563	99	105,853	28,475	369	NA	NA	NA
GTM	126,222	8,488	1,549	69	163,878	43,098	1,428	NA	NA	NA
HND	71,637	14,967	1,614	27	69,469	11,692	153	710	23	0
MEX	2,167,733	82,365	0	0	2,950,876	865,508	0	NA	NA	NA
NIC	74,955	82,902	7,499	448	NA	NA	NA	NA	NA	NA
PAN	56,294	3,970	NR	NR	50,147	747	60	2,984	NR	NR
PRY	85,997	9,266	447	NR	83,866	6,688	NR	NA	NA	NA
PER	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	78,515	11,206	2,078	2	90,749	21,417	2	84	25	0
URY	90,471	60,081	13,547	0	58,009	14,072	0	NA	NA	NA
VEN	299,879	NR	NR	NR	NR	NR	NR	NA	NA	NA

Incomplete: It refers to people selected as donors, but for whom the extraction/collection could not be performed or was performed incompletely (problems that may be encountered in accessing a vein, insufficient or exceeded volume, among others).
NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

TABLE 4. DEFERRAL OF ALLOGENEIC DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	VOLUNTARY		REPLACEMENT		REMUNERATED	
		NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED
ARG	1,025,679	514,510	8.78	683,598	18.21	NA	NA
BOL	108,072	60,335	23.57	95,366	33.01	NA	NA
BRA	3,089,122	2,326,194	18.66	1,500,854	20.24	NA	NA
CHL	239,549	85,978	20.71	222,508	22.98	NA	NA
COL	795,688	883,968	17.96	86,366	18.39	NA	NA
CRI	75,732	53,922	14.94	44,688	31.54	NA	NA
CUB	416,923	440,098	4.63	NA	NA	NA	NA
ECU	246,769	193,614	12.11	102,372	22.97	NA	NA
SLV	92,819	18,472	13.88	105,853	26.90	NA	NA
GTM	126,222	8,488	18.25	163,878	26.30	NA	NA
HND	71,637	14,967	10.78	69,469	18.83	710	3.24
MEX	2,167,733	82,365	0	2,950,876	29.33	NA	NA
NIC	74,955	82,902	9.05	NA	NA	NA	NA
PAN	56,294	3,970	NR	50,147	1.49	2,984	NR
PRY	85,997	9,266	4.82	83,866	7.97	NA	NA
PER	NR	NR	NR	NR	NR	NR	NR
DOM	78,515	11,206	18.54	90,749	23.60	84	29.76
URY	90,471	60,081	22.55	58,009	24.26	NA	NA
VEN	299,879	NR	NR	NR	NR	NA	NA

NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

Figure 2. Percentage of deferred donors by allogeneic donor type, Latin America 2015



TABLE 4.1. VOLUNTARY NON-REMUNERATED DONATIONS FROM FIRST-TIME AND REPEAT DONORS, 2015

COUNTRY	TOTAL OF VOLUNTARY NON-REMUNERATED BLOOD DONATIONS	FIRST-TIME		REPEAT	
		NUMBER	%	NUMBER	%
ARG	468,361	NR	40*	NR	60*
BOL	44,188	32,827	74.29	11,361	25.71
BRA	1,892,114	NR	NR	NR	NR
CHL	68,176	44,023	64.57	24,153	35.43
COL	725,209	569,780*	78.57	155,429	21.43
CRI	45,733	NR	NR	NR	NR
CUB	416,923	NR	NR	NR	NR
ECU	168,464	163,082	96.81	5,382	3.19
SLV	15,810	11,299	71.47	4,511	28.53
GTM	6,870	NR	NR	NR	NR
HND	13,326	NR	NR	NR	NR
MEX	82,365	NR	NR	NR	NR
NIC	74,955	29,982	40	44,937	60
PAN	3,970	NR	NR	NR	NR
PRY	8,819	NR	NR	NR	NR
PER	NR	NR	NR	NR	NR
DOM	9,126	NR	NR	NR	NR
URY	46,534	NR	NR	NR	NR
VEN	17,420	NR	NR	NR	NR

ARG: Approximate number.
COL: Family / replacement donations are included as well.
NR: Not Reported.

TABLE 4.2. APHERESIS, 2015

COUNTRY	NUMBER OF BLOOD DONATIONS COLLECTED THROUGH APHERESIS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST-TIME	REPEAT		
ARG	8,169			NA
BOL	NR	NR	NR	NA
BRA	67,987			NA
CHL	3,742			NA
COL	17,987	16,824	6,614	NA
CRI	14,342			NA
CUB	13,711		NA	NA
ECU	4,914			NA
SLV	12,842			NA
GTM	NR	NR	2,301	NA
HND	NR	NR	NR	NR
MEX	75,951*	0	0	NA
NIC	0	0	NA	NA
PAN	4,455			
PRY	NR	NR	NR	NA
PER	NR	NR	NR	NR
DOM	NR	NR	NR	NR
URY	2,442			NA
VEN	10,384			NA

MEX: The data represents only platelets. The data about Red Blood Cells and Plasma are not known.
NR: Not Reported.

TABLE 4.3. NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL), 2015

COUNTRY	NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL)				
	LOW WEIGHT	LOW HAEMOGLOBIN	HIGH-RISK BEHAVIOR	TRAVEL HISTORY	OTHER
ARG	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR
BRA	NR	NR	NR	NR	NR
CHL	NR	NR	NR	NR	NR
COL	NR	NR	NR	NR	NR
CRI	NR	NR	NR	NR	NR
CUB	NR	NR	NR	NR	NR
ECU	NR	NR	NR	NR	NR
SLV	NR	NR	NR	NR	NR
GTM	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR
MEX	NR	NR	NR	NR	NR
NIC	184	437	815	0	6,063*
PAN	NR	5,501	3,373	NR	NR
PRY	NR	NR	NR	NR	NR
PER	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR
URY	NR	NR	NR	NR	NR
VEN	NR	NR	NR	NR	NR

NIC: Acupuncture, alcohol, among others.
NR: Not Reported.

TABLE 4.4. NUMBER OF UNITS COLLECTED BY AGE GROUPS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED BY AGE GROUPS				
	UNDER 18 YEARS	18 TO 24 YEARS	25 TO 44 YEARS	45 TO 64 YEARS	65 YEARS OR OLDER
ARG	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR
BRA*	1,182,446		1,946,864		
CHL*	0	137,410	58,084	50,055	0
COL*	0	428,002	191,634	217,310	271
CRI	NR	NR	NR	NR	NR
CUB	NR	NR	NR	NR	NR
ECU*	201,312	57,608	35,542	1,167	496
SLV	0	21,915	60,099	13,886	858
GTM	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR
MEX	NR	NR	NR	NR	NR
NIC	2,045	29,686	36,696	6,506	22
PAN	NR	NR	NR	NR	NR
PRY	NR	NR	NR	NR	NR
PER	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR
URY	NR	NR	NR	NR	NR
VEN	NR	NR	NR	NR	NR

BRA: Age groups: 18 - 29 years and older than 29 years.
CHL: Age groups: 18-34, 35-44, 45-64 years old.
COL: age groups: 18-30, 31-40, 41-65 years old.
ECU: Data is calculated based on the total number of donors served.
NR: Not Reported.

TABLE 4.5. NUMBER OF UNITS COLLECTED BY MALE AND FEMALE DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	
	MALE DONORS	FEMALE DONORS
ARG	NR	NR
BOL	NR	NR
BRA	1,945,874	1,193,152
CHL	126,447	113,102
COL	463,422	373,795
CRI	NR	NR
CUB	NR	NR
ECU*	189,388	106,737
SLV	86,379	38,009
GTM	NR	NR
HND	NR	NR
MEX	NR	NR
NIC	44,223	30,732
PAN	NR	NR
PRY	NR	NR
PER	NR	NR
DOM	NR	NR
URY	NR	NR
VEN	NR	NR

ECU: Data is calculated based on the total number of donors served.
NR: Not Reported.

TABLE 5. EFFICIENCY OF BLOOD PROCESSING, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF COLLECTING CENTERS	NUMBER OF PROCESSING CENTERS	ANNUAL PROCESSING PER BANK	DAILY PROCESSING PER BANK (260 DAYS)
ARG	1,026,845	600	259	3,965	15.25
BOL	108,132	18	18	6,007	23.11
BRA	3,098,338	544	530	5,846	22.48
CHL	239,549	47	17	14,091	54.2
COL	795,792	83	83	9,588	36.88
CRI	75,733	34	32	2,367	9.1
CUB	416,923	46*	46*	9,064	34.86
ECU	246,887	22	22	11,222	43.16
SLV	92,882	27	13	7,145	27.48
GTM	126,244	60	60	2,104	8.09
HND	71,646	29	16	4,478	17.22
MEX	2,170,002	572	572	3,794	14.59
NIC	74,955	5	2	37,477	144.14
PAN	56,313	27	22	2,560	9.84
PRY	86,120	11	6	14,353	55.2
PER	NR	NR	NR	NR	NR
DOM	78,533	71	71	1,106	4.25
URY	90,669	62	54	1,679	6.46
VEN	299,879	339	339	884	3.4

CUB: Data from 2014.
NR: Not Reported.

TABLE 6. COVERAGE (%) OF SCREENING FOR INFECTIOUS MARKERS, 2015

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	Anti-HBc
ARG	100	100	100	100	100	100	100
BOL	100	100	100	100	100	0	0
BRA	100	100	100	100	100	100	100
CHL	100	100	100	100	100	100	0
COL	100	100	100	100	100	100	100
CRI	100	100	100	100	100	100	100
CUB	100	100	100	100	NR	NR	NR
ECU	100	100	100	100	100	6.83	11.47
SLV	100	100	100	100	100	0	0
GTM	100	100	100	100	100	0	93.82
HND	100	100	100	100	100	99.85	100
MEX	100	100	100	100	99.94	NR	NR
NIC	100	100	100	100	100	NR	NR
PAN	100	100	100	100	100	100	100
PRY	100	100	100	100	100	100	100
PER	NR	NR	NR	NR	NR	NR	NR
DOM	100	100	100	100	NR	99.64	74.20
URY	100	100	100	100	100	100	100
VEN	100	100	100	100	100	100	100

NR: Not Reported.

TABLE 7. PERCENTAGE OF UNITS NOT SCREENED FOR INFECTIOUS MARKERS, 2015

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*
MEX					0.06

TABLE 8. PROPORTION (%) OF REACTIVE/POSITIVE UNITS, 2015

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	Anti-HBc
ARG	0.21	0.51	0.34	1.04	1.50	0.14	0.93
BOL	0.24	0.23	0.38	0.77	2.51	NR	NR
BRA	0.23	0.21	0.33	1.08	0.22	0.24	1.3
CHL	0.04	0.01	0.02	0.32	0.13	0.11	NR
COL	0.20	0.15	0.35	1.43	0.38	0.32	1.56
CRI	0.11	0.12	0.22	0.44	0.13	0.13	0.9
CUB	0.01	0.58	1.19	0.52	NR	NR	NR
ECU	0.37	0.23	0.25	1.42	0.34	0.06	0.15
SLV	0.13	0.12	0.10	1.50	2.65	NR	NR
GTM	0.24	0.38	0.54	1.41	0.93	0	3.14
HND	0.09	0.18	0.38	0.70	0.74	0.15	1.62
MEX	0.24	0.15	0.48	0.56	0.37	NR	NR
NIC	0.09	0.18	0.34	0.32	0.34	NR	NR
PAN	0.16	0.21	0.36	0.88	0.52	0.44	1.74
PRY	0.29	0.30	0.34	6	2.37	0.32	2.75
PER	NR	NR	NR	NR	NR	NR	NR
DOM	0.17	0.95	0.15	0.59	NA	0.21	1.18
URY	0.11	0.11	0.31	0.41	0.19	0.22	0.79
VEN	0.25	0.39	0.34	1.55	0.31	0.18	2.56

NR: Not Reported.

Figure 3. Proportion (%) of reactive/positive units for markers, Latin America 2015



TABLE 8.1. PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS, 2015

COUNTRY	PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST TIME	REPEAT		
ARG	NR	NR	NR	NA
BOL	NR	NR	NR	NA
BRA	NR	NR	NR	NA
CHL	0.06	0.01	0.05	NA
COL	0.27	0.09	0.17	NA
CRI	NR	NR	NR	NA
CUB	0.01		NR	NA
ECU	NR	NR	NR	NA
SLV	NR	NR	NR	NA
GTM	NR	NR	NR	NA
HND	NR	NR	NR	NR
MEX	NR	NR	NR	NA
NIC	0.06	0.03	NA	NA
PAN	NR	NR	NR	NR
PRY	NR	NR	NR	NA
PER	NR	NR	NR	NR
DOM	NR	NR	NR	NA
URY	NR	NR	NR	NA
VEN	NR	NR	NR	NA

NR: Not Reported.

TABLE 9. SEPARATION INTO COMPONENTS (NUMBER), 2015

COUNTRY	UNITS RECEIVED	RBC	FFP	FP	CRYO	PL
ARG	1,026,845	871,937	677,137	159,753	33,585	517,383
BOL	108,132	104,762	92,196	12,407	7,275	45,776
BRA	3,098,338	2,674,925	2,409,077	314,038	134,917	1,582,347
CHL	255,774	241,133	213,117	33,964	16,441	164,993
COL	795,792	764,697	618,727	126,182	63,353	298,517
CRI	75,733	73,418	72,614	0	15,831	52,201
CUB	406,966	359,164	61,818	136,485	15,473	51,967
ECU	246,875	238,245	179,906	43,179	9,512	122,225
SLV	92,882	109,798	70,516	0	15,067	83,675
GTM	126,244	112,170	63,411	3,714	5,523	44,664
HND	71,825	56,223	44,278	797	784	29,656
MEX	2,170,002	2,061,282	1,728,650	193,321	113,405	825,934
NIC	74,955	72,440	38,927	3,670	3,864	40,034
PAN	56,313	49,226	32,287	NR	4,374	31,976
PRY	86,120	84,032	65,204	8,543	7,357	50,164
PER	NR	NR	NR	NR	NR	NR
DOM	80,903	40,372	1,155	1,892	NR	2,826
URY	93,928	69,024	60,881	3,776	2,611	41,795
VEN	299,879	283,282	234,468	16,250	16,250	175,270

NR: Not Reported.

TABLE 9.1. BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER), 2015

COUNTRY	WB	RBC	FFP	FP	CRYO	PL
ARG	1,379	73,607	44,690	10,543	578	70,881
BOL	3,583	6,154	28,522	10,842	2,672	16,225
BRA	NR	NR	NR	NR	NR	NR
CHL	0	18,374	44,751	0	1,106	39,666
COL	6,027	53,669	369,721	103,882	13,110	79,562
CRI	0	10,868	55,482	0	3,838	19,724
CUB	11,898	32,698	6,904	NR	1,284	10,908
ECU	2,832	12,513	45,175	19,359	1,194	39,238
SLV	639	6,547	11,840	0	512	9,555
GTM	9,672	5,684	13,174	12,127	231	10,705
HND	3,402	3,621	26,727	7,146	634	5,676
MEX	65,050	130,596	649,876	385,104	17,745	258,560
NIC	612	1,021	32,369	4,030	81	1,043
PAN	117	8,189	8,275	35	507	11,375
PRY	1,241	12,094	18,402	11,659	599	23,442
PER	NR	NR	NR	NR	NR	NR
DOM	11,010	1,427	82	1	NR	110
URY	107	19,206	620	57	53	15,362
VEN	NR	36,189	NR	NR	NR	NR

NR: Not Reported.

TABLE 10. AVAILABILITY OF BLOOD COMPONENTS (%), 2015

COUNTRY	% SEPARATED INTO COMPONENTS					% BLOOD AND BLOOD COMPONENTS DISCARDED					
	RBC	FFP	FP	CRYO	PL	WB	RBC	FFP	FP	CRYO	PL
ARG	84.91	65.94	15.56	3.27	50.39	0.13	8.44	6.60	6.60	1.72	13.70
BOL	96.88	85.26	11.47	6.73	42.33	3.31	5.87	30.94	87.39	36.73	35.44
BRA	86.33	77.75	10.14	4.35	51.07	NR	NR	NR	NR	NR	NR
CHL	94.28	83.32	13.28	6.43	64.51	NR	7.62	21	0	6.73	24.04
COL	96.09	77.75	15.86	7.96	37.51	0.76	7.02	59.76	82.33	20.69	26.65
CRI	96.94	95.88	0	20.90	68.93	NR	14.8	76.41	NR	24.24	37.79
CUB	88.20	15.10	33.50	3.80	12.70	1.70	8.03	1.60	NR	0.30	2.60
ECU	96.50	72.87	17.49	3.85	49.51	1.15	5.25	25.11	44.83	12.55	32.10
SLV	*	75.92	0	16.22	90.09	0.69	5.96	16.79	*	3.40	11.42
GTM	88.85	50.23	2.94	4.37	35.38	7.66	5.07	20.78	*	4.18	23.97
HND	78.28	61.65	1.11	1.09	41.29	4.74	6.44	60.36	**	80.87	19.14
MEX	94.99	79.66	8.91	5.23	38.06	3	6.34	37.59	***	15.65	31.31
NIC	96.65	51.93	4.9	5.15	53.41	0.82	1.41	83.15	**	2.10	2.61
PAN	88.28	57.90	NR	7.84	57.34	0.21	16.64	25.63	NR	11.59	35.57
PRY	97.57	75.71	9.92	8.54	58.25	1.44	14.39	28.22	**	8.14	46.73
PER	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	49.9	1.43	2.34	NR	3.49	13.61	3.54	7.10	0.05	NR	3.89
URY	73.49	64.82	4.02	2.78	44.50	0.11	27.83	1.02	1.51	2.03	36.76
VEN	94.47	78.19	5.42	5.42	58.45	NR	12.78	NR	NR	NR	NR

*SLV and GTM: Non-concordant data.
**HND, NIC and PRY: Due to the storage period of the frozen plasma, many of the discarded units were produced in 2014, meaning that the number of units discarded in 2015 exceeds those produced in that year.
***MEX: Based on Mexican regulations, the allowed time for the storage of plasma is 36 months, so blood banks can report the discarding of units of plasma of previous years and not necessarily of the units obtained in the current year.
NR: Not Reported.

Figure 4. Percentage of blood and blood components discarded, Latin America 2015



TABLE 10.1. BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES, 2015

COUNTRY	BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES		
	RBC	PLATELETS	PLASMA
ARG	907	7,262	0
BOL	0	0	0
BRA	67,987		
CHL	0	3,742	0
COL	32,679	177,402	4,390
CRI	13,615	726	1
CUB	0	13,711	0
ECU	0	4,914	0
SLV	701	12,125	16
GTM	39	2,301	0
HND	NR	NR	NR
MEX	NR	75,951	NR
NIC	0	0	0
PAN	205	4,250	0
PRY	NR	NR	NR
PER	NR	NR	NR
DOM	NR	NR	NR
URY	0	2,048	394
VEN	0	10,384	0

NR: Not Reported.

TABLE 10.2. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER), 2015

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER)																	
	WB			RBC			FFP			FP			CRYO			PL		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
ARG	0	1,379	0	26,158	39,602	7,847	12,865	31,825	0	3,035	7,508	0	0	578	0	46,564	24,317	0
BOL	42	239	3,302	950	4,766	438	3,067	3,711	21,744	3,358	326	7,158	1,016	677	979	10,118	1,719	4,388
BRA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CHL	0	0	0	8,941	4,780	4,653	450	4,413	39,888	0	0	0	299	45	762	21,004	2,263	16,399
COL	58	864	5,105	11,250	30,541	11,878	2,002	26,177	341,542	3,721	1,707	98,454	216	872	12,022	28,475	10,821	40,266
CRI	0	0	0	8,948	1,663	257	44,809	1,584	9,089	0	0	0	3,838	0	0	17,897	1,584	243
CUB	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ECU	0	0	2,832	0	0	12,513	0	0	45,175	0	0	19,359	0	0	1,194	0	0	39,238
SLV	289	219	131	875	5,316	356	193	3,995	7,652	0	0	0	42	231	239	4,502	3,448	1,605
GTM	114	9,334	224	3,819	NR	1,865	1,239	NR	11,935	1,921	NR	10,206	98	NR	133	9,458	NR	1,247
HND	588	1,799	1,015	1,866	501	1,254	1,722	481	24,524	1,434	0	5,712	412	26	196	4,237	244	1,195
MEX	1,980	13,797	49,273	57,370	31,934	41,292	72,474	24,181	553,221	66,653	5,641	312,810	3,931	1,876	11,938	175,237	14,636	68,687
NIC	0	87	525	144	863	14	0	396	31,973	85	0	3,945	0	60	21	309	668	66
PAN	10	17	90	5,100	2,126	963	458	1,199	6,618	0	0	35	157	75	275	6,518	1,348	3,509
PRY	83	285	873	1,951	9,221	922	2,169	6,328	9,905	946	587	10,126	107	101	391	12,879	5,688	4,875
PER	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	855	3,815	6,340	24	0	1,403	27	0	55	0	0	1	NR	NR	NR	14	0	96
URY	15	7	85	7,574	2,965	8,667	0	308	312	0	26	31	0	26	27	13,968	257	1,137
VEN	NR	NR	NR	14,601	16,702	4,886	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 10.3. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE), 2015

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE)																	
	WB			RBC			FFP			FP			CRYO			PL		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
ARG	0	100	0	35.54	53.8	10.66	28.79	71.21	0	28.79	71.21	0	0	100	0	65.69	34.31	0
BOL	1.17	6.67	92.16	15.44	77.44	7.12	10.75	13.01	76.24	30.97	3.01	66.02	38.02	25.34	36.64	62.36	10.60	27.04
BRA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CHL	0	0	0	48.66	26.02	25.32	1.01	9.86	89.13	0	0	0	27.03	4.07	68.90	52.95	5.71	41.34
COL	0.96	14.34	84.70	20.96	56.91	22.13	0.54	7.08	92.38	3.58	1.64	94.78	1.65	6.65	91.70	35.79	13.6	50.61
CRI	0	0	0	82.33	15.3	2.37	80.76	2.86	16.38	0	0	0	100	0	0	90.74	8.03	1.23
CUB	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ECU	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
SLV	45.23	34.27	20.5	13.36	81.20	5.44	1.63	33.74	64.63	0	0	0	8.20	45.12	46.68	47.12	36.09	16.79
GTM	1.18	96.50	2.32	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HND	17.28	52.88	29.84	51.53	13.84	34.63	6.44	1.80	91.76	20.07	0	79.93	64.98	4.10	30.92	74.65	4.30	21.05
MEX	3.04	21.21	75.75	43.93	24.45	31.62	11.15	3.72	85.13	17.31	1.46	81.23	22.15	10.57	67.28	67.77	5.66	26.57
NIC	0	14.22	85.78	14.1	84.53	1.37	0	1.22	98.78	2.11	0	97.89	0	74.07	25.93	29.63	64.04	6.33
PAN	8.55	14.53	76.92	62.28	25.96	11.76	5.53	14.49	79.98	0	0	100	30.97	14.79	54.24	57.30	11.85	30.85
PRY	6.69	22.96	70.35	16.13	76.25	7.62	11.79	34.39	53.82	8.11	5.04	86.85	17.86	16.86	65.28	54.94	24.26	20.80
PER	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	7.77	34.65	57.58	1.68	0	98.32	32.93	0	67.07	0	0	100	NR	NR	NR	12.73	0	87.27
URY	14.02	6.54	79.44	39.43	15.44	45.13	0	49.68	50.32	0	45.61	54.39	0	49.06	50.94	90.93	1.67	7.40
VEN	NR	NR	NR	40.35	46.15	13.50	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 11. TRANSFUSION, 2015

COUNTRY	NUMBER OF COMPONENTS TRANSFUSED							
	WB	RBC	FFP	FP	CRYO	PL	APH-PL	APH-RBC
ARG	1,120	524,136	226,922	31,769	86,230	445,676	3,692	NR
BOL	NR	NR	NR	NR	NR	NR	NR	NR
BRA	2,666	1,871,862	471,960	8,607	91,421	720,618	NR	NR
CHL	0	220,252	79,962	0	12,416	93,087	3,342	0
COL	1,338	662,721	211,723	0	48,863	177,547	121,854	NR
CRI	19	63,533	17,202	0	13,326	33,133	71	NR
CUB	0	241,071	39,139	5,917	12,071	49,254	NR	NR
ECU	0	51,711	35,711	3,112	2,688	29,120	130	0
SLV	3,109	100,227	42,310	0	14,184	41,073	13,204	1,207
GTM	1,159	131,840	37,876	1,020	4,567	28,155	4,257	27
HND	1,767	53,245	16,732	798	2,292	15,901	503	NR
MEX	NR	1,500,941	959,869	36,558	94,560	344,414	75,951	NR
NIC	0	37,493	13,129	0	1,614	15,942	0	0
PAN	104	40,550	14,693	NR	3,233	17,819	5,529	NR
PRY	223	69,001	25,108	96	8,133	25,803	NR	NR
PER	NR	NR	NR	NR	NR	NR	NR	NR
DOM	6,152	13,785	39	NR	NR	197	NR	NR
URY	1,116	75,607	20,803	164	1,748	34,176	2,050	0
VEN	NR	NR	NR	NR	NR	NR	NR	NR

APH-PL: Platelets by apheresis.
APH-RBC: Red Blood Cells by apheresis.
NR: Not Reported.

TABLE 11.1 HOSPITALS AND TRANSFUSIONS, 2015

COUNTRY	# OF TRANSFUSION SERVICES	# OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS	NUMBER OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS AND PARTICIPATE/HAVE:					
			TRANSFUSION COMMITTEE		CLINICAL AUDIT		SYSTEM FOR REPORTING ADVERSE REACTIONS	
			#	%	#	%	#	%
ARG	1,135	2,365	NR	10	NR	50	NR	NR
BOL	NR	NR	NR	NR	NR	NR	NR	NR
BRA	1,988	NR	NR	NR	NR	NR	NR	NR
CHL	60	74	74	100	NR	NR	74	100
COL	517	517	517	100	NR	NR	517	100
CRI	32	32	3	9.38	2	6.25	32	100
CUB	NR	NR	NR	NR	NR	NR	NR	NR
ECU*	217	217	76	35.02	0	0	76	35.02
SLV	48	32	NR	NR	NR	NR	NR	NR
GTM	66	53	10	14.28	NR	NR	NR	NR
HND	62	NR	NR	NR	NR	NR	NR	NR
MEX	4,541	4,741	251	5.29	NR	NR	NR	NR
NIC	42	42	12	29	26	62	12	29
PAN	2	29	6	21	0	0	29	100
PRY	64	52	5	9.61	0	0	52	100
PER	NR	NR	NR	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR	NR	NR	NR
URY	74	72	NR	NR	NR	NR	74	100
VEN	339	339	NR	NR	NR	NR	NR	NR

ECU: The information represents those hospitals that belong to the Ministry of Public Health.
NR: Not Reported.

TABLE 11.2. NUMBER OF PATIENTS TRANSFUSED BY AGE, 2015

COUNTRY	# OF PATIENTS TRANSFUSED IN THE COUNTRY	NUMBER OF PATIENTS TRANSFUSED BY AGE				
		<5	05-14	15 - 44	45 - 59	>60
ARG	NR	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR	NR
BRA	NR	NR	NR	NR	NR	NR
CHL	404,390	44,669*		359,721*		
COL*	306,253	13,032	14,655	NR	278,566	NR
CRI	36,928	NR	NR	NR	NR	NR
CUB	NR	NR	NR	NR	NR	NR
ECU	154,016	NR	NR	NR	NR	NR
SLV	130,172	NR	NR	NR	NR	NR
GTM	NR	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR	NR
MEX	1,215,965	NR	NR	NR	NR	NR
NIC	NR	NR	NR	NR	NR	NR
PAN	NR	NR	NR	NR	NR	NR
PRY	NR	NR	NR	NR	NR	NR
PER	NR	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR	NR
URY	32,475	NR	NR	NR	NR	NR
VEN	558,926*	NR	NR	NR	NR	NR

CHL: Data is consolidated into 2 groups: ≤ 15 years and > 15 years.
COL: This information represents 86.9% of establishments.
VEN: Data represents total of transfusions, but not the total of transfused patients.
NR: Not Reported.

TABLE 11.3. ADVERSE TRANSFUSION REACTIONS, 2015

COUNTRY	ADVERSE TRANSFUSION REACTIONS															
	Haemolysis due to ABO incompatibility	Haemolysis due to other allo-antibody	Non-immunological haemolysis	Post-transfusion purpura	Anaphylaxis-hypersensitivity	TRALI	Graft versus host disease	Transfusion-associated HIV infection	Transfusion-associated HBV infection	Transfusion-associated HCV infection	Other transfusion-associated viral infection	Sepsis due to bacterial contamination	Transfusion-associated malaria infection	Other parasitical infection	Transfusion-associated circulatory overload	Other serious adverse transfusion reaction
ARG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BOL	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BRA	NR	NR	NR	NR	1,785	NR	NR	NR	NR	NR	NR	5	NR	NR	201	3,133*
CHL	9	2	489	0	490	6	0	0	0	0	0	0	0	0	17	134
COL	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CRI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CUB	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ECU	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
SLV	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GTM	NR	NR	NR	NR	73	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
MEX	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
NIC	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
PAN	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	84*
PRY	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
PER	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
URY	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
VEN	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

BRA: Febrile non-haemolytic transfusion reactions; Metabolic disorder and others.
PAN: Urticaria, fever, precordial pain and chills.
NR: Not Reported.

TABLE 12. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: LAW, POLICY AND COORDINATION, 2015

COUNTRY	SPECIFIC LAW	RESPONSIBLE UNIT	SPECIFIC BUDGET	NATIONAL POLICY	NATIONAL COMMISSION
ARG	YES	YES	YES	YES	YES
BOL	YES	YES	YES	YES	YES
BRA	YES	YES	YES	YES	YES
CHL	PARTIAL*	YES	YES	YES	YES
COL	NO	YES	YES	YES	NO
CRI	NO	YES	NO	NO	NO
CUB*	YES	YES	NO	YES	YES
ECU	YES	YES	YES	YES	YES
SLV	NO	YES	NO	YES	NO
GTM	YES	YES	YES	YES	NO
HND	NO	NO	YES	PARTIAL*	YES
MEX	YES	YES	YES	YES	NO
NIC	YES	YES	YES	YES	YES
PAN	YES	YES	NO	YES	NO
PRY	YES	YES	YES	YES	NO
PER	NR	YES	NR	NR	NR
DOM	NO	YES	NO	YES	NO
URY	YES	NO	NO	NO	NO
VEN	YES	YES	YES	NO	NO

CHL: In process of revision and approval.
CUB: Data from 2014.
HND: In process of elaboration and approval.
NR: Not Reported.

TABLE 13. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: GUIDELINES, NORMS AND INFORMATION SYSTEM, 2015

COUNTRY	REFERENCE CENTER	NATIONAL PLAN	DONOR NORMS	OPERATION NORMS	CLINICAL GUIDELINES	SERVICE REGISTRATION	INFORMATION SYSTEM
ARG	YES	YES	YES	YES	YES	YES	YES
BOL	YES	YES	YES	YES	YES	YES	YES
BRA	NO	YES	YES	YES	YES	YES	YES
CHL	YES	YES	YES	YES	YES	YES	NO
COL	YES	YES	YES	YES	YES	YES	NO
CRI	PARTIAL*	NO	NO	YES	NO	YES	YES
CUB*	YES	YES	YES	YES	YES	YES	YES
ECU	YES	YES	YES	YES	YES	YES	NO
SLV	YES	YES	YES	YES	YES	YES	NO
GTM	YES	YES	YES	YES	YES	YES	YES
HND	PARTIAL*	NO	YES	YES	NO	NO	NO
MEX	YES	YES	YES	YES	YES	YES	NO
NIC	YES	YES	YES	YES	YES	YES	YES
PAN	YES	YES	YES	YES	YES	YES	YES
PRY	YES	YES	YES	YES	YES	YES	YES
PER	NR	NR	NR	NR	NR	NR	NR
DOM	NO	YES	YES	YES	YES	YES	NO
URY	YES	NO	YES	YES	NO	YES	YES
VEN	YES	NO	YES	YES	NO	YES	YES

CRI: The reference center for HIV is San Juan de Dios Hospital, and for Chagas it is the INCIENSA.
CUB: Data from 2014.
HND: The Network of Clinical Laboratories of the country has a reference center in Tegucigalpa (called the National Surveillance Laboratory), which also serves as reference in screening tests to blood units when requested.
NR: Not Reported.

TABLE 14. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM : QUALITY, 2015

COUNTRY	QUALITY ASSURANCE POLICY	NATIONAL QUALITY MANAGEMENT PROGRAM	NATIONAL PROGRAM OF EXTERNAL EVALUATION SEROLOGY-TTI	NATIONAL PROGRAM OF EXTERNAL EVALUATION IMMUNO-HEMATOLOGY	INSPECTION PROGRAM	CONTINUED EDUCATION
ARG	YES	YES	YES	PARTIAL*	YES	YES
BOL	YES	YES	YES	NO	YES	YES
BRA	YES	YES	YES	YES	YES	YES
CHL	YES	YES	YES	YES	YES	YES
COL	YES	YES	YES	YES	YES	YES
CRI	NO	NO	YES*	YES	YES	NO
CUB*	YES	YES	YES	YES	YES	YES
ECU	PARTIAL*	YES	YES	NO	YES	YES
SLV	NO	YES	YES	NO	PARTIAL*	YES
GTM	NO	NO	NO	NO	YES	NO
HND	NO	NO	NO	NO	NO	NO
MEX	YES	YES	YES	YES	YES	YES
NIC	YES	YES	YES	YES	YES	YES
PAN	YES	NO	NO	NO	YES	NO
PRY	YES	YES	YES	NO	YES	YES
PER	NR	NR	NR	NR	NR	NR
DOM	NO	NO	YES	NO	YES	NO
URY	NO	NO	NO	NO	YES	NO
VEN	YES	NO	NO	NO	NO	YES

ARG: Five panels are sent and distributed in provincial reference centers.
CRI: The Caja Costarricense del Seguro Social has its own program for both serology and immunohematology.
CUB: Data from 2014.
ECU: Blood services are subject to the activities undertaken by the Dirección Nacional de Calidad.
SLV: Inspections are carried out in follow-up to the results of the External Performance Evaluation Program.
NR: Not Reported.

TABLE 15. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: CERTIFICATION AND ACCREDITATION, 2015

COUNTRY	STAFF CERTIFICATION	SERVICE ACCREDITATION
ARG	YES	YES
BOL	YES	YES
BRA	YES	YES
CHL	YES	YES
COL	YES	YES
CRI	YES	YES
CUB*	YES	YES
ECU	NO	YES
SLV	NO	NO
GTM	NO	NO
HND	NO	NO
MEX	YES	NO
NIC	YES	NO
PAN	NO	YES
PRY	NO	NO
PER	NR	NR
DOM	NO	NO
URY	NO	YES
VEN	NO	NO

CUB: Data from 2014.
NR: Not Reported.

TABLE 16. ORGANIZATION OF THE TRANSFUSION SERVICES AND HAEMOVIGILANCE, 2015

COUNTRY	NATIONAL TRANSFUSION COMMITTEE	INTRAHOSPITAL TRANSFUSION COMMITTEE	NATIONAL HAEMOVIGILANCE PROGRAM	BLOOD UNITS NEEDED TO COVER THE NATIONAL REQUIREMENTS
ARG	NO	YES	YES	YES
BOL	NO	YES	NO	NR
BRA	NO	YES	YES	NO
CHL	NO	YES	YES*	YES
COL	NO	YES	YES	PARTIAL*
CRI	PARTIAL*	PARTIAL*	NO	NO
CUB*	YES	YES	YES	YES
ECU	NO	YES	NO	YES
SLV	NO	YES	NO	YES
GTM	NO	PARTIAL*	NO	NO
HND	NO	NO	NO	NO
MEX	NO	YES	PARTIAL*	YES
NIC	YES	YES	NO	YES
PAN	NO	PARTIAL*	NO	NO
PRY	PARTIAL*	PARTIAL*	PARTIAL*	YES
PER	NR	NR	NR	NR
DOM	NO	NO	NO	NO
URY	NO	NO	NO	NO
VEN	NO	PARTIAL*	PARTIAL*	YES

CHL: Program executed by Epidemiología MINSAL.
COL: In progress of establishing blood needs according to the protocol developed by PAHO.
CRI: It has the National Commission on Transfusion Safety, which is not currently active. It also has intra-hospital transfusion committees in some hospitals.
CUB: Data from 2014.
GTM: It was reported by the Services that there are 10 functioning committees and some inactive committees.
MEX: In process of authorization of the registration documents.
PAN: Only 6 blood services have transfusion committees.
PRY: In process of implementation in pilot mode.
VEN: The Program is awaiting approval by the MPPS. There is currently a pilot test with the Society of Hematology.
NR: Not Reported.

TABLE 17. FINANCING AND COSTS OF BLOOD SERVICES, 2015

COUNTRY	ANNUAL REPORT ON ACTIVITIES	SYSTEM OF COST-RECOVERY	FINANCIAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	TECHNICAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	ESTIMATED TOTAL FUNDING (IN US DOLLARS)				APPROXIMATE COST (IN US DOLLARS) OF PRODUCING:	
					TOTAL	FROM THE NATIONAL GOVERNMENT	FROM FEES AND COST RECOVERY	FROM EXTERNAL DONORS	WHOLE BLOOD	RED BLOOD CELLS
ARG	YES	YES	NO	YES	180,000,000	126,000,000	54,000,000	0	100	80
BOL	NO	NO	NO	NR	86,207	86,207		0	35.9	28.7
BRA	YES	NO	NO	NO	302,558,587	6,632,531	295,926,055	0	NR	NR
CHL	NO	NO	NO	YES	17,536,232	17,536,232	0	0	25.62	70.99
COL	YES	YES	NO	YES	NR	NR	NR	NR	NR	NR
CRI	NO	YES	NO	YES	NR	NR	NR	NR	119	37
CUB*	YES	NO	NO	NO	NR	NR	NR	NR	NR	NR
ECU	YES	YES	NO	YES	2,908,737	2,908,737	0	0	NR	52.67
SLV	YES	NO	NO	YES	NR	NR	NR	NR	65	75
GTM	NO	NO	NO	YES	NR	NR	NO	NO	NR	NR
HND	NO	YES	NO	YES	NR	NR	NR	NR	70*	NR
MEX	YES	YES	NO	NO	4,936,336.4*	4,936,336.4*	0	0	NA*	40
NIC	YES	YES	NO	YES	5,000,000	1	0	0	16	16
PAN	YES	NR	NR	YES	46,553	42,553	0	4,000	175	NR
PRY	YES	YES	YES	YES	3,959,624	3,890,023	69,601	400,000*	NR	39
PER	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	YES	YES	YES	YES	NR	NR	NR	NR	NR	NR
URY	YES	NO	NO	NO	NR	NR	NR	NR	NR	NR
VEN	YES	NO	NO	NO	NR	NR	NR	NR	NR	NR

CUB: Data from 2014.
HND: Amount provided by the Honduran Red Cross.
MEX: The budget corresponds only to the CNTS. Whole Blood is not used for transfusion therapies, so cost per unit is not estimated.
PRY: The funds from external donors are not reflected in the "Total of the financing", since these contributions are not annual but by project.
NR: Not Reported.

TABLE 18. STOCKS OF CONSUMABLES, 2015

COUNTRY	DID STOCKS OF ANY OF THE FOLLOWING CONSUMABLES RUN OUT:			
	BLOOD COLLECTION BAGS	TEST KITS FOR TRANSFUSION-TRANSMISSIBLE INFECTIONS	REAGENTS FOR ROUTINE BLOOD GROUPING	OTHERS
ARG	NO	NO	NO	NO
BOL	NO	NO	NO	NO
BRA	NO	NO	NO	NO
CHL	NO	NO	NO	NO
COL	NO	NO	NO	NO
CRI	NO	NO	NO	NO
CUB*	NO	NO	NO	NO
ECU	NO	NO	NO	NO
SLV	NO	NO	NO	NO
GTM	YES	YES	YES	NO
HND	NR	NR	NR	NR
MEX	NO	NO	NO	NO
NIC	NO	NO	NO	NO
PAN	NO	NO	NO	NO
PRY	NO	NO	NO	NO
PER	NR	NR	NR	NR
DOM	NO	NO	NO	NO
URY	NO	NO	NO	NO
VEN	NO	NO	NO	NO

CUB: Data from 2014.
NR: Not Reported.

TABLE 19. NOTIFICATION SYSTEM, 2015

COUNTRY	SPECIFIC BUDGET FOR THE BLOOD DONOR PROGRAMME	CELEBRATION OF WORLD BLOOD DONOR DAY	REGISTER-DATABASE FOR BLOOD DONORS	NATIONAL DONOR SELECTION CRITERIA	DONOR NOTIFICATION SYSTEM FOR TEST RESULTS					SYSTEM OF POST-DONATION COUNSELLING AND REFERRAL TO CARE AND TREATMENT
					HIV	HEPATITIS B	HEPATITIS C	SYPHILIS	OTHER	
ARG	YES	YES	YES	YES	YES	YES	YES	YES	Brucellosis and HTLV I-II	YES
BOL	YES	YES	YES	YES	YES	NO	NO	NO	Chagas	NO
BRA	YES	YES	YES	YES	YES	YES	YES	YES	NO	YES
CHL	NO	YES	YES	YES	YES	YES	YES	YES	Irregular Antibodies and Red Blood Cell sensitization reactions	YES
COL	NO	YES	YES	YES	YES	YES	YES	YES	Chagas, HTLV I-II	YES
CRI	NO	YES	YES	NO	YES	YES	YES	YES	Chagas, HTLV I-II	YES
CUB*	NO	YES	YES	YES	YES	YES	YES	YES	NO	YES
ECU	YES	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
SLV	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
GTM	NO	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
HND	NO	YES	NO	YES	YES	YES	NO	NO	NO	NO
MEX	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
NIC	YES	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
PAN	NO	YES	YES	YES	YES	YES	YES	YES	Chagas, HTLV I-II	YES
PRY	YES	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
PER	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DOM	NO	YES	NO	NO	NO	NO	NO	NO	NO	YES
URY	NO	YES	YES	YES	YES	YES	YES	YES	HTLV I-II, Chagas, CMV	YES
VEN	YES	YES	YES	YES	YES	YES	YES	YES	YES	PARTIAL*

CUB: Data from 2014.
VEN: It is carried out only at the regional centers.
NR: Not Reported.

TABLE 20. ORGANIZATION OF THE BLOOD SERVICES, 2015

COUNTRY	# OF BLOOD SERVICES IN THE COUNTRY			# OF BLOOD SERVICES COVERED BY THIS REPORT			PERCENTAGE OF BLOOD DONATIONS COVERED BY THIS REPORT
	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	
ARG	45	209	254	38	175	213	95
BOL	11	7	18	11	7	18	100
BRA	2,126	NR	2,126	2,126	NR	2,126	NR
CHL	4	74	78	4	74	78	80
COL	24	59	83	24	59	83	92.40
CRI	2	32	34	2	32	34	100
CUB*	16	21	37	NR	NR	NR	100
ECU	7	15	22	7	15	22	100
SLV	1	28	29	1	28	29	100
GTM	13	57	70	10	56	66	NR
HND	2	15	17	2	12	14	97
MEX	44	528	572	44	528	572	100
NIC	2	0	2	2	0	2	100
PAN	0	29	29	0	29	29	100
PRY	1	7	8	1	7	8	100
PER	NR	NR	NR	NR	NR	NR	NR
DOM	37	34	71	25	17	42	NR
URY	3	71	74	3	71	74	92
VEN	4	335	339	4	335	339	80.05

CUB: Data from 2014.
NR: Not Reported.

TABLE 21. COUNTRIES WITH 100% SCREENING FOR INFECTIOUS MARKERS, 2015

HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	FIVE MARKERS	HTLV I-II	Anti-HBc
ARG	ARG	ARG	ARG	ARG	ARG	ARG	ARG
BOL	BOL	BOL	BOL	BOL	BOL		
BRA	BRA	BRA	BRA	BRA	BRA	BRA	BRA
CHL	CHL	CHL	CHL	CHL	CHL	CHL	
COL	COL	COL	COL	COL	COL	COL	COL
CRI	CRI	CRI	CRI	CRI	CRI	CRI	CRI
CUB	CUB	CUB	CUB				
ECU	ECU	ECU	ECU	ECU	ECU		
SLV	SLV	SLV	SLV	SLV	SLV		
GTM	GTM	GTM	GTM	GTM	GTM		
HND	HND	HND	HND	HND	HND		HND
MEX	MEX	MEX	MEX				
NIC	NIC	NIC	NIC	NIC	NIC		
PAN	PAN	PAN	PAN	PAN	PAN	PAN	PAN
PRY	PRY	PRY	PRY	PRY	PRY	PRY	PRY
DOM	DOM	DOM	DOM				
URY	URY	URY	URY	URY	URY	URY	URY
VEN	VEN	VEN	VEN	VEN	VEN	VEN	VEN
18	**18**	**18**	**18**	**15**	**15**	**9**	**9**

TABLE 22. PLASMA DERIVED MEDICAL PRDUCTS (PDMP), 2015

COUNTRY	THE ESSENTIAL MEDICINES LIST INCLUDES THE FOLLOWING PDMP:					PROVISION OF PDMP FOR THE COVERAGE OF THE COUNTRY NEEDS:		
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS	FRACTIONATION (DOMESTIC OR/ AND CONTRACT) OF PLASMA COLLECTED IN THE COUNTRY	PLASMA COLLECTED IN THE COUNTRY WAS SOLD TO THE MANUFACTURERS OF PDMP, AND PRODUCTS ARE PURCHASED FROM PDMP SUPPLIERS	NO PLASMA COLLECTED IN THE COUNTRY ARE USED FOR FRACTIONATION AND ALL PDMP PRODUCTS ARE IMPORTED FROM ABROAD
ARG	YES	YES	YES	YES	Prothrombin complex	YES	NO	NO
BOL	NR	NR	NR	NR	NR	NR	NR	NR
BRA	YES	YES	YES	YES	Fibrinogen, Prothrombin Complex, Partially Activated Prothrombin Complex, Factor VIII, Factor VIII with von Willebrand, Recombinant Factor VIII, Recombinant Factor VII	YES	NO	NO
CHL	YES	YES	YES	NO	NO	YES	NO	NO
COL	YES	YES	YES	YES	NR	NO	NO	YES
CRI	YES	YES	YES	YES	NR	NO	NO	YES*
CUB*	YES	YES	NO	NO	Albumin (Human) 20%, normal human immunoglobulin and transfer factor.	YES	NO	NO
ECU	NO	NO	YES	YES	normal human immunoglobulin	NO	NO	YES
SLV	YES	YES	YES	YES	NR	NO	NO	YES
GTM	YES	YES	YES	YES	NR	NO	NO	YES
HND	NR	NR	NR	NR	NR	NR	NR	NR
MEX	YES	YES	YES	YES	NO	YES	NO	NO
NIC	YES	NO	NO	NO	NR	NR	NR	NR
PAN	YES	YES	YES	YES	NR	NO	NO	YES
PRY	YES	YES	YES	NO	NR	YES	NO	YES
PER	NR	NR	NR	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR	NR	NR	NR
URY	YES	YES	YES	YES	NR	YES	NO	NO
VEN	YES	YES	YES	YES	Anti D (Vial 300 ml) Anti T (Vial 250UI)	YES	YES	NO

CRI: In the process of an agreement with the Seguridad Social and the Universidad de Costa Rica to perform the fractionation.
CUB: Data from 2014.
NR: Not Reported.

TABLE 23. PLASMA FRACTIONATION, 2015

COUNTRY	PLASMA FRACTIONATION		
	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE PUBLIC/NOT FOR PROFIT SECTOR	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE FOR-PROFIT SECTOR	THERE IS AN AGREEMENT WITH ANOTHER COUNTRY FOR THE SHIPPING OF PLASMA TO BE FRACTIONED
ARG	YES	NO	NO
BOL	NR	NR	NR
BRA	YES	NO	YES
CHL	NO	NO	YES*
COL	NR	NR	NR
CRI	NO	NO	NO
CUB*	YES	NO	NO
ECU	NO	NO	NO
SLV	NO	NO	NO
GTM	NR	NR	NR
HND	NR	NR	NR
MEX	NO	NO	YES
NIC	NR	NR	NR
PAN	YES	NO	NO
PRY	NO	NO	YES*
PER	NR	NR	NR
DOM	NR	NR	NR
URY	YES	NO	YES*
VEN	YES	NO	NO

CHL: Agreement with Universidad Nacional de Córdoba, Argentina.
CUB: Data from 2014.
PRY: Agreement with Universidad Nacional de Córdoba, Argentina.
URU: Agreement with Universidad Nacional de Córdoba, Argentina.
NR: Not Reported.

TABLE 24. TABLE 24. PLASMA MANUFACTURING OF PDMP, 2015

COUNTRY	MANUFACTURING OF PDMP				
	PDMP MANUFACTURED BY FRACTIONATION WITHIN THE COUNTRY OR THROUGH CONTRACT FRACTIONATION				
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS
ARG	YES	YES	YES	YES	Prothrombin complex - Ig. Anti D
BOL	NR	NR	NR	NR	NR
BRA	YES	YES	YES	YES	NR
CHL	YES	YES	YES	NO	NO
COL	NR	NR	NR	NR	NR
CRI	NR	NR	NR	NR	NR
CUB*	YES	YES	NR	NR	AntiD Human Immunoglobulin
ECU	NR	NR	NR	NR	NR
SLV	NR	NR	NR	NR	NR
GTM	NR	NR	NR	NR	NR
HND	NR	NR	NR	NR	NR
MEX	YES	YES	YES	YES	NR
NIC	NR	NR	NR	NR	NR
PAN	NR	NR	NR	NR	NR
PRY	NO	NO	NO	NO	NO
PER	NR	NR	NR	NR	NR
DOM	NR	NR	NR	NR	NR
URY	YES	YES	YES	NO	NR
VEN	YES	YES	YES	YES	Anti D (Vial 300 ml) Anti T (Vial 250UI)

CUB: Data from 2014.
NR: Not Reported.

2015 NATIONAL STAFF WHO SUBMITTED THE OFFICIAL REPORT TO THE PAN AMERICAN HEALTH ORGANIZATION

LATIN AMERICAN COUNTRIES

COUNTRY	NAME	POSITION	ADDRESS
ARGENTINA	Esther Mabel Maschio	A/C Dirección de Sangre y Hemoderivados	Ministerio de Salud de la Nación Av. 9 de Julio 1925, 9no. Piso Ciudad Autónoma de Buenos Aires Tel.: (54 011) 4384-0324/25 Int. 115 Tel.: (54 011) 4379-9000 Int. 4825 e-mail: mmaschio@msal.gov.ar
BOLIVIA	Ericka Lucía Machicao	Coordinadora Nacional del Programa Nacional de Sangre del Ministerio de Salud	Programa Nacional de Sangre del Ministerio de Salud Calle Capitán Ravelo N° 2199, 4° Piso, Escuela Nacional de Salud TEL. 2 2126046 email: prgnal.sangre@minsalud.gob.bo
BRAZIL	João Paulo Baccara Araujo	Coordinador General de Sangre y Hemoderivados/ CGSH	Departamento de Atenção Especializada e Temática/DAET Secretaria de Atenção à Saúde/SAS Ministério da Saúde/MS SAF SUL - Trecho 2 - Bloco F - Ala B - Torre 2 - 2º Andar - Sala 202 - Ed. Premium Brasília-DF, Brasil. Tel.: (61) 3315-6178/8843 e-mail: sangue@saude.gov.br
CHILE	Ana Jara Rojas	Coordinadora Nacional de Servicios de Sangre	Ministerio de Salud Enrique Mac iver 541, Santiago Centro, Chile Tel. 56 2 25681911 e-mail: ana.jara@minsal.cl;
COLOMBIA	Fernando Ramírez Campos / Martha Lucía Ospina Martínez	Director de Medicamentos y Tecnologías en Salud - MSPS / Directora del Instituto Nacional de Salud	Ministerio de Salud y Protección Social / Instituto Nacional de Salud Carrera 13 No 32 - 76 Tel.: 57 1 3305000 e-mail: jguzman@minsalud.gov.co
COSTA RICA	Gerardo Solano Elizondo	Unidad Servicios de Salud de Atención Directa a las Personas	Ministerio de Salud San José, Distrito Hospital, calle 16, avenidas 6 y 8 Tel.: (506) 2222-9115 e-mail: gerardo.solano@misalud.go.cr
CUBA	Luis Enrique Pérez Ulloa	Jefe del Programa Nacional de Sangre	MINSAP Calle 23 Esquina N.Vedado. La Habana.Cuba Tel.: 8396328 e-mail: luisenriquep@infomed.sld.cu
ECUADOR	Isabel Miño Lara	Coordinadora del Programa Nacional de Sangre	Ministerio de Salud Pública República del Salvador y Suecia Tel.:(593)-2 381-4400 Ext: 1455-1458 e-mail: isabel.mino@msp.gob.ec

COUNTRY	NAME	POSITION	ADDRESS
EL SALVADOR	Maryuri Villatoro	Coordinadora de la Red Nacional de Bancos de Sangre	Direccion Nacional de Hospitales, MINSAL Calle Arce, # 827 San Salvador, El Salvador Tel.: (503) 25917628 / (503) 70337235 e-mail: maryuri.villatoro@gmail.com
GUATEMALA	Claudia María García	Coordinadora del Programa Nacional de Medicina Transfusional y Bancos de Sangre	Programa Nacional de Medicina Transfusional y Bancos de Sangre 5 Av. 11-40 zona 11, Ciudad Guatemala, Guatemala Tel.: (502)2471-9540 e-mail: pmtbs.mspas@gmail.com
HONDURAS	Ada Pavon	Coordinadora de Servicios de Sangre	Secretaría de Salud Col. El Jasmin Tegucigalpa, Honduras Tel: 504- 2237-5800 e-mail: adapavon@yahoo.com.mx
MEXICO	Julieta Rojo Medina	Director General	Centro Nacional de la Transfusión Sanguínea Othon de Mendizabal 195 Col. Zacatenco del Gustavo A. Madero, México D.F CP 07360 Tel: (5255)51192832 y 51193963 e-mail: julieta.rojo@salud.gob.mx
NICARAGUA	Alcides González Mairena	Secretario Ejecutivo Comisión Nacional de Sangre / MINSA	Ministerio de Salud Complejo Concepción Palacios, Managua Tel.: (505)-2289-4700 ext. 1195 e-mail: conasa01@minsa.gob.ni
PANAMA	Arinda Alemán / Esmeralda Tuy	Coordinadora Médica / Coordinadora Técnica	Programa Nacional de Sangre-Ministerio de Salud Ancón, Calle Gorgas. Edificio 261. Tercer piso. Apdo.0-6812 Panamá 1, Panamá Tel.: (507)5129436 e-mail: sistemanacionaldesangre@hotmail.com
PARAGUAY	Nelson Marquez	Jefe de la Red Nacional de Servicios de Sangre	Programa Nacional de Sangre-Ministerio de Salud Pública y Bienestar Social Juan de Salazar esquina Padre Cardozo Asunción – Paraguay Tel.: 595 21 205 840 e-mail: pnsangre2004@gmail.com
DOMINICAN REPUBLIC	Sócrates E. Sosa Peña	Director del Programa Nacional de Bancos de Sangre	Ministerio de Salud Pública Av. Dr. Homero Hernandez Esq. Tiradentes, Ens. La Fé, Santo Domingo Tel: 809 541 3121 Ext. 2473-2474 e-mail: socratessosa@hotmail.com
URUGUAY	Lourdes Viano / Laura Ucar	Directora y Sub Directora	Servicio Nacional de Sangre 8 de Octubre, 2720 Tel. 24872414 int 302 e-mail: direccion.sns@asse.com.uy
VENEZUELA	Roraima Nuñez	Coordinadora del Programa Nacional de Bancos de Sangre	Ministerio del Poder Popular para la Salud Centro Simón Bolívar Torre Sur Piso 8, Oficina 824, Caracas Tel: 212 408 0576 / 4080543 e-mail: psbancodesangre@mpps.gob.ve / adbasaca@gmail.com


CARIBBEAN
COUNTRIES
2015

TABLE 1. BLOOD COLLECTION, 2015

COUNTRY	TOTAL UNITS COLLECTED	NUMBER OF DONORS				BLOOD DONATION RATE PER 1000 PEOPLE*
		AUTOLOGOUS	ALLOGENEIC			
			VOLUNTARY	REPLACEMENT	REMUNERATED	
AIA	97	0	43	54	0	6.06
ATG	NR	NR	NR	NR	NR	NR
ABW	3,065	0	3,065	0	0	27.37
BHS	5,747	8	1,610	4,129	0	14.81
BRB *2014	4,638	57	529	4,052	0	15.94
BLZ	5,564	0	783	4,781	0	15.99
BMU	1,676	0	1,676	0	0	23.94
VGB *2014	350	NR	NR	NR	NR	10.61
CYM	1,115	0	1,115	0	0	19.91
CUW	5,844	0	5,844	0	0	39.49
DMA *2014	1,006	0	66	940	0	13.59
GUF*	NA	NA	NA	NA	NA	NA
GRD *2014	1,267	1	509	757	0	11.41
GLP	7,891	0	7,891	0	0	16.79
GUY	9,702	0	9,702	0	0	12.01
HTI	27,752	0	13,239	14,513	0	2.62
JAM	31,554	183	11,246	20,125	0	11.22
MTQ	11,217	0	11,217	0	0	27.63
MSR	NR	NR	NR	NR	NR	NR
KNA	408	0	42	366	0	7.85
LCA	2,463	2	1,563	898	0	15.01
VCT	1,043	15	144	884	0	10
SUR	10,296	6	10,290	0	0	18.79
TCA	437	0	237	200	0	8.74
TTO	21,121	123	3,866	17,132	0	15.68

*GUF: No blood collections in this country. Blood units are shipped from Guadeloupe.
*Demographic data is obtained from: Pan American Health Organization/World Health Organization, Communicable Diseases and Health Analysis/ Health Information and Analysis. Health Situation in the Americas: Basic Indicators 2014. Washington, D.C., United States of America, 2015.
NR: Not Reported.

TABLE 2. BLOOD COLLECTION FROM ALLOGENEIC DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	TYPE OF ALLOGENEIC DONOR (PERCENTAGE)		
		VOLUNTARY	REPLACEMENT	REMUNERATED
AIA	97	44.33	55.67	0
ATG	NR	NR	NR	NR
ABW	3,065	100	0	0
BHS	5,739	28.05	71.95	0
BRB *2014	4,581	11.55	88.45	0
BLZ	5,564	14.07	85.93	0
BMU	1,676	100	0	0
VGB *2014	350	NR	NR	NR
CYM	1,115	100	0	0
CUW	5,844	100	0	0
DMA *2014	1,006	6.56	93.44	0
GRD *2014	1,266	40.20	59.80	0
GLP	7,891	100	0	0
GUY	9,702	100	0	0
HTI	27,752	47.70	52.30	0
JAM	31,371	35.85	64.15	0
MTQ	11,217	100	0	0
MSR	NR	NR	NR	NR
KNA	408	10.29	89.71	0
LCA	2,461	63.51	36.49	0
VCT	1,028	14.01	85.99	0
SUR	10,290	100	0	0
TCA	437	54.23	45.77	0
TTO	20,998	18.41	81.59	0

NR: Not Reported.

Figure 1. Percentage of blood collection ranked from greatest to least by voluntary donations, Caribbean 2015



TABLE 2.1. BLOOD COLLECTION ACCORDING TO THE SITE, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
AIA	97	43	0	54	0	0	0
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	3,065	3,065	0	0	0	0	0
BHS	5,739	583	1,027	4,091	38	0	0
BRB *2014	4,581	480	49	4,052	0	0	0
BLZ	5,564	190	593	4,781	0	0	0
BMU	1,676	1,676	0	0	0	0	0
VGB *2014	350	NR	NR	NR	NR	NR	NR
CYM	1,115	1,115	0	0	0	0	0
CUW	5,844	5,844	0	0	0	0	0
DMA *2014	1,006	66	0	940	0	0	0
GRD *2014	1,266	458	51	757	0	0	0
GLP	7,891	1,327	6,564	0	0	0	0
GUY	9,702	4,952	4,750	0	0	0	0
HTI	27,752	3,257	9,982	14,513	0	0	0
JAM	31,371	5,848	5,398	20,125	0	0	0
MTQ	11,217	3,185	8,032	0	0	0	0
MSR	NR	NR	NR	NR	NR	NR	NR
KNA	408	42	0	366	0	0	0
LCA	2,461	76	1,487	763	135	0	0
VCT	1,028	144	0	884	0	0	0
SUR	10,290	9,234	1,056	0	0	0	0
TCA	437	217	20	200	0	0	0
TTO	20,998	2,117	1,749	17,132	0	0	0

EM: Extramural.
NR: Not Reported.

TABLE 2.2. BLOOD COLLECTION ACCORDING TO THE SITE, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	PERCENTAGE OF ALLOGENEIC DONORS					
		VOLUNTARY		REPLACEMENT		REMUNERATED	
		ON SITE	EM	ON SITE	EM	ON SITE	EM
AIA	97	44.33	0	55.67	0	0	0
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	3,065	100	0	0	0	0	0
BHS	5,739	10.16	17.90	71.28	0.66	0	0
BRB *2014	4,581	10.48	1.07	88.45	0	0	0
BLZ	5,564	3.41	10.66	85.93	0	0	0
BMU	1,676	100	0	0	0	0	0
VGB *2014	350	NR	NR	NR	NR	NR	NR
CYM	1,115	100	0	0	0	0	0
CUW	5,844	100	0	0	0	0	0
DMA *2014	1,006	6.56	0	93.44	0	0	0
GRD *2014	1,266	36.18	4.03	59.79	0	0	0
GLP	7,891	16.82	83.18	0	0	0	0
GUY	9,702	51.04	48.96	0	0	0	0
HTI	27,752	11.74	35.97	52.29	0	0	0
JAM	31,371	18.64	17.21	64.15	0	0	0
MTQ	11,217	28.39	71.61	0	0	0	0
MSR	NR	NR	NR	NR	NR	NR	NR
KNA	408	10.29	0	89.71	0	0	0
LCA	2,461	3.09	60.42	31	5.49	0	0
VCT	1,028	14.01	0	85.99	0	0	0
SUR	10,290	89.74	10.26	0	0	0	0
TCA	437	49.66	4.57	45.77	0	0	0
TTO	20,998	10.08	8.33	81.59	0	0	0

EM: Extramural.
NR: Not Reported.

TABLE 3. SELECTION OF ALLOGENEIC DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF ALLOGENEIC DONORS								
		VOLUNTARY			REPLACEMENT			REMUNERATED		
		INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE	INTERVIEWED	DEFERRED	INCOMPLETE
AIA	97	51	8	0	131	76	1	NA	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	3,065	3,211	75	71	NA	NA	NA	NA	NA	NA
BHS	5,739	2,134	493	31	5,180	979	72	NA	NA	NA
BRB *2014	4,581	529	0	0	4,819	709	58	NA	NA	NA
BLZ	5,564	1,066	283	0	6,995	2,193	0	NA	NA	NA
BMU	1,676	1,837	161	0	NA	NA	NA	NA	NA	NA
VGB *2014	350	NR	NR	NR	NR	NR	NR	NR	NR	NR
CYM	1,115	1,316	186	15	NA	NA	NA	NA	NA	NA
CUW	5,844	5,869	3	22	NA	NA	NA	NA	NA	NA
DMA *2014	1,006	67	0	1	1,499	550	9	NA	NA	NA
GRD *2014	1,266	530	21	0	846	89	0	NA	NA	NA
GLP	7,891	10,965	3,074	0	NA	NA	NA	NA	NA	NA
GUY	9,702	10,376	674	0	NA	NA	NA	NA	NA	NA
HTI	27,752	18,976	5,737	0	20,191	5,678	0	NA	NA	NA
JAM	31,371	11,246	NR	NR	20,125	NR	NR	NA	NA	NA
MTQ	11,217	13,988	2,771	0	NA	NA	NA	NA	NA	NA
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	408	42	0	0	507	141	0	NA	NA	NA
LCA	2,461	2,026	463	0	1,319	421	0	NA	NA	NA
VCT	1,028	186	42	0	1,538	649	5	NA	NA	NA
SUR	10,290	11,982	1,500	192	NA	NA	NA	NA	NA	NA
TCA	437	NR	NR	NR	NR	NR	NR	NA	NA	NA
TTO	20,998	5,336	1,470	0	31,882	14,750	0	NA	NA	NA

Incomplete: It refers to people selected as donors, but for whom the extraction/collection could not be performed or was performed incompletely (problems that may be encountered in accessing a vein, insufficient or exceeded volume, among others).
NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

TABLE 4. DEFERRAL OF ALLOGENEIC DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	VOLUNTARY		REPLACEMENT		REMUNERATED	
		NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED	NUMBER INTERVIEWED	% DEFERRED
AIA	97	51	15.69	131	58.02	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	3,065	3,211	2.34	NA	NA	NA	NA
BHS	5,739	2,134	23.10	5,180	18.90	NA	NA
BRB *2014	4,581	529	0	4,819	14.71	NA	NA
BLZ	5,564	1,066	26.55	6,995	31.35	NA	NA
BMU	1,676	1,837	8.76	NA	NA	NA	NA
VGB *2014	350	NR	NR	NR	NR	NR	NR
CYM	1,115	1,316	14.13	NA	NA	NA	NA
CUW	5,844	5,869	0.05	NA	NA	NA	NA
DMA *2014	1,006	67	0	1,499	36.69	NA	NA
GRD *2014	1,266	530	3.96	846	10.52	NA	NA
GLP	7,891	10,965	28.03	NA	NA	NA	NA
GUY	9,702	10,376	6.50	NA	NA	NA	NA
HTI	27,752	18,976	30.23	20,191	28.12	NA	NA
JAM	31,371	11,246	NR	20,125	NR	NA	NA
MTQ	11,217	13,988	19.81	NA	NA	NA	NA
MSR	NR	NR	NR	NR	NR	NR	NR
KNA	408	42	0	507	27.81	NA	NA
LCA	2,461	2,026	22.85	1,319	31.92	NA	NA
VCT	1,028	186	23	1,538	42.20	NA	NA
SUR	10,290	11,982	12.52	NA	NA	NA	NA
TCA	437	NR	NR	NR	NR	NA	NA
TTO	20,998	5,336	27.55	31,882	46.26	NA	NA

NA: Not Applicable. It is used in those categories that do not apply to the country. For example, those countries that only collect voluntary blood donations report NA on replacement and remunerated donations.
NR: Not Reported.

Figure 2. Percentage of deferred donors by allogeneic donor type, Caribbean 2015



TABLE 4.1. VOLUNTARY NON-REMUNERATED DONATIONS FROM FIRST-TIME AND REPEAT DONORS, 2015

COUNTRY	TOTAL OF VOLUNTARY NON-REMUNERATED BLOOD DONATIONS	FIRST-TIME		REPEAT	
		NUMBER	%	NUMBER	%
AIA	43	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR
ABW	3,065	209	6.82	2,856	93.18
BHS	1,610	914	56.77	696	43.23
BRB *2014	529	NR	NR	NR	NR
BLZ	783	491	62.71	292	37.29
BMU	1,676	56	3.34	1,620	96.66
VGB *2014	NR	NR	NR	NR	NR
CYM	1,115	168	15.07	947	84.93
CUW	5,844	NR	NR	NR	NR
DMA *2014	66	NR	NR	NR	NR
GRD *2014	509	55	10.81	454	89.19
GLP	7,891	NR	NR	NR	NR
GUY	9,702	2,482	25.58	7,220	74.42
HTI	13,239	NR	NR	NR	NR
JAM	11,246	NR	NR	NR	NR
MTQ	11,217	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR
KNA	42	30	71.43	12	28.57
LCA	1,563	634	40.56	929	59.44
VCT	144	NR	NR	NR	NR
SUR	10,290	368	3.58	9,922	96.42
TCA	237	NR	NR	NR	NR
TTO	3,866	564*	14.59*	3,302*	85.41*

TTO: This information is not collected at the National level; data is estimated with the results of the mobile/external collection.
NR: Not Reported.

TABLE 4.2. APHERESIS, 2015

COUNTRY	NUMBER OF BLOOD DONATIONS COLLECTED THROUGH APHERESIS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST-TIME	REPEAT		
AIA	0	0	0	0
ATG	NR	NR	NR	NR
ABW	0	0	0	0
BHS	0	0	0	0
BRB *2014	86			0
BLZ	NR	NR	NR	NR
BMU	0	158	0	0
VGB *2014	0	0	0	0
CYM	0	0	0	0
CUW	0	0	0	0
DMA *2014	0	0	0	0
GRD *2014	0	0	0	0
GLP	22		0	0
GUY	0	0	0	0
HTI	NR	NR	NR	NR
JAM	0	0	0	0
MTQ	787		0	0
MSR	NR	NR	NR	NR
KNA	0	0	0	0
LCA	0	0	0	0
VCT	0	0	0	0
SUR	0	0	0	0
TCA	0	0	0	0
TTO	0	0	0	0

NR: Not Reported.

TABLE 4.3. NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL), 2015

COUNTRY	NUMBER OF DEFERRALS (BY REASONS OF DEFERRAL)				
	LOW WEIGHT	LOW HAEMOGLOBIN	HIGH-RISK BEHAVIOR	TRAVEL HISTORY	OTHER
AIA	0	38	1	0	45
ATG	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR
BHS*	12	1,382	66	45	486
BRB *2014	NR	NR	NR	NR	NR
BLZ	8	490	320	9	654
BMU	0	90	4	6	67
VGB *2014	NR	NR	NR	NR	NR
CYM	0	123	4	6	35*
CUW	0	0	0	2	1
DMA *2014	0	79	101	27	334*
GRD *2014	0	61	1	0	45*
GLP	NR	NR	NR	NR	NR
GUY	75	163	199	20	195
HTI	NR	NR	NR	NR	NR
JAM	NR	NR	NR	NR	NR
MTQ	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR
KNA	0	33	4	9	95*
LCA	NR	216	225	0	442
VCT	6	338	33	6	310
SUR	0	1,084	106	0	310*
TCA	0	7	0	0	7*
TTO	NR	NR	NR	NR	NR

BHS: Information from 1 hospital is not included.
CYM: Piercings, anxiety, tattoos, antibiotics, pregnancy, among others.
DMA: On medication/ fever.
GRD: Difficult venipuncture, low blood pressure, pregnancy.
KNA: Recent vaccination, piercings, tattoos, tobacco.
SUR: Recent vaccination.
TCA: Tattoos and alcohol consumption.
NR: Not Reported.

TABLE 4.4. NUMBER OF UNITS COLLECTED BY AGE GROUPS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED BY AGE GROUPS				
	UNDER 18 YEARS	18 TO 24 YEARS	25 TO 44 YEARS	45 TO 64 YEARS	65 YEARS OR OLDER
AIA	0	7	58	31	2
ATG	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR
BRB *2014	NR	NR	NR	NR	NR
BLZ	0	1,107	3,616	837	4
BMU	0	NR	NR	NR	NR
VGB *2014	NR	NR	NR	NR	NR
CYM	5	86	506	438	87
CUW	NR	NR	NR	NR	NR
DMA *2014	0	148	183	681	4
GRD *2014	2	204	736	331	0
GLP	0	1,185	2,242	1,196	147
GUY	206	2,436	4,924	2,101	31
HTI	NR	NR	NR	NR	NR
JAM	NR	NR	NR	NR	NR
MTQ	0	1,157	2,146	3,161	238
MSR	NR	NR	NR	NR	NR
KNA	7	52	255	93	0
LCA	33	457	1,377	573	23
VCT	6	148	599	272	18
SUR	0	875	4,732	4,548	303
TCA	NR	NR	NR	NR	NR
TTO	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 4.5. NUMBER OF UNITS COLLECTED BY MALE AND FEMALE DONORS, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	
	MALE DONORS	FEMALE DONORS
AIA	82	16
ATG	NR	NR
ABW	940	775
BHS*	3,225	1,961
BRB *2014	3,093	1,585
BLZ	4,704	860
BMU	684	992
VGB *2014	NR	NR
CYM	612	479
CUW	3,932	1,912
DMA *2014	715	301
GRD *2014	1,008	178
GLP	2,538	3,032
GUY	6,710	2,986
HTI	NR	NR
JAM	NR	NR
MTQ	3,103	4,199
MSR	NR	NR
KNA	308	100
LCA	1,376	1,087
VCT	766	277
SUR	2,653	1,456
TCA	348	89
TTO	NR	NR

BHS: Information from 1 hospital is not included.
NR: Not Reported.

TABLE 5. EFFICIENCY OF BLOOD PROCESSING, 2015

COUNTRY	NUMBER OF UNITS COLLECTED	NUMBER OF COLLECTING CENTERS	NUMBER OF PROCESSING CENTERS	ANNUAL PROCESSING PER BANK	DAILY PROCESSING PER BANK (260 DAYS)
AIA	97	1	1	97	0.37
ATG	NR	NR	NR	NR	NR
ABW	3,065	1	1	3,065	11.79
BHS	5,747	3	3	1,916	7.37
BRB *2014	4,638	1	1	4,638	17.84
BLZ	5,564	7	1	5,564	21.4
BMU	1,676	1	1	1,676	6.45
VGB *2014	350	1	1	350	1.35
CYM	1,115	3	2	558	2.14
CUW	5,844	1	1	5,844	22.48
DMA *2014	1,006	NR	NR	NR	NR
GRD *2014	1,267	1	1	1,267	4.87
GLP	7,891	1	1	7,891	30.35
GUY	9,702	5	1	9,702	37.32
HTI	27,752	1	1	27,752	106.74
JAM	31,554	10	3	10,518	40.45
MTQ	11,217	1	1	11,217	43.14
MSR	NR	NR	NR	NR	NR
KNA	408	1	1	408	1.57
LCA	2,463	2	1	2,463	9.47
VCT	1,043	1	1	1,043	4.01
SUR	10,296	5	1	10,296	39.60
TCA	437	1	1	437	1.68
TTO	21,121	7	2	10,560	40.62

NR: Not Reported.

TABLE 6. COVERAGE (%) OF SCREENING FOR INFECTIOUS MARKERS, 2015

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	Anti-HBc
AIA	100	100	100	100	0	0	0
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	100	100	100	100	0	100	100
BHS	100	100	100	100	0	100	100
BRB *2014	100	100	100	100	0	100	0
BLZ	100	100	100	100	100	NR	NR
BMU	100	100	100	100	0.06	100	100
VGB *2014	100	100	100	100	0	100	63.43
CYM	100	100	100	100	0	100	0
CUW	100	100	100	100	0	100	0
DMA *2014	100	100	NR	100	NR	100	NR
GRD *2014	100	100	100	100	0	100	0
GLP	100	100	100	100	9.75	100	100
GUY	100	100	100	100	100	100	0
HTI	100	100	100	100	0	100	0
JAM	100	100	100	100	0	100	0
MTQ	100	100	100	100	100	100	100
MSR	NR	NR	NR	NR	NR	NR	NR
KNA	100	100	100	100	0	100	0
LCA	100	100	100	100	0	100	0
VCT	98.56	98.56	98.56	98.56	0	98.56	0
SUR	100	100	100	100	100	100	0
TCA	100	100	100	100	0	100	100
TTO *2013	100	100	100	100	100	100	NR

NR: Not Reported.

TABLE 7. PERCENTAGE OF UNITS NOT SCREENED FOR INFECTIOUS MARKERS, 2015

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	HTLV I-II
VCT	1.44	1.44	1.44	1.44	1.44

TABLE 8. PROPORTION (%) OF REACTIVE/POSITIVE UNITS, 2015

COUNTRY	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	Anti-HBc
AIA	0	0	0	0	NA	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	0	0	0.03	0	NA	0.03	0
BHS	0.14	0.50	0.28	0.78	NA	0.33	0.16
BRB *2014	0.15	0.32	0.51	1.22	NA	0.43	NA
BLZ	0.20	0.25	0.09	0.45	0.13	NR	NR
BMU	0	0	0	0	0	0	0.06
VGB *2014	0	0	0.57	0.86	NA	0.57	4.05
CYM	0.18	0	0.18	0.09	NA	0.36	NA
CUW	0	0	0	0	NA	0	NA
DMA *2014	0	0.20	NR	1.89	NA	0.80	NA
GRD *2014	0.32	0.71	0.24	0.24	NA	0	NA
GLP	0.03	0.04	0.01	0.22	0	0.01	0.81
GUY	0.98	1.41	1.07	0.85	0.33	1.01	NA
HTI	0.79	3.68	0.85	3.50	NA	0.78	NA
JAM	0.30	0.64	0.50	2.01	NA	1.52	NA
MTQ	0	0.020	0	0.12	0	0.02	0.34
MSR	NR	NR	NR	NR	NR	NR	NR
KNA	0	2.94	0.25	1.72	NA	1.47	NA
LCA	0.16	0.89	0.04	1.38	NA	0.85	NA
VCT	0.10	0.49	0.20	2.24	NA	2.14	NA
SUR	0	0.06	0.01	0.02	0	0	NA
TCA	0	0	0.23	1.60	NA	0	7.78
TTO	NR	NR	NR	NR	NR	NR	NR

NA: Not Applicable. It is used in those countries that do not report prevalence of infectious markers because they do not perform those screening tests.
NR: Not Reported.

Figure 3. Proportion (%) of reactive/positive units, Caribbean 2015



TABLE 8.1. PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS, 2015

COUNTRY	PREVALENCE OF HIV INFECTIONS BY TYPE OF DONATIONS			
	VOLUNTARY		REPLACEMENT	REMUNERATED
	FIRST-TIME	REPEAT		
AIA	0	0	0	NA
ATG	NR	NR	NR	NR
ABW	NR	NR	NA	NA
BHS*	0.12		0.12	NA
BRB *2014	NR	NR	NR	NA
BLZ	NR	NR	NR	NA
BMU	NR	NR	NA	NA
VGB *2014	NR	NR	NR	NR
CYM	NR	NR	NA	NA
CUW	0	0	NA	NA
DMA *2014	0	0	0	NA
GRD *2014	NR	NR	NR	NA
GLP	0.03		NA	NA
GUY	3.6	0.08	NA	NA
HTI	NR	NR	NR	NA
JAM	NR	NR	NR	NA
MTQ	0	0	NA	NA
MSR	NR	NR	NR	NR
KNA	NA	NA	NA	NA
LCA	0.04	0.04	0.08	NA
VCT	0	0	0.1	NA
SUR	0	0	NA	NA
TCA	NA	NA	NA	NA
TTO	NR	NR	NR	NA

BHS: Information from 1 hospital of the 3 that the country has.
NR: Not Reported.

TABLE 9. SEPARATION INTO COMPONENTS (NUMBER), 2015

COUNTRY	UNITS RECEIVED	RBC	FFP	FP	CRYO	PL
AIA	97	54	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR
ABW	2,994	2,994	513	0	0	2,534
BHS	5,198	5,191	1,785	0	20	1,751
BRB *2014	4,588	1,023	1,023	0	14	945
BLZ	5,564	1,629	921	688	20	733
BMU	1,676	1,546	181	NR	NR	158*
VGB *2014	350	350	84	266	0	0
CYM	1,115	1,057	600	NR	NR	NR
CUW	5,844	5,844	NR	1,200	NR	1,350
DMA *2014	1,006	510	510	0	0	475
GRD *2014	1,267	1,255	50	20	0	142
GLP	7,891	7,734	0	0	0	638
GUY	9,696	9,696	6,404	0	209	2,031
HTI	25,234	20,495	466	NR	10	1,522
JAM	28,869	21,078	14,982	2,692	2,106	5,956
MTQ	11,217	10,265	0	0	0	1,788
MSR	NR	NR	NR	NR	NR	NR
KNA	408	20	20	0	0	0
LCA	2,463	2,368	791	26	2	1,105
VCT	1,043	1,028	296	0	0	296
SUR	10,296	10,265	1,979	0	0	2,936
TCA	437	437	355	2	0	6
TTO	NR	NR	NR	NR	NR	NR

BMU: Platelets were obtained through apheresis.
NR: Not Reported.

TABLE 9.1. BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER), 2015

COUNTRY	WB	RBC	FFP	FP	CRYO	PL
AIA	10	0	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR
ABW	NR	230	71	0	0	1,654
BHS	0	342	477	0	0	925
BRB *2014	313	135	NR	NR	NR	NR
BLZ	411	195	153	127	NR	339
BMU	29	97	39	NR	NR	120*
VGB *2014	0	41	14	0	0	0
CYM	54	196	169	0	13	111*
CUW	0	165	120	NR	NR	179
DMA *2014	49	53	138	0	0	289
GRD *2014	12	124	1	1,186	0	0
GLP	NR	NR	NR	NR	NR	NR
GUY	0	1,016	160	0	6	299
HTI	2,498	NR	NR	NR	NR	NR
JAM	NR	2,379	401	NR	21	468
MTQ	NR	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR	NR
KNA	59	12	0	0	0	0
LCA	22	188	146	0	0	519
VCT	6	94	9	0	0	205
SUR	0	96	28	0	0	583
TCA	0	142	0	0	0	0
TTO	NR	NR	NR	NR	NR	NR

BMU: The units of platelets discarded were obtained through apheresis.
CYM: The units of platelets discarded were obtained through apheresis.
NR: Not Reported.

TABLE 10. AVAILABILITY OF BLOOD COMPONENTS (%), 2015

COUNTRY	% SEPARATED INTO COMPONENTS					% BLOOD AND BLOOD COMPONENTS DISCARDED					
	RBC	FFP	FP	CRYO	PL	WB	RBC	FFP	FP	CRYO	PL
AIA	55.1	0	0	0	0	10.2	0	NA	NA	NA	NA
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	100	17.13	0	0	84.64	0	7.68	13.84	NA	NA	65.27
BHS	99.87	34.34	0	0.39	33.69	0	6.59	26.72	NA	NR	52.83
BRB *2014	22.30	22.30	0	0.31	20.60	6.82	13.20	NR	NA	NR	NR
BLZ	29.28	16.55	12.37	0.36	13.17	10.44	11.97	16.61	18.46	NR	46.25
BMU	92.24	10.80	0	0	9.43	1.73*	6.27	21.55	NA	NA	75.95
VGB *2014	100	24	76	0	0	0	11.71	16.67	0	NA	NA
CYM	94.8	53.81	0	0	0	4.84	18.54	28.17	NA	NA	NA
CUW	100	NR	20.53	NR	23.10	0	2.82	NR	NR	NR	13.26
DMA *2014	50.7	50.70	0	0	47.22	9.88	10.39	27.06	NA	NA	60.84
GRD *2014	99.05	3.95	1.58	0	11.21	0.95	9.88	2	NA	NA	0
GLP	98.01	0	0	0	8.09	NR	NR	NA	NA	NA	NR
GUY	100	66.05	0	2.16	20.95	0	10.48	2.50	NA	2.87	14.72
HTI	81.22	1.85	NR	0.04	6.03	9.9	NR	NR	NR	NR	NR
JAM	73.01	51.90	9.33	7.30	20.63	NR	11.29	2.68	NR	1	7.86
MTQ	91.51	0	0	0	15.94	NR	NR	NA	NA	NA	NR
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	4.90	4.90	0	0	0	14.46	60	0	NA	NA	NA
LCA	96.14	32.11	1.06	0.08	44.86	0.89	7.94	18.46	NR	NR	46.97
VCT	98.56	28.38	0	0	28.38	0.58	9.14	3.04	NA	NA	69.26
SUR	99.70	19.22	0	0	28.52	0	0.94	1.42	NA	NA	19.86
TCA	100	81.24	0.46	0	1.37	0	32.49	0	0	NA	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

BMU: 28 whole blood units were not separated due to incomplete donations. The 28 units were discarded.
*NA: Used in those cases where there are no blood components discarded because those components were not separated/prepared. NA is also used in those cases were discarded units include units that were separated/prepared in previous years.
NR: Not Reported.

Figure 4. Percentage of blood and blood components discarded, Caribbean 2015



TABLE 10.1. BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES, 2015

COUNTRY	BLOOD COMPONENTS PREPARED THROUGH APHERESIS PROCEDURES		
	RBC	PLATELETS	PLASMA
AIA	0	0	0
ATG	NR	NR	NR
ABW	0	0	0
BHS	0	0	0
BRB *2014	0	86	0
BLZ	NR	NR	NR
BMU	130	158	150
VGB *2014	0	0	0
CYM	NR	NR	NR
CUW	0	0	0
DMA *2014	0	0	0
GRD *2014	0	0	0
GLP	0	638	0
GUY	0	0	0
HTI	0	0	0
JAM	0	0	0
MTQ	0	1,788	0
MSR	NR	NR	NR
KNA	0	0	0
LCA	0	0	0
VCT	0	0	0
SUR	0	0	0
TCA	0	0	0
TTO	0	0	0

NR: Not Reported.

TABLE 10.2. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER), 2015

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (NUMBER)																	
	WB			RBC			FFP			FP			CRYO			PL		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
AIA	9	0	1	0	0	0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BHS	0	0	0	196	108	38	43	108	326	0	0	0	0	0	0	764	101	60
BRB *2014	186	102	25	81	17	37	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	225	152	34	35	160	0	14	134	5	6	26	95	NR	NR	NR	205	134	0
BMU	0	0	29	86	4	7	38	1	0	NR	NR	NR	NR	NR	NR	120	0	0
VGB *2014	0	0	0	27	14	0	0	14	0	0	0	0	0	0	0	0	0	0
CYM	42	12	0	196	0	0	169	0	0	NR	NR	NR	13	0	0	111	0	0
CUW	0	0	0	165	0	0	120	0	0	NR	NR	NR	NR	NR	NR	179	0	0
DMA *2014	30	18	1	37	13	3	122	13	3	0	0	0	0	0	0	276	10	3
GRD *2014	0	12	0	92	32	0	0	1	0	1	0	1,185	0	0	0	0	0	0
GLP	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GUY	0	0	0	450	548	18	4	117	39	0	0	0	577	950	134	120	87	92
HTI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
JAM	NR	NR	NR	71	1,755	553	0	248	153	NR	NR	NR	0	21	0	139	141	188
MTQ	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	19	35	5	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LCA	0	0	22	93	95	0	41	95	10	NR	NR	NR	NR	NR	NR	424	95	0
VCT	6	0	0	34	54	6	0	9	0	0	0	0	0	0	0	196	9	0
SUR	0	0	0	39	38	19	24	0	4	0	0	0	0	0	0	540	13	30
TCA	0	0	0	90	47	5	0	0	0	0	0	0	0	0	0	0	0	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 10.3. BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE), 2015

COUNTRY	BLOOD AND BLOOD COMPONENTS DISCARDED BY CAUSE (PERCENTAGE)																	
	WB			RBC			FFP			FP			CRYO			PL		
	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O	E	M	O
AIA	90	0	10	0	0	0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BHS	0	0	0	57.31	31.58	11.11	9.02	22.64	68.34	0	0	0	0	0	0	82.59	10.92	6.49
BRB *2014	59.42	32.59	7.99	60	12.59	27.41	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	54.75	36.98	8.27	17.95	82.05	0	9.15	87.58	3.27	4.73	20.47	74.80	NR	NR	NR	60.47	39.53	0
BMU	0	0	100	88.66	4.12	7.22	97.44	2.56	0	NR	NR	NR	NR	NR	NR	100	0	0
VGB *2014	0	0	0	65.85	34.15	0	0	100	0	0	0	0	0	0	0	0	0	0
CYM	77.78	22.22	0	100	0	0	100	0	0	NR	NR	NR	100	0	0	100	0	0
CUW	0	0	0	100	0	0	100	0	0	NR	NR	NR	NR	NR	NR	100	0	0
DMA *2014	61.22	36.73	2.05	69.81	24.53	5.66	88.41	9.42	2.17	0	0	0	0	0	0	95.50	3.46	1.04
GRD *2014	0	100	0	74.19	25.81	0	0	100	0	0.08	0	99.92	0	0	0	0	0	0
GLP	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GUY	0	0	0	44.29	53.94	1.77	2.50	73.13	24.37	0	0	0	34.74	57.19	8.07	40.13	29.10	30.77
HTI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
JAM	NR	NR	NR	2.98	73.77	23.25	0	61.85	38.15	NR	NR	NR	0	100	0	29.70	30.13	40.17
MTQ	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	32.20	59.32	8.48	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LCA	0	0	100	49.47	50.53	0	28.08	65.07	6.85	NR	NR	NR	NR	NR	NR	81.70	18.30	0
VCT	100	0	0	36.17	57.45	6.38	0	100	0	0	0	0	0	0	0	95.61	4.39	0
SUR	0	0	0	40.63	39.58	19.79	85.71	0	14.29	0	0	0	0	0	0	92.62	2.23	5.15
TCA	0	0	0	63.38	33.10	3.52	0	0	0	0	0	0	0	0	0	0	0	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

E: Expiration.
M: TTI Markers.
O: Other (This includes: insufficient volume, failed extraction/collection, self-exclusion, open circuit, damaged bags, lipemia, hemolysis, loss of the cold chain, among others).
NR: Not Reported.

TABLE 11. TRANSFUSION, 2015

COUNTRY	NUMBER OF COMPONENTS TRANSFUSED							
	WB	RBC	FFP	FP	CRYO	PL	APH-PL	APH-RBC
AIA	34	54	NR	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	2,634	224	NR	NR	880	NR	NR
BHS	NR	NR	NR	NR	NR	NR	NR	NR
BRB *2014	0	4,293	967	0	0	523	82	0
BLZ	1,764	1,291	452	174	6	227	0	0
BMU	0	1,552	NR	NR	NR	NR	NR	NR
VGB *2014	NR	NR	NR	NR	NR	NR	NR	NR
CYM	12	1,055	354	0	0	0	105	0
CUW	NR	4,357	960	NR	NR	1,171	0	0
DMA *2014	7	954	86	0	0	186	0	0
GRD *2014	1	520	44	4	0	21	0	0
GLP	NR	NR	NR	NR	NR	NR	NR	NR
GUY	NR	NR	NR	NR	NR	NR	NR	NR
HTI	2,988	25,247	355	0	1	583	0	0
JAM	NR	37,655	13,438	563	1,424	4,885	0	0
MTQ	NR	NR	NR	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	10	386	12	0	0	0	0	0
LCA	0	1,572	591	0	0	599	0	0
VCT	NR	NR	NR	NR	NR	NR	NR	NR
SUR	0	10,132	2,055	0	0	2,004	0	0
TCA	NR	273	NR	NR	NR	NR	0	0
TTO	NR	NR	NR	NR	NR	NR	NR	NR

APH-PL: Platelets by apheresis.
APH-RBC: Red Blood Cells by apheresis.
NR: Not Reported.

TABLE 11.1 HOSPITALS AND TRANSFUSIONS, 2015

COUNTRY	# OF TRANSFUSION SERVICES	# OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS	NUMBER OF HOSPITALS THAT PERFORM BLOOD TRANSFUSIONS AND PARTICIPATE/HAVE:					
			TRANSFUSION COMMITTEE		CLINICAL AUDIT		SYSTEM FOR REPORTING ADVERSE REACTIONS	
			#	%	#	%	#	%
AIA	2	2	NR	NR	NR	NR	1	50
ATG	NR	NR	NR	NR	NR	NR	NR	NR
ABW	1	1	1	100	0	0	1	100
BHS	3	NR	NR	NR	NR	NR	NR	NR
BRB *2014	3	3	1	33.30	1	33.30	3	100
BLZ	14	14	NR	NR	NR	NR	NR	NR
BMU	1	1	1	100	1	100	1	100
VGB *2014	2	2	0	0	0	0	1	50
CYM	4	4	0	0	0	0	0	0
CUW	1	3	3	100	3	100	3	100
DMA *2014	1	1	NR	NR	NR	NR	NR	NR
GRD *2014	NR	NR	NR	NR	NR	NR	NR	NR
GLP	12	12	12	100	12	100	12	100
GUY	1	14	1	7.14	1	7.14	14	100
HTI*	37	90	20	22.22	0	0	0	0
JAM	1	42	2	4.76	0	0	2	4.76
MTQ	10	10	10	100	10	100	10	100
MSR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	1	1	0	0	0	0	0	0
LCA	NR	3	NR	NR	NR	NR	NR	NR
VCT	1	3	NR	NR	NR	NR	3	100
SUR	5	5	5	100	0	0	5	100
TCA	1	2	NR	NR	NR	NR	NR	NR
TTO	1	NR	NR	NR	NR	NR	NR	NR

HTI: Data from 2014.
NR: Not Reported.

TABLE 11.2. NUMBER OF PATIENTS TRANSFUSED BY AGE, 2015

COUNTRY	# OF PATIENTS TRANSFUSED IN THE COUNTRY	NUMBER OF PATIENTS TRANSFUSED BY AGE				
		<5	05 - 14	15-44	45-59	>60
AIA	37	2	1	11	6	17
ATG	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR	NR
BRB *2014	NR	NR	NR	NR	NR	NR
BLZ	3,592	553	373	NR	NR	NR
BMU	402	0	4	82	82	234
VGB *2014	NR	NR	NR	NR	NR	NR
CYM	344	22	7	79	88	167
CUW	1,171	NR	NR	NR	NR	NR
DMA *2014	1,233	81	17	343	277	515
GRD *2014	NR	NR	NR	NR	NR	NR
GLP	2,705	108	109	508	509	1,471
GUY	7,800	NR	NR	NR	NR	NR
HTI	770*	39	29	490	94	78
JAM	NR	NR	NR	NR	NR	NR
MTQ	3,120	111	64	387	519	2,039
MSR	NR	NR	NR	NR	NR	NR
KNA	351	8	4	95	73	171
LCA*	592	48	12	248	107	177
VCT	1,000	131	28	276	287	295
SUR	NR	NR	NR	NR	NR	NR
TCA	273	NR	NR	NR	NR	NR
TTO	NR	NR	NR	NR	NR	NR

LCA: Data from 2 of the 3 hospitals that perform blood transfusions in the country.
HTI: Of the total transfusions, there are 40 of which the age of the recipients is not known. Non-concordant data.
NR: Not Reported.

TABLE 11.3. ADVERSE TRANSFUSION REACTIONS, 2015

COUNTRY	ADVERSE TRANSFUSION REACTIONS															
	Haemolysis due to ABO incompatibility	Haemolysis due to other allo-antibody	Non-immunological haemolysis	Post-transfusion purpura	Anaphylaxis-hypersensitivity	TRALI	Graft versus host disease	Transfusion-associated HIV infection	Transfusion-associated HBV infection	Transfusion-associated HCV infection	Other transfusion-associated viral infection	Sepsis due to bacterial contamination	Transfusion-associated malaria infection	Other parasitical infection	Transfusion-associated circulatory overload	Other serious adverse transfusion reaction
AIA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BRB *2014	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	NR	3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BMU	NR	NR	NR	NR	3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
VGB *2014	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CYM	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
CUW	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DMA *2014	0	0	0	0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GRD *2014	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GLP	0	0	0	0	3	0	0	0	0	0	0	1	0	0	0	5
GUY	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
HTI	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
JAM	1	1	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
MTQ	0	0	0	0	9	0	0	0	0	0	0	0	0	0	5	0
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
VCT	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
SUR	NR	NR	NR	NR	NR	NR	0	0	0	0	0	0	0	0	0	0
TCA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
TTO	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 12. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: LAW, POLICY AND COORDINATION, 2015

COUNTRY	SPECIFIC LAW	RESPONSIBLE UNIT	SPECIFIC BUDGET	NATIONAL POLICY	NATIONAL COMMISSION
AIA	NO	NO	NO	NO	NO
ATG	NR	NR	NR	NR	NR
ABW	YES	YES	YES	YES	YES
BHS	NO	NO	NO	NO	YES
BRB *2014	NR	NR	NR	NR	NR
BLZ	NO	YES	NO	NO	NO
BMU	YES	YES	YES	YES	YES
VGB *2014	NO	NO	NO	NO	NO
CYM	NO	NO	NO	NO	NO
CUW	YES	NO	NO	YES	NO
DMA *2014	NR	NR	NR	NR	NR
GRD *2014	NO	NO	NO	NO	NO
GLP	YES	YES	YES	YES	YES
GUY	NO	YES	YES	YES	YES
HTI	NO	YES	YES	YES	YES
JAM	NO	YES	YES	NO	NO
MTQ	YES	YES	YES	YES	YES
MSR	NR	NR	NR	NR	NR
KNA	NR	NR	NR	NR	NR
LCA	NO	NO	NO	NO	NO
VCT	NO	NO	NO	NO	NO
SUR	YES	NO	YES	YES	YES
TCA	NO	YES	NR	NO	NO
TTO	NO	YES	YES	YES	NO

NR: Not Reported.

TABLE 13. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: GUIDELINES, NORMS AND INFORMATION SYSTEM, 2015

COUNTRY	REFERENCE CENTER	NATIONAL PLAN	DONOR NORMS	OPERATION NORMS	CLINICAL GUIDELINES	SERVICE REGISTRATION	INFORMATION SYSTEM
AIA	NO	NO	YES	NO	NO	NO	NO
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	YES	YES	YES	YES	YES	YES	YES
BHS	NO	YES	NO	YES	NO	YES	YES
BRB *2014	NR	NR	NR	NR	NR	NR	NR
BLZ	YES	NO	YES	YES	NO	YES	YES
BMU	NO	YES	YES	YES	YES	YES	YES
VGB *2014	NO	NO	YES	YES	NO	NO	NO
CYM	NO	NO	YES	YES	NO	NO	NO
CUW	YES	YES	YES	YES	YES	YES	YES
DMA *2014	NR	NR	NR	NR	NR	NR	NR
GRD *2014	NO	NO	YES	NO	NO	YES	NO
GLP	YES	NO	YES	YES	YES	YES	YES
GUY	NO	YES	YES	YES	YES	YES	YES
HTI	NO	YES	NO	NO	YES	NO	NO
JAM	YES	YES	YES	YES	YES	NO	NO
MTQ	YES	NO	YES	YES	YES	YES	YES
MSR	NR	NR	NR	NR	NR	NR	NR
KNA	NR	NR	NR	NR	NR	NR	NR
LCA	YES	NO	YES	YES	NO	NO	NR
VCT	NO	NO	YES	NO	NO	NO	NO
SUR	NO	NO	YES	YES	NO	YES	YES
TCA	NO	NO	YES	NO	NO	YES	NO
TTO	YES	NO	NO	YES	YES	YES	NO

NR: Not Reported.

TABLE 14. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: QUALITY, 2015

COUNTRY	QUALITY ASSURANCE POLICY	NATIONAL QUALITY MANAGEMENT PROGRAM	NATIONAL PROGRAM OF EXTERNAL EVALUATION SEROLOGY-TTI	NATIONAL PROGRAM OF EXTERNAL EVALUATION IMMUNOHEMATOLOGY	INSPECTION PROGRAM	CONTINUED EDUCATION
AIA	NO	NO	YES	NO	NO	NO
ATG	NR	NR	YES	NR	NR	NR
ABW	PARTIAL*	YES	NO	YES	YES	YES
BHS	NO	NO	NO	NO	NO	NO
BRB *2014	NR	NR	YES	YES	NR	NR
BLZ	NO	NO	YES	NO	YES	NO
BMU	YES	YES	NO	NO	YES	YES
VGB *2014	NO	NO	NO	NO	NO	NO
CYM	NO	YES	NO	NO	YES	YES
CUW	YES	YES	YES	YES	YES	YES
DMA *2014	NR	NR	YES	NR	NR	NR
GRD *2014	NO	NO	YES	NO	NO	NO
GLP	YES	YES	YES	YES	YES	YES
GUY	NO	NO	YES	YES	YES	NO
HTI	NO	NO	YES	YES	NO	YES
JAM	NO	PARTIAL*	NO	NO	YES	YES
MTQ	YES	YES	YES	YES	YES	YES
MSR	NR	NR	YES	NR	NR	NR
KNA	NO	NO	YES	NO	NO	NO
LCA	NO	NO	YES	YES	NO	NO
VCT	NO	NO	YES	YES	NO	NO
SUR	YES	NO	YES	YES	NO	YES
TCA	NO	NO	NO	NO	YES	YES
TTO	YES	NO	YES	NO	NO	NO

ABW: In development process.
JAM: In development process.
NR: Not Reported.

TABLE 15. ORGANIZATION OF THE NATIONAL BLOOD SYSTEM: CERTIFICATION AND ACCREDITATION, 2015

COUNTRY	STAFF CERTIFICATION	SERVICE ACCREDITATION
AIA	NO	NO
ATG	NR	NR
ABW	YES	NR
BHS	YES	NO
BRB *2014	NR	NR
BLZ	NO	NO
BMU	YES	YES
VGB *2014	NO	NO
CYM	YES	YES
CUW	NO	YES
DMA *2014	NR	NR
GRD *2014	NO	NO
GLP	YES	YES
GUY	YES	NO
HTI	NO	NO
JAM	YES	NO
MTQ	YES	YES
MSR	NR	NR
KNA	NO	NO
LCA	YES	NO
VCT	NO	NO
SUR	YES	NO
TCA	YES	NO
TTO	NO	NO

NR: Not Reported.

TABLE 16. ORGANIZATION OF THE TRANSFUSION SERVICES AND HAEMOVIGILANCE, 2015

COUNTRY	NATIONAL TRANSFUSION COMMITTEE	INTRAHOSPITAL TRANSFUSION COMMITTEE	NATIONAL HAEMOVIGILANCE PROGRAM	BLOOD UNITS NEEDED TO COVER THE NATIONAL REQUIREMENTS
AIA	NO	NO	NO	NR
ATG	NR	NR	NR	NR
ABW	NR	YES	YES	NO
BHS	NO	YES	NO	NR
BRB *2014	NR	NR	NR	NR
BLZ	NO	NO	NO	NR
BMU	YES	YES	NO	NO
VGB *2014	NO	NO	NO	NO
CYM	NO	NO	NO	YES
CUW	NO	YES	YES	YES
DMA *2014	NR	NR	NR	NR
GRD *2014	NO	NO	NO	NR
GLP	YES	YES	YES	NO*
GUY	YES	YES	NO	YES
HTI	NO	YES	NO	YES
JAM	NO	PARTIAL*	PARTIAL*	YES
MTQ	YES	YES	YES	NO*
MSR	NR	NR	NR	NR
KNA	NO	NO	NO	NR
LCA	NO	NO	NO	NR
VCT	NO	NO	NO	YES
SUR	YES	YES	NO	YES
TCA	NO	NR	NO	YES
TTO	NO	PARTIAL*	NO	NO

GLP: The collection of blood does not cover national needs. 50% of the units of red blood cells and platelets are imported from France, as well as 100% of the plasma.
JAM: In development process.
MTQ: The collection of blood does not cover national needs. 20% of the units of red blood cells and platelets are imported from France, as well as 100% of the plasma.
TTO: The public facilities have a transfusion committees.
NR: Not Reported.

TABLE 17. FINANCING AND COSTS OF BLOOD SERVICES, 2015

COUNTRY	ANNUAL REPORT ON ACTIVITIES	SYSTEM OF COST-RECOVERY	FINANCIAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	TECHNICAL SUPPORT FROM INTERNATIONAL AGENCIES/ ORGANIZATIONS	ESTIMATED TOTAL FUNDING (IN US DOLLARS)				APPROXIMATE COST (IN US DOLLARS) OF PRODUCING:	
					TOTAL	FROM THE NATIONAL GOVERNMENT	FROM FEES AND COST RECOVERY	FROM EXTERNAL DONORS	WHOLE BLOOD	RED BLOOD CELLS
AIA	NO	YES	NO	YES	NR	NR	NR	NR	150	150
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	YES	NR	NO	YES	NR	NR	NR	NR	NR	NR
BHS	NO	NO	NO	NO	NR	NR	NR	NR	185	160
BRB *2014	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	NO	NO	YES	NO	NR	NR	NR	NR	NR	NR
BMU	NO	NO	NO	NO	636,199	NR	NR	NR	246	246
VGB *2014	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
CYM	NO	YES	NO	YES	NR	NR	NR	NR	300	320
CUW	YES	YES	NO	NO	3,000,000	0	3,000,000	0	NR	328
DMA *2014	NO	NR	NO	NO	NR	NR	NR	NR	NR	NR
GRD *2014	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
GLP	YES	NR	NR	NR	NR	NR	NR	NR	NR	NR
GUY	YES	YES	NO	NO	775,000	470,000	19,512	0	200	220
HTI	YES	NO	YES	YES	3,500,000	525,000	0	2,975,000	83.33	100
JAM	NO	YES	NO	NO	NR	NR	NR	NR	NR	NR
MTQ	YES	NR	NR	NR	NR	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
VCT	NO	NO	NO	YES	NR	NR	NR	NR	200	NR
SUR	NO	YES	YES	YES	1,525,000	223,000	1,102,000	200,000	NA	71
TCA	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR
TTO	NO	NO	NO	NO	NR	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 18. STOCKS OF CONSUMABLES, 2015

COUNTRY	DID STOCKS OF ANY OF THE FOLLOWING CONSUMABLES RUN OUT:			
	BLOOD COLLECTION BAGS	TEST KITS FOR TRANSFUSION-TRANSMISSIBLE INFECTIONS	REAGENTS FOR ROUTINE BLOOD GROUPING	OTHERS
AIA	NO	NO	NO	NO
ATG	NR	NR	NR	NR
ABW	NR	NR	NR	NR
BHS	NO	NO	NO	NR
BRB *2014	NR	NR	NR	NR
BLZ	NO	YES	NO	NR
BMU	NO	NO	NO	NO
VGB *2014	NO	NO	NO	NR
CYM	NO	NO	NO	NO
CUW	NO	NO	NO	NO
DMA *2014	NO	NO	NO	NR
GRD *2014	NO	NO	NO	NR
GLP	NO	NO	NO	NO
GUY	NO	NO	NO	NO
HTI	YES	NO	NO	NR
JAM	NO	YES	NO	NO
MTQ	NO	NO	NO	NO
MSR	NR	NR	NR	NR
KNA	NR	NR	NR	NR
LCA	YES	YES	YES	NO
VCT	NO	YES*	NO	NO
SUR	NO	NO	NO	NO
TCA	NO	NO	NO	NR
TTO	YES	NR	NR	NR

VCT: Hepatitis B surface antigen ran out in December 2015.
NR: Not Reported.

TABLE 19. NOTIFICATION SYSTEM, 2015

COUNTRY	SPECIFIC BUDGET FOR THE BLOOD DONOR PROGRAMME	CELEBRATION OF WORLD BLOOD DONOR DAY	REGISTER-DATABASE FOR BLOOD DONORS	NATIONAL DONOR SELECTION CRITERIA	DONOR NOTIFICATION SYSTEM FOR TEST RESULTS					SYSTEM OF POST-DONATION COUNSELLING AND REFERRAL TO CARE AND TREATMENT
					HIV	HEPATITIS B	HEPATITIS C	SYPHILIS	OTHER	
AIA	NO	YES	YES	YES	YES	YES	YES	YES	NO	YES*
ATG	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
ABW	YES	YES	YES	YES	YES	YES	YES	YES	NR	YES
BHS	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
BRB *2014	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
BMU	YES	YES	YES	YES	YES	YES	YES	YES	HTLV , Chagas and West Nile Virus	YES
VGB *2014	NO	NO	YES	NO	YES	YES	YES	YES	NR	YES
CYM	NO	YES	YES	YES	YES	YES	YES	YES	HTLV	YES
CUW	YES	YES	YES	YES	YES	YES	YES	YES	HTLV I-II	YES
DMA *2014	NO	YES	YES	YES	YES	YES	NR	YES	HTLV	YES
GRD *2014	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
GLP	NR	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
GUY	YES	YES	YES	YES	YES	YES	YES	YES	Malaria, HTLV I-II	YES
HTI	YES	YES	YES	YES	YES	YES	YES	YES	HTLV I-II	YES*
JAM	YES	YES	NO	YES	YES	YES	YES	YES	HTLV	YES
MTQ	NR	YES	YES	YES	YES	YES	YES	YES	Chagas	YES
MSR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
LCA	NO	NO	YES	YES	YES	YES	YES	YES	NR	YES
VCT	NO	YES	NO	NO	NO	NO	NO	NO	NO	YES
SUR	YES	YES	YES	YES	YES	YES	YES	YES	HTLV, Malaria and Chagas	YES
TCA	NO	YES	YES	YES	YES	YES	YES	YES	NR	YES
TTO	NO	YES	YES	YES	NO	NO	NO	NO	NO	YES

NR: Not Reported.

TABLE 20. ORGANIZATION OF THE BLOOD SERVICES, 2015

COUNTRY	# OF BLOOD SERVICES IN THE COUNTRY			# OF BLOOD SERVICES COVERED BY THIS REPORT			PERCENTAGE OF BLOOD DONATIONS COVERED BY THIS REPORT
	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	STAND-ALONE BLOOD SERVICES	HOSPITAL-BASED BLOOD SERVICES	TOTAL	
AIA	0	1	1	0	1	1	100
ATG	NR	NR	NR	NR	NR	NR	NR
ABW	1	0	1	1	0	1	NR
BHS	0	3	3	0	3	3	100
BRB *2014	0	1	1	0	1	1	NR
BLZ	1	13	14	1	13	14	NR
BMU	0	1	1	0	1	1	100
VGB *2014	0	1	1	0	1	1	NR
CYM	0	3	3	0	2	2	99
CUW	1	0	1	1	0	1	100
DMA *2014	0	1	1	0	1	1	NR
GRD *2014	0	1	1	0	1	1	NR
GLP	1	0	1	1	0	1	100
GUY	1	0	1	1	5*	6	100
HTI*	9	6	15	9	6	15	95*
JAM	1	9	10	1	9	10	100
MTQ	1	0	1	1	0	1	100
MSR	NR	NR	NR	NR	NR	NR	NR
KNA	NR	NR	NR	0	1	1	NR
LCA	NR	NR	NR	0	2	2	NR
VCT	0	1	1	0	1	1	NR
SUR	1	0	1	1	0	1	100
TCA	1	1	2	1	1	2	NR
TTO	1	5	6	1	5	6	100

GUY: This data represents collection centers.
HTI: Doctors without borders collected 2000 blood units that represent 5% of the total collection. Data from 2014.
NR: Not Reported.

TABLE 21. COUNTRIES WITH 100% SCREENING FOR INFECTIOUS MARKERS, 2015

HIV	HBsAg	HCV	SYPHILIS	HTLV I-II
AIA	AIA	AIA	AIA	
ABW	ABW	ABW	ABW	ABW
BHS	BHS	BHS	BHS	BHS
BRB	BRB	BRB	BRB	BRB
BLZ	BLZ	BLZ	BLZ	
BMU	BMU	BMU	BMU	BMU
VGB	VGB	VGB	VGB	VGB
CYM	CYM	CYM	CYM	CYM
CUW	CUW	CUW	CUW	CUW
DMA	DMA		DMA	DMA
GRD	GRD	GRD	GRD	GRD
GLP	GLP	GLP	GLP	GLP
GUY	GUY	GUY	GUY	GUY
HTI	HTI	HTI	HTI	HTI
JAM	JAM	JAM	JAM	JAM
MTQ	MTQ	MTQ	MTQ	MTQ
KNA	KNA	KNA	KNA	KNA
LCA	LCA	LCA	LCA	LCA
SUR	SUR	SUR	SUR	SUR
TCA	TCA	TCA	TCA	TCA
20	**20**	**19**	**20**	**18**

TABLE 22. PLASMA DERIVED MEDICAL PRDUCTS (PDMP), 2014

COUNTRY	THE ESSENTIAL MEDICINES LIST INCLUDES THE FOLLOWING PDMP:					PROVISION OF PDMP FOR THE COVERAGE OF THE COUNTRY NEEDS:		
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS	FRACTIONATION (DOMESTIC OR/ AND CONTRACT) OF PLASMA COLLECTED IN THE COUNTRY	PLASMA COLLECTED IN THE COUNTRY WAS SOLD TO THE MANUFACTURERS OF PDMP, AND PRODUCTS ARE PURCHASED FROM PDMP SUPPLIERS	NO PLASMA COLLECTED IN THE COUNTRY ARE USED FOR FRACTIONATION AND ALL PDMP PRODUCTS ARE IMPORTED FROM ABROAD
AIA	NO	NO	NO	NO	NO	NO	NO	YES
ATG	NR	NR	NR	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR	NR	NR	NR
BRB *2014	NR	NR	NR	NR	NR	NR	NR	NR
BLZ	NO	NO	NO	NO	NR	YES	NO	NO
BMU	YES	YES	YES	YES	Coagulation Factor VIIa (Recombinant), Rh Immunoglobulin, Fibrinogen Concentrate	NO	NO	YES
VGB *2014	NR	NR	NR	NR	NR	NO	NO	YES
CYM	YES	YES	YES	YES	Tissue Plasminogen Activator, Caffeine Citrate	NO	NO	YES
CUW	NR	NR	NR	NR	NR	NR	NR	NR
DMA *2014	NO	NO	NO	NO	NO	NO	NO	YES
GRD *2014	NR	NR	NR	NR	NR	NR	NR	NR
GLP	YES	YES	YES	YES	NR	NO	YES	NO
GUY	YES	YES	NO	NO	NR	NO	NO	YES
HTI	NR	NR	NR	NR	NR	NR	NR	NR
JAM	YES	YES	YES	YES	NO	NO	NO	YES
MTQ	YES	YES	YES	YES	NR	NO	YES	NO
MSR	NR	NR	NR	NR	NR	NR	NR	NR
KNA	NO	NO	NO	NO	NO	NO	NO	YES
LCA	NO	NO	NO	NO	NR	NO	NO	YES
VCT	YES	YES	YES	YES	NR	NO	NO	NO
SUR	NO	NO	NR	NR	NR	NO	NO	YES
TCA	NO	NO	NO	NO	NR	NO	NO	NR
TTO	NR	NR	NR	NR	NR	NR	NR	NR

NR: Not Reported.

TABLE 23. PLASMA FRACTIONATION, 2015

COUNTRY	PLASMA FRACTIONATION		
	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE PUBLIC/NOT FOR PROFIT SECTOR	PLASMA FRACTIONATION IS CARRIED OUT THROUGH THE FOR-PROFIT SECTOR	THERE IS AN AGREEMENT WITH ANOTHER COUNTRY FOR THE SHIPPING OF PLASMA TO BE FRACTIONED
AIA	NR	NR	NR
ATG	NR	NR	NR
ABW	NR	NR	NR
BHS	NR	NR	NR
BRB *2014	NR	NR	NR
BLZ	YES	YES	NO
BMU	NR	NR	NR
VGB *2014	NR	NR	NR
CYM	NR	NR	NR
CUW	NO	NO	NO
DMA *2014	NO	NO	NO
GRD *2014	NR	NR	NR
GLP	YES	NO	NO
GUY	NO	NO	NO
HTI	NR	NR	NR
JAM	NR	NR	NR
MTQ	NR	NR	NR
MSR	NR	NR	NR
KNA	NR	NR	NR
LCA	NR	NR	NR
VCT	NR	NR	NR
SUR	NR	NR	NR
TCA	NR	NR	NR
TTO	NR	NR	NR

NR: Not Reported.

TABLE 24. PLASMA MANUFACTURING OF PDMP, 2015

COUNTRY	MANUFACTURING OF PDMP				
	PDMP MANUFACTURED BY FRACTIONATION WITHIN THE COUNTRY OR THROUGH CONTRACT FRACTIONATION				
	ALBUMIN	INTRAVENOUS IMMUNOGLOBULIN (IVIG)	FACTOR VIII	FACTOR IX	OTHERS
AIA	NR	NR	NR	NR	NR
ATG	NR	NR	NR	NR	NR
ABW	NR	NR	NR	NR	NR
BHS	NR	NR	NR	NR	NR
BRB *2014	NR	NR	NR	NR	NR
BLZ	NO	NO	NO	NO	NR
BMU	NR	NR	NR	NR	NR
VGB *2014	NR	NR	NR	NR	NR
CYM	NR	NR	NR	NR	NR
CUW	NR	NR	NR	NR	NR
DMA *2014	NR	NR	NR	NR	NR
GRD *2014	NR	NR	NR	NR	NR
GLP	YES	YES	YES	YES	NR
GUY	NO	NO	NO	NO	NO
HTI	NR	NR	NR	NR	NR
JAM	NR	NR	NR	NR	NR
MTQ	NR	NR	NR	NR	NR
MSR	NR	NR	NR	NR	NR
KNA	NR	NR	NR	NR	NR
LCA	NR	NR	NR	NR	NR
VCT	NR	NR	NR	NR	NR
SUR	NR	NR	NR	NR	NR
TCA	NR	NR	NR	NR	NR
TTO	NR	NR	NR	NR	NR

NR: Not Reported.

2015 NATIONAL STAFF WHO SUBMITTED THE OFFICIAL REPORT TO THE PAN AMERICAN HEALTH ORGANIZATION
CARIBBEAN COUNTRIES

COUNTRY	NAME	POSITION	ADDRESS
ANGUILLA	Everette Duncan	Coordinator, Laboratory Services	Princess Alexandra Hospital Stoney Ground Tel. 1 264 497 2551 Email: evie@anguillanet.com
ARUBA	Raymond Maxwell	Bloodbank Analist	Bloodbank Aruba TEL. 2975870002 Email: ajduits@gmail.com
BAHAMAS	George Bruney	Director of Pathology and Laboratory Medicine	Princess Margaret Hospital Shirley Street Tel. 1242-322-2861 EXT 1234 Email: gbruney@pmh.phabahamas.org
BARBADOS	Adrian Howard	Senior Laboratory Technologist	Queen Elizabeth Hospital Martindale Road, Bridgetown, Saint Michael Tel. 2468363959 Email: yowardan@hotmail.com
BELIZE	Joy Robateau	Senior Medical Laboratory Technologist	Belize National Blood Transfusion Services Princess Margaret Drive Tel. 501-224-5010 Email: j_robateau@yahoo.com
BERMUDA	Cheryl Peek-Ball	Chief Medical Officer	Ministry of Health, Seniors and Environment Continental Building, 25 Church Street, Hamilton HM12 Tel. (441) 278-4900 Email: cepeekball@gov.bm
BRITISH VIRGIN ISLANDS	Allene Brewley-Roach	Laboratory Director	Peebles Hospital (BVIHSA) # 32 Main Street Tel. 284-852-7500 Email: peebleslab@hotmail.com
CAYMAN ISLANDS	Judith Clarke	Laboratory Manager	Cayman Island Health Services Authority 95 Hospital Road, PO Box 915, Grand Cayman, KY1-1103 Tel. 13452442670 / 13459498600 Email: judith.clarke@hsa.ky
CURACAO	A.J. Duits	Director	Red Cross Blood Bank Foundation Pater Euwensweg 36 Tel. 59994618433 Email: ajduits@gmail.com
DOMINICA	Richard Anselm	Lab Technologist	PMH Laboratory Federation Drive Roseau Tel. 17672662144 Email: pmhlab@dominica.gov.dm

NR: Not Reported.

COUNTRY	NAME	POSITION	ADDRESS
GRENADA	B. MC Barnette	Haemotologist	General Hospital St Georges Tel: 473 435 1976 E-mail: bcgmcbarnette@yahoo.com
GUADELOUPE	Christian Rud	Regional Coordinator of Haemovigilance	Agence Régionale de Santé Parc de Dothémare 97139 abymes Tel: 0590 99 44 83 E-mail: christian.rud@ars.sante.fr
GUYANA	Pedro Lewis	Director (ag) NBTS	National Blood Transfusion Service Tel: 592-22337182 E-mail: pedrolewis592@gmail.com
HAITI	Ernst NOEL	Directeur	Programme National de Sécurité Transfusionnelle / MSPP 1, Angle Rue Jacques Roumain et Ave Mais Gate, Delmas, Haiti Tel. (509)2227-4137 Email: enoel18@gmail.com
JAMAICA	Veronica Taylor	Acting Director	National Blood Transfusion Service 21 Slipe Pen Road Kingston Tel. (876)922 5181 Email: veronicataylor201@hotmail.com
MARTINIQUE	Christian Rud	Regional Coordinator of Haemovigilance	Agence Régionale de Santé Parc de Dothémare 97139 abymes Tel: 0590 99 44 83 E-mail: christian.rud@ars.sante.fr
SAINT KITTS AND NEVIS	Domina Christmas-Brisport	Senior Medical Technologist	Joseph N. France Pathology Laboratory Buckley's Site Basseterre Tel. 8694652551 Email: pathlabskb@yahoo.com
SAINT LUCIA	Veronica Lee	Medical Technologist	St Lucia Blood Bank Service Victoria Hospital Tel. (758)452-5430 Email: slubloodbank@gmail.com
ST. VINCENT AND THE GRENADINES	kamarla Questelles	Medical Technologist	Blood Bank, Mcmh Pathology Laboratory Bentick Square, Kingstown Tel. 784-456-1185 EXT 149 Email: KQUESTELLES@YAHOO.COM
SURINAME	Maria Tjon A Loi	Medical director	National Blood Bank of the Suriname Red Cross Society Rode Kruislaan 24 Tel. 597 499175 Email: Maria.Tjonaloi@redcross.sr
TURKS AND CAICOS	Peggy . P. Samuels	Chief Medical Technologist	Turks & Caicos Islands blood Bank Cheshire Hall Hospital, 10 Hospital Road Tel. 1649- 338-5132 Email: ppsamuels@gov.tc
TRINIDAD AND TOBAGO	Adanna John-Caraballo Young	Nurse Manager	The National Blood Transfusion Service 160 Charlotte Street, Port of Spain Tel. 1 (868) 627-2619 Email: adana.john-young@health.gov.tt

SUBREGIONAL SUMMARIES

BLOOD UNITS COLLECTED

NUMBER OF UNITS COLLECTED							
YEAR	CENTRAL AMERICA AND SPANISH SPEAKING CARIBBEAN	CARIBBEAN	ANDEAN COMMUNITY	SOUTHERN CONE	MEXICO	BRAZIL	TOTAL
2012	980,173	133,355	1,525,067	1,456,371	1,768,862	3,335,035	9,198,863
2013	1,005,812	140,190	1,276,208	1,381,177	1,364,395	NR	5,167,782
2014	966,882	133,793	1,606,670	1,284,595	1,939,060	3,335,035	9,266,035
2015	993,229	154,253	1,655,561	1,443,183	2,170,002	3,098,338	9,514,566

BLOOD DONATIONS

AUTOLOGOUS DONORS													
YEAR	CENTRAL AMERICA AND SPANISH SPEAKING CARIBBEAN		CARIBBEAN		ANDEAN COMMUNITY		SOUTHERN CONE		MEXICO		BRAZIL		TOTAL	
	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%
2012	210	0.02	188	0.14	642	0.04	367	0.03	1,716	0.10	2,056	0.06	32,972	0.36
2013	190	0.02	132	0.09	499	0.04	12,175	0.88	1,065	0.08	NR	NR	14,061	0.27
2014	105	0.01	277	0.21	23,504	1.46	5,705	0.44	0	0	2,056	0.06	31,647	0.34
2015	132	0.01	395	0.26	400	0.02	1,487	0.10	2,269	0.10	9,216	0.30	13,899	0.15

VOLUNTARY DONORS													
YEAR	CENTRAL AMERICA AND SPANISH SPEAKING CARIBBEAN		CARIBBEAN		ANDEAN COMMUNITY		SOUTHERN CONE		MEXICO		BRAZIL		TOTAL	
	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%
2012	569,208	58.07	68,956	52	703,166	46	446,865	31	48,892	3	1,983,857	60	3,820,944	41.54
2013	581,702	57.83	69,426	50	828,034	65	470,524	34	41,708	3	NR	NR	1,991,394	38.53
2014	581,919	60.18	64,785	48.42	853,070	53.01	533,039	41.49	49,794	2.57	1,983,857	60	4,066,464	43.89
2015	586,713	59.07	84,677	54.89	964,621	58.27	591,890	41.01	82,365	3.80	1,892,114	61.25	4,202,380	44.17

REPLACEMENT DONORS													
YEAR	CENTRAL AMERICA AND SPANISH SPEAKING CARIBBEAN		CARIBBEAN		ANDEAN COMMUNITY		SOUTHERN CONE		MEXICO		BRAZIL		TOTAL	
	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%
2012	402,593	41	64,211	48	821,259	54	905,155	62	1,718,254	97	1,349,122	40	5,260,594	57.19
2013	415,834	41	49,332	35	447,665	35	898,478	65	1,321,622	97	NR	NR	3,132,931	60.62
2014	376,887	38.98	68,381	51.11	730,086	45.44	745,851	58.06	1,889,266	97.43	1,349,122	40	5,159,593	55.68
2015	402,654	40.54	68,831	44.62	690,530	41.71	849,806	58.88	2,085,368	96.20	1,197,008	38.75	5,294,197	55.64

REMUNERATED DONORS													
YEAR	CENTRAL AMERICA AND SPANISH SPEAKING CARIBBEAN		CARIBBEAN		ANDEAN COMMUNITY		SOUTHERN CONE		MEXICO		BRAZIL		TOTAL	
	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%	NUMBER	%
2012	8,162	0.80	0	0	0	0	0	0	0	0	0	0	8,162	0.09
2013	8,086	0.80	0	0	10	0.001	0	0	0	0	NR	NR	8,096	0.16
2014	7,971	0.82	0	0	10	0.001	0	0	0	0	0	0	7,981	0.09
2015	3,730	0.38	0	0	10	0.001	0	0	0	0	0	0	3,740	0.04

SCREENING

CENTRAL AMERICA AND SPANISH-SPEAKING CARIBBEAN

NUMBER OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	980,173	980,173	980,173	980,173	472,307	293,177	276,389
2013	1,005,812	1,005,812	1,005,812	1,005,812	483,487	298,995	310,136
2014	966,793	966,791	966,850	966,851	457,000	263,011	295,603
2015	993,229	993,229	993,229	993,229	497,773	202,617	281,805

PERCENTAGE OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	100	100	100	100	48.19	29.91	28.20
2013	100	100	100	100	48.07	29.73	30.83
2014	99.99	99.99	99.99	99.99	47.27	27.20	30.57
2015	100	100	100	100	50.12	20.40	28.37

CARIBBEAN

NUMBER OF UNITS SCREENED					
YEAR	HIV	HBsAg	HCV	SYPHILIS	HTLV I-II
2012	132,034	132,034	131,088	132,034	127,124
2013	139,496	139,496	138,425	139,496	134,157
2014	133,707	133,707	133,707	133,707	133,507
2015	154,238	154,238	154,238	154,238	154,141

PERCENTAGE OF UNITS SCREENED					
YEAR	HIV	HBsAg	HCV	SYPHILIS	HTLV I-II
2012	99.01	99.01	98.30	99.01	95.33
2013	99.50	99.50	98.74	99.50	95.70
2014	99.94	99.94	99.94	99.94	99.79
2015	99.99	99.99	99.99	99.99	99.93

ANDEAN COMMUNITY

NUMBER OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	1,495,545	1,495,545	1,495,545	1,495,545	1,495,545	1,117,918	1,126,947
2013	1,267,689	1,267,689	1,267,689	1,267,689	1,259,055	790,603	828,308
2014	1,606,670	1,606,670	1,606,670	1,606,670	1,606,670	1,236,541	1,305,317
2015	1,655,561	1,655,561	1,655,561	1,655,561	1,655,561	1,317,400	1,328,852

PERCENTAGE OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	98.06	98.06	98.06	98.06	98.06	73.30	73.89
2013	99.33	99.33	99.33	99.33	98.66	61.95	64.90
2014	100	100	100	100	100	76.96	81.24
2015	100	100	100	100	100	79.57	80.27

SOUTHERN CONE

NUMBER OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	1,455,743	1,455,743	1,455,743	1,455,743	1,455,743	1,455,743	1,222,578
2013	1,374,602	1,375,590	1,372,900	1,373,820	1,375,820	1,375,636	1,151,266
2014	1,284,595	1,284,595	1,284,595	1,284,595	1,284,595	1,284,595	1,043,684
2015	1,443,183	1,443,183	1,443,183	1,443,183	1,443,183	1,443,183	1,203,634

PERCENTAGE OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	99.96	99.96	99.96	99.96	99.96	99.96	83.95
2013	99.52	99.60	99.40	99.47	99.61	99.60	83.35
2014	100	100	100	100	100	100	81.25
2015	100	100	100	100	100	100	83.40

MEXICO

NUMBER OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	1,741,091	1,739,853	1,741,798	1,737,022	1,745,690	0	0
2013	1,343,247	1,343,247	1,343,110	1,340,791	1,253,197	0	0
2014	1,939,060	1,939,060	1,939,060	1,939,060	1,870,303	0	0
2015	2,170,002	2,170,002	2,170,002	2,170,002	2,168,737	0	0

PERCENTAGE OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	98	98	98	98	99	0	0
2013	98	98	98	98	92	0	0
2014	100	100	100	100	96.45	0	0
2015	100	100	100	100	99.94	0	0

BRAZIL

NUMBER OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	3,335,035	3,335,035	3,335,035	3,335,035	3,335,035	3,335,035	3,335,035
2013	NR	NR	NR	NR	NR	NR	NR
2014	3,335,035	3,335,035	3,335,035	3,335,035	3,335,035	3,335,035	3,335,035
2015	3,098,338	3,098,338	3,098,338	3,098,338	3,098,338	3,098,338	3,098,338

PERCENTAGE OF UNITS SCREENED							
YEAR	HIV	HBsAg	HCV	SYPHILIS	*T. cruzi*	HTLV I-II	HBC
2012	100	100	100	100	100	100	100
2013	NR	NR	NR	NR	NR	NR	NR
2014	100	100	100	100	100	100	100
2015	100	100	100	100	100	100	100

SEPARATION INTO COMPONENTS

CENTRAL AMERICA AND SPANISH-SPEAKING CARIBBEAN

SEPARATION INTO COMPONENTS (NUMBER)						
YEAR	RBC	FFP	FP	CRYO	PL	TOTAL
2012	663,452	282,778	56,613	66,458	312,836	1,382,137
2013	888,223	343,693	56,679	70,619	313,764	1,672,978
2014	870,703	369,966	47,518	71,230	341,846	1,701,263
2015	872,811	385,006	146,558	60,916	336,999	1,802,290

PERCENTAGE OF RED BLOOD CELLS PREPARED	
YEAR	RBC (%)
2012	67.69
2013	88.31
2014	90.05
2015	87.88

BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER)							
YEAR	WB	RBC	FFP	FP	CRYO	PL	TOTAL
2012	14,750	65,172	83,620	61,772	1,943	57,525	284,782
2013	16,608	44,061	106,173	35,868	12,050	55,763	270,523
2014	18,748	54,138	142,686	8,649	12,815	69,170	306,206
2015	37,350	70,055	154,853	23,339	7,087	69,096	361,780

PERCENTAGE OF RED BLOOD CELLS DISCARDED	
YEAR	RBC (%)
2012	9.82
2013	4.96
2014	6.22
2015	8.03

CARIBBEAN

SEPARATION INTO COMPONENTS (NUMBER)						
YEAR	RBC	FFP	FP	CRYO	PL	TOTAL
2012	86,065	13,585	1,354	470	15,705	117,179
2013	57,680	23,589	4,234	2,539	21,663	109,705
2014	83,898	52,627	3,277	2,761	21,349	163,912
2015	104,839	30,960	4,894	2,381	24,366	167,440

PERCENTAGE OF RED BLOOD CELLS PREPARED	
YEAR	RBC (%)
2012	64.54
2013	41.14
2014	62.71
2015	67.97

BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER)							
YEAR	WB	RBC	FFP	FP	CRYO	PL	TOTAL
2012	9,500	3,035	943	733	0	6,166	20,377
2013	5,660	3,935	1,795	589	10	6,918	18,907
2014	3,920	3,817	1,422	1,328	72	2,776	13,335
2015	3,463	5,505	1,926	1,313	40	5,691	17,938

PERCENTAGE OF RED BLOOD CELLS DISCARDED	
YEAR	RBC (%)
2012	3.53
2013	6.82
2014	4.55
2015	5.25

ANDEAN COMMUNITY

SEPARATION INTO COMPONENTS (NUMBER)						
YEAR	RBC	FFP	FP	CRYO	PL	TOTAL
2012	1,346,190	667,883	648,328	91,032	730,306	3,483,739
2013	1,214,594	947,436	185,004	91,440	557,710	2,996,184
2014	1,545,890	1,222,147	196,519	116,401	743,940	3,824,897
2015	1,576,703	1,263,641	227,160	114,461	746,933	3,928,898

PERCENTAGE OF RED BLOOD CELLS PREPARED	
YEAR	RBC (%)
2012	88.27
2013	95.17
2014	96.22
2015	95.24

BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER)							
YEAR	WB	RBC	FFP	FP	CRYO	PL	TOTAL
2012	19,798	271,207	646,302	165,839	16,148	297,334	1,416,628
2013	17,053	105,763	488,073	162,792	16,573	201,161	991,415
2014	52,874	107,023	483,222	162,001	22,681	179,406	1,007,207
2015	14,612	133,938	486,192	161,027	18,381	163,168	977,318

* Venezuela 2014, only reported data on the discarding of whole blood units.
* Venezuela 2015, only reported data on the discarding of Red Blood Cells units.

PERCENTAGE OF RED BLOOD CELLS DISCARDED	
YEAR	RBC (%)
2012	20.15
2013	8.71
2014	6.92
2015	8.49

SOUTHERN CONE

SEPARATION INTO COMPONENTS (NUMBER)						
YEAR	RBC	FFP	FP	CRYO	PL	TOTAL
2012	1,251,188	654,863	588,949	68,631	521,861	3,085,492
2013	1,105,759	573,439	419,218	34,312	622,709	2,755,437
2014*	1,181,788	634,673	541,192	35,169	717,460	3,110,282
2015	1,266,126	1,016,339	206,036	59,994	774,335	3,322,830

*There is no data from Uruguay.

PERCENTAGE OF RED BLOOD CELLS PREPARED	
YEAR	RBC (%)
2012	85.91
2013	80.06
2014	92
2015	87.73

BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER)							
YEAR	WB	RBC	FFP	FP	CRYO	PL	TOTAL
2012	41,299	113,089	37,262	54,420	5,955	88,618	340,643
2013	51,900	252,113	138,069	60,141	6,269	245,981	754,473
2014	11,391	185,321	126,985	97,342	5,128	241,716	667,883
2015	2,727	123,281	108,463	22,259	2,336	149,351	408,417

PERCENTAGE OF RED BLOOD CELLS DISCARDED	
YEAR	RBC (%)
2012	9.04
2013	22.80
2014	15.68
2015	9.74

MEXICO

SEPARATION INTO COMPONENTS (NUMBER)						
YEAR	RBC	FFP	FP	CRYO	PL	TOTAL
2012	1,625,920	1,311,483	279,037	99,018	722,113	4,037,571
2013	1,321,413	905,769	264,522	151,122	659,179	3,302,005
2014	1,815,839	1,340,336	285,176	101,196	737,999	4,280,546
2015	2,061,282	1,728,650	193,321	113,405	825,934	4,922,592

PERCENTAGE OF RED BLOOD CELLS PREPARED	
YEAR	RBC (%)
2012	91.92
2013	96.85
2014	93.65
2015	94.99

BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER)							
YEAR	WB	RBC	FFP	FP	CRYO	PL	TOTAL
2012	56,877	113,605	522,760	330,766	15,337	223,012	1,262,357
2013	56,877	113,597	522,760	330,766	15,337	223,012	1,262,349
2014	58,128	116,672	535,306	340,689	15,858	231,040	1,297,693
2015	65,050	130,596	649,876	385,104	17,745	258,560	1,506,931

PERCENTAGE OF RED BLOOD CELLS DISCARDED	
YEAR	RBC (%)
2012	6.99
2013	8.60
2014	6.43
2015	6.34

BRAZIL

SEPARATION INTO COMPONENTS (NUMBER)						
YEAR	RBC	FFP	FP	CRYO	PL	TOTAL
2012	3,231,788	2,689,156	477,826	215,615	2,031,891	8,646,276
2013	NR	NR	NR	NR	NR	NR
2014	3,231,788	2,689,156	477,826	215,615	2,031,891	8,646,276
2015	2,674,925	2,409,077	314,038	134,917	1,582,347	7,115,304

PERCENTAGE OF RED BLOOD CELLS PREPARED	
YEAR	RBC (%)
2012	96.90
2013	NR
2014	96.90
2015	86.33

BLOOD AND BLOOD COMPONENTS DISCARDED (NUMBER)							
YEAR	WB	RBC	FFP	FP	CRYO	PL	TOTAL
2012	8,840	308,229	964,329	44,729	3,051	279,635	1,608,813
2013	NR	NR	NR	NR	NR	NR	NR
2014	8,840	308,229	964,329	44,729	3,051	279,635	1,608,813
2015	NR	NR	NR	NR	NR	NR	NR

PERCENTAGE OF RED BLOOD CELLS DISCARDED	
YEAR	RBC (%)
2012	9.54
2013	NR
2014	9.54
2015	NR

INDIVIDUAL COUNTRY SUMMARIES

LATIN AMERICAN COUNTRIES

ARGENTINA (ARG)	2012	2013	2014	2015
Number of Units Collected	1,056,710	966,059	859,233	1,026,845
Number of Autologous Donors	0	11,455	5,400	1,166
Percentage type of allogeneic donors				
Voluntary, altruistic donors	36.4	38	48.88	45.66
Family/Replacement donors	63.6	62	51.12	54.34
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	100	100	100	100
Anti-HBc	100	100	100	100
Percentage of units reactive/positive				
HIV	0.17	0.18	0.2	0.21
HBsAg	0.18	0.17	0.22	0.51
HCV	0.36	0.35	0.45	0.34
Syphilis	0.82	0.91	1.12	1.04
T. cruzi	2.07	2.27	2.46	1.50
HTLV I-II	0.2	0.18	0.18	0.14
Anti-HBc	1.37	1.39	1.54	0.93
Percentage of units separated into components				
Packed red blood cells	94.26	88.93	90.56	84.91
Fresh frozen plasma	42.42	42.72	38.97	65.94
Frozen plasma	51.84	38.21	51.69	15.56
Cryoprecipitate	4.71	1.71	1.36	3.27
Platelets	32.99	49.16	54.33	50.39
Percentage of units discarded				
Whole blood	51,00	53.21	1.03	0.13
Packed red blood cells	10	25.29	15.85	8.44
Fresh frozen plasma	6.32	22.38	16.73	6.60
Frozen plasma	6.60	15.25	16.91	6.60
Cryoprecipitate	10.31	25.42	22.49	1.72
Platelets	12.11	36.4	26.05	13.7

BOLIVIA (BOL)	2012	2013	2014	2015
Number of Units Collected	83,391	102,146	101,166	108,132
Number of Autologous Donors	59	76	62	60
Percentage type of allogeneic donors				
Voluntary, altruistic donors	36.7	45.23	39.99	40.89
Family/Replacement donors	63.3	54.77	60.01	59.11
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	91.66	100	100
HBsAg	100	91.66	100	100
HCV	100	91.66	100	100
Syphilis	100	91.66	100	100
T. cruzi	100	91.67	100	100
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	0.23	0.21	0.25	0.24
HBsAg	0.34	0.28	0.25	0.23
HCV	0.30	0.27	0.36	0.38
Syphilis	0.68	0.93	0.75	0.77
T. cruzi	3.34	2.73	3.90	2.51
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	NR	88.24	97.26	96.88
Fresh frozen plasma	78.91	75.06	81.53	85.26
Frozen plasma	11.77	9.76	11.77	11.47
Cryoprecipitate	7.18	6.31	6.93	6.73
Platelets	40.6	30.94	40.87	42.33
Percentage of units discarded				
Whole blood	NR	65.23	3.15	3.31
Packed red blood cells	NR	7.10	6.61	5.87
Fresh frozen plasma	25.98	36.53	37.2	30.94
Frozen plasma	77.04	79.33	86.84	87.39
Cryoprecipitate	17.47	18.40	27.73	36.73
Platelets	38.31	39.18	34.98	35.44

NR: Not Reported.

BRAZIL (BRA)	2012	2013	2014	2015
Number of Units Collected	3,335,035	NR	NR	3,098,338
Number of Autologous Donors	2,056	NR	NR	9,216
Percentage type of allogeneic donors				
Voluntary, altruistic donors	59.52	NR	NR	61.25
Family/Replacement donors	40.48	NR	NR	38.75
Remunerated donors	0	NR	NR	0
Percentage of units screened				
HIV	100	NR	NR	100
HBsAg	100	NR	NR	100
HCV	100	NR	NR	100
Syphilis	100	NR	NR	100
T. cruzi	100	NR	NR	100
HTLV I-II	100	NR	NR	100
Anti-HBc	100	NR	NR	100
Percentage of units reactive/positive				
HIV	0.42	NR	NR	0.23
HBsAg	0.16	NR	NR	0.21
HCV	0.30	NR	NR	0.33
Syphilis	0.82	NR	NR	1.08
T. cruzi	0.31	NR	NR	0.22
HTLV I-II	0.19	NR	NR	0.24
Anti-HBc	1.62	NR	NR	1.30
Percentage of units separated into components				
Packed red blood cells	96.9	NR	NR	86.33
Fresh frozen plasma	80.63	NR	NR	77.75
Frozen plasma	14.33	NR	NR	10.14
Cryoprecipitate	6.47	NR	NR	4.35
Platelets	60.93	NR	NR	51.07
Percentage of units discarded				
Whole blood	8.56	NR	NR	NR
Packed red blood cells	9.54	NR	NR	NR
Fresh frozen plasma	35.86	NR	NR	NR
Frozen plasma	9.36	NR	NR	NR
Cryoprecipitate	1.42	NR	NR	NR
Platelets	13.76	NR	NR	NR

NR: Not Reported.

CHILE (CHL)	2012	2013	2014	2015
Number of Units Collected	233,165	229,911	240,911	239,549
Number of Autologous Donors	0	NR	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	23.62	23.52	24.79	28.46
Family/Replacement donors	76.38	76.48	75.21	71.54
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	97.14	100	100
HBsAg	100	97.57	100	100
HCV	100	96.4	100	100
Syphilis	100	96.8	100	100
T. cruzi	100	97.67	100	100
HTLV I-II	100	97.59	100	100
Anti-HBc	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	0.03	0.06	0.12	0.04
HBsAg	0.01	0.01	0.01	0.01
HCV	0.03	0.02	0.01	0.02
Syphilis	0.83	0.32	0.94	0.32
T. cruzi	0.14	0.15	0.12	0.13
HTLV I-II	0.12	0.09	0.10	0.11
Anti-HBc	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	95.68	75.96	96.88	94.28
Fresh frozen plasma	77.56	43.43	83.47	83.32
Frozen plasma	15.49	10.25	13.84	13.28
Cryoprecipitate	7.83	5.17	6.27	6.43
Platelets	67.37	42.65	63.62	64.51
Percentage of units discarded				
Whole blood	51.85	NR	0	NR
Packed red blood cells	3.21	9.34	9.66	7.62
Fresh frozen plasma	NR	36.32	20.84	21
Frozen plasma	45.29	NR	NR	0
Cryoprecipitate	3.59	15.23	9.94	6.73
Platelets	22.55	46.9	39.42	24.04

NR: Not Reported.

COLOMBIA (COL)	2012	2013	2014	2015
Number of Units Collected	746,059	740,173	756,370	795,792
Number of Autologous Donors	272	217	23,246	104
Percentage type of allogeneic donors				
Voluntary, altruistic donors	84.38	86.75	88.29	91.14
Family/Replacement donors	15.62	13.25	11.71	8.86
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	70.53	75.44	93.11	100
Anti-HBc	71.2	76.32	95.5	100
Percentage of units reactive/positive				
HIV	0.22	0.21	0.23	0.20
HBsAg	0.16	0.16	0.14	0.15
HCV	0.49	0.41	0.39	0.35
Syphilis	1.50	1.50	1.51	1.43
T. cruzi	0.43	0.40	0.41	0.38
HTLV I-II	0.29	2.23	0.30	0.32
Anti-HBc	1.77	1.75	1.80	1.56
Percentage of units separated into components				
Packed red blood cells	97.54	97.02	97.76	96.09
Fresh frozen plasma	14.42	75.36	77.51	77.75
Frozen plasma	78.11	15.96	16.76	15.86
Cryoprecipitate	5.93	8.27	9.07	7.96
Platelets	44.91	43.39	41.71	37.51
Percentage of units discarded				
Whole blood	91.72	40.84	1.04	0.76
Packed red blood cells	14.55	9.08	8.50	7.02
Fresh frozen plasma	NR	66.26	60.40	59.76
Frozen plasma	24.91	99.56	86.40	82.33
Cryoprecipitate	29.63	22.12	27.15	20.69
Platelets	78.08	42.65	32.56	26.65

NR: Not Reported.

COSTA RICA (CRI)	2012	2013	2014	2015
Number of Units Collected	70,182	68,209	73,057	75,733
Number of Autologous Donors	3	0	6	1
Percentage type of allogeneic donors				
Voluntary, altruistic donors	67.74	68.12	63.23	60.39
Family/Replacement donors	34.26	31.88	36.77	39.61
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	100	100	100	100
Anti-HBc	100	100	100	100
Percentage of units reactive/positive				
HIV	0.15	0.08	0.08	0.11
HBsAg	0.09	0.13	0.41	0.12
HCV	1.12	0.38	0.21	0.22
Syphilis	0.56	0.59	0.62	0.44
T. cruzi	0.38	0.22	0.15	0.13
HTLV I-II	0.29	0.15	0.08	0.13
Anti-HBc	1.88	1.50	0.74	0.90
Percentage of units separated into components				
Packed red blood cells	95.07	99.97	97.75	96.94
Fresh frozen plasma	NR	98.5	97.19	95.88
Frozen plasma	NR	0.10	0.53	0
Cryoprecipitate	21.41	22.85	20.88	20.90
Platelets	65.73	67.06	73.4	68.93
Percentage of units discarded				
Whole blood	2.08	NR	0.003	NR
Packed red blood cells	14.43	18.49	12.72	14.8
Fresh frozen plasma	NR	49.48	77.82	76.41
Frozen plasma	NR	NR	NR	NA
Cryoprecipitate	0.65	16.75	19.32	24.24
Platelets	4.14	51.24	52.66	37.79

NR: Not Reported.

CUBA (CUB)	2012	2013	2014	2015
Number of Units Collected	401,575	411,545	415,902	416,923
Number of Autologous Donors	NR	NR	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	100	100
Family/Replacement donors	0	0	0	0
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	NR	NR	NR	NR
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	0.02	0.02	0.02	0.01
HBsAg	0.41	0.51	0.41	0.58
HCV	0.76	1.24	0.92	1.19
Syphilis	0.57	0.73	0.51	0.52
T. cruzi	NR	NR	NR	NR
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	51.5	98.94	97.19	88.20
Fresh frozen plasma	12.9	9.21	12.94	15.10
Frozen plasma	11.76	11.27	7.95	33.50
Cryoprecipitate	7.12	6.44	4.99	3.80
Platelets	18.92	17.73	16.60	12.70
Percentage of units discarded				
Whole blood	0	NR	NR	1.70
Packed red blood cells	13.65	1.61	1.62	8.03
Fresh frozen plasma	6.41	3.37	2.37	1.60
Frozen plasma	18.37	4.52	6.34	NR
Cryoprecipitate	3.23	4.81	6.14	0.30
Platelets	12.83	17.12	18.09	2.60

NR: Not Reported.

ECUADOR (ECU)	2012	2013	2014	2015
Number of Units Collected	83,611	229,018	232,215	246,887
Number of Autologous Donors	16	88	78	118
Percentage type of allogeneic donors				
Voluntary, altruistic donors	5.25	57.05	60.12	68.27
Family/Replacement donors	94.75	42.95	39.88	31.73
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	96.23	100	100
HTLV I-II	11.05	11.94	6.61	6.83
Anti-HBc	15.87	25.56	28.46	11.47
Percentage of units reactive/positive				
HIV	0.35	0.42	0.3	0.37
HBsAg	0.35	0.49	0.23	0.23
HCV	0.54	0.25	0.25	0.25
Syphilis	1.16	1.11	1.25	1.42
T. cruzi	0.22	0.3	0.25	0.34
HTLV I-II	0.02	0.02	0.01	0.06
Anti-HBc	3.52	1.24	0.10	0.15
Percentage of units separated into components				
Packed red blood cells	94.26	96.33	96.45	96.5
Fresh frozen plasma	77.12	76.27	74.98	72.87
Frozen plasma	4.09	12.12	12.36	17.49
Cryoprecipitate	4.22	2.50	3.21	3.85
Platelets	51.71	43.59	46.19	49.51
Percentage of units discarded				
Whole blood	NR	44.78	2.18	1.15
Packed red blood cells	NR	3.98	5.45	5.25
Fresh frozen plasma	NR	27.33	31.94	25.11
Frozen plasma	NR	37.20	52.93	44.83
Cryoprecipitate	NR	7.85	9.39	12.55
Platelets	NR	23.70	31.78	32.10

NR: Not Reported.

EL SALVADOR (SLV)	2012	2013	2014	2015
Number of Units Collected	94,494	98,088	98,090	92,882
Number of Autologous Donors	2	9	2	63
Percentage type of allogeneic donors				
Voluntary, altruistic donors	11.51	14.30	14.95	17.03
Family/Replacement donors	88.49	85.70	85.05	82.97
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	0.05	0.07	0.09	0.13
HBsAg	0.13	0.12	0.12	0.12
HCV	0.11	0.15	0.22	0.10
Syphilis	0.75	0.75	1.19	1.50
T. cruzi	1.51	3.21	2.30	2.65
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	94.25	99.88	87.81	NR
Fresh frozen plasma	58.83	66.32	65.87	75.92
Frozen plasma	NR	NR	NR	0
Cryoprecipitate	11.63	16.4	14.52	16.22
Platelets	56.18	55.17	75.6	90.09
Percentage of units discarded				
Whole blood	NI	NI	0.68	0.69
Packed red blood cells	2.23	5.78	6.57	5.96
Fresh frozen plasma	20.16	19.31	19.44	16.79
Frozen plasma	NR	NR	NR	NA
Cryoprecipitate	0.76	47.81	54.03	3.40
Platelets	6.31	1.18	0.86	11.42

NR: Not Reported.

GUATEMALA (GTM)	2012	2013	2014	2015
Number of Units Collected	113,041	121,921	114,404	126,244
Number of Autologous Donors	23	14	16	22
Percentage type of allogeneic donors				
Voluntary, altruistic donors	4.34	4.81	6.66	5.44
Family/Replacement donors	95.66	95.19	93.34	94.56
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	NR	NR	NR	NR
Anti-HBc	77.41	100	82.91	93.82
Percentage of units reactive/positive				
HIV	0.27	0.39	0.15	0.24
HBsAg	0.38	0.46	0.45	0.38
HCV	0.61	0.97	0.57	0.54
Syphilis	1.90	2.67	1.56	1.41
T. cruzi	1.02	1.04	1.04	0.93
HTLV I-II	NR	NR	NR	NR
Anti-HBc	3.94	3.92	3.4	3.14
Percentage of units separated into components				
Packed red blood cells	87.27	88.21	87.7	88.85
Fresh frozen plasma	47.42	46.82	48.1	50.23
Frozen plasma	NR	2.07	2.31	2.94
Cryoprecipitate	1.08	1.13	2.57	4.37
Platelets	37.71	36.14	38.22	35.38
Percentage of units discarded				
Whole blood	22.53	21.89	1.72	0.27
Packed red blood cells	12.59	13.52	15.43	5.26
Fresh frozen plasma	29.5	28.03	30.11	20.5
Frozen plasma	NR	NR	12.74	NR
Cryoprecipitate	18.53	23.91	12.21	4.18
Platelets	29.23	24.48	26.44	23.98

NR: Not Reported.

HONDURAS (HND)	2012	2013	2014	2015
Number of Units Collected	66,519	69,082	58,612	71,646
Number of Autologous Donors	10	6	1	9
Percentage type of allogeneic donors				
Voluntary, altruistic donors	15.66	15	17.25	18.6
Family/Replacement donors	84.11	84.13	82.08	80.44
Remunerated donors	0.23	0.87	0.67	0.96
Percentage of units screened				
HIV	100	100	99.14	100
HBsAg	100	100	99.17	100
HCV	100	100	99.24	100
Syphilis	100	100	99.21	100
T. cruzi	100	100	99.25	100
HTLV I-II	94.02	96.23	98.65	99.85
Anti-HBc	95.64	96.23	98.68	100
Percentage of units reactive/positive				
HIV	0.16	0.15	0.28	0.09
HBsAg	0.20	0.28	0.26	0.18
HCV	0.38	0.35	0.45	0.38
Syphilis	0.95	1.01	0.80	0.70
T. cruzi	1.23	1.06	0.96	0.74
HTLV I-II	0.31	0.14	0.18	0.15
Anti-HBc	2.21	2.23	1.96	1.62
Percentage of units separated into components				
Packed red blood cells	41.62	46.66	60.56	78.28
Fresh frozen plasma	38.49	37.46	48.93	61.65
Frozen plasma	NR	NR	NR	1.11
Cryoprecipitate	3.14	3.87	5.27	1.09
Platelets	31.89	30.27	40.24	41.29
Percentage of units discarded				
Whole blood	28.04	NR	7.11	4.74
Packed red blood cells	12.14	6.64	6.72	6.44
Fresh frozen plasma	46.94	24.25	52.4	60.36
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	4.98	1.68	2.69	80.87
Platelets	17.74	25.82	12.05	19.14

NR: Not Reported.

MEXICO (MEX)	2012	2013	2014	2015
Number of Units Collected	1,768,862	1,364,395	1,939,060	2,170,002
Number of Autologous Donors	1,716	1,065	0	2,269
Percentage type of allogeneic donors				
Voluntary, altruistic donors	2.77	3.06	2.57	3.80
Family/Replacement donors	97.23	96.94	97.43	96.2
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	98.43	98.45	100	100
HBsAg	98.36	98.45	100	100
HCV	98.47	98.44	100	100
Syphilis	98.2	98.27	100	100
T. cruzi	90.69	91.85	96.45	99.94
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	0.25	0.29	0.26	0.24
HBsAg	0.15	0.18	0.16	0.15
HCV	0.57	0.68	0.60	0.48
Syphilis	0.59	0.70	0.58	0.56
T. cruzi	0.45	0.53	0.48	0.37
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	91.92	96.85	93.65	94.99
Fresh frozen plasma	74.14	66.39	69.12	79.66
Frozen plasma	15.77	19.39	14.71	8.91
Cryoprecipitate	5.60	11.08	5.22	5.23
Platelets	40.82	48.31	38.07	38.06
Percentage of units discarded				
Whole blood	69.92	NR	3	3
Packed red blood cells	6.99	8.60	6.42	6.34
Fresh frozen plasma	39.86	57.71	39.94	37.59
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	15.49	10.15	15.67	15.65
Platelets	30.88	33.83	31.31	31.31

NR: Not Reported.

NICARAGUA (NIC)	2012	2013	2014	2015
Number of Units Collected	72,988	72,658	75,035	74,955
Number of Autologous Donors	0	NR	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	100	100
Family/Replacement donors	0	0	0	0
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	0.06	0.04	0.07	0.09
HBsAg	0.22	0.21	0.21	0.18
HCV	0.34	0.32	0.30	0.34
Syphilis	0.60	0.36	0.30	0.32
T. cruzi	0.27	0.40	0.31	0.34
HTLV I-II	NR	NR	NR	NR
Anti-HBc	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	98.76	98.63	97.6	96.65
Fresh frozen plasma	91.93	86.43	89.73	51.93
Frozen plasma	6.83	3.58	8.39	4.90
Cryoprecipitate	6.85	6.58	9.68	5.15
Platelets	52.93	55.88	57.87	53.41
Percentage of units discarded				
Whole blood	78.70	68.21	1.09	0.82
Packed red blood cells	2.24	2	1.83	1.41
Fresh frozen plasma	50.31	50.83	50.92	83.15
Frozen plasma	97.65	NR	89.66	NR
Cryoprecipitate	2.72	2.07	2.29	2.10
Platelets	4.62	4.27	2.36	2.61

NR: Not Reported.

PANAMA (PAN)	2012	2013	2014	2015
Number of Units Collected	55,083	53,529	37,833	56,313
Number of Autologous Donors	138	115	22	19
Percentage type of allogeneic donors				
Voluntary, altruistic donors	4.44	5.79	7.98	7.05
Family/Replacement donors	86.18	85.9	72.87	87.65
Remunerated donors	9.38	8.09	19.15	5.30
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	98.33	100	100	100
Anti-HBc	100	100	100	100
Percentage of units reactive/positive				
HIV	0.23	0.17	0.11	0.16
HBsAg	0.32	0.22	0.20	0.21
HCV	0.60	0.50	0.34	0.36
Syphilis	1.17	1.38	1.04	0.88
T. cruzi	0.48	0.40	0.37	0.52
HTLV I-II	0.50	0.33	0.32	0.44
Anti-HBc	1.96	1.97	1.67	1.74
Percentage of units separated into components				
Packed red blood cells	89.61	81.21	90.91	88.28
Fresh frozen plasma	41.94	38.49	45.51	57.9
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	6.29	6.63	13.81	7.84
Platelets	51.04	51.73	51.88	57.34
Percentage of units discarded				
Whole blood	12.37	NR	0.18	0.21
Packed red blood cells	13.98	NR	16.89	16.64
Fresh frozen plasma	8.51	NR	25.51	25.63
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	10.70	NR	3.79	11.59
Platelets	18.25	NR	40.98	35.57

NR: Not Reported.

PARAGUAY (PRY)	2012	2013	2014	2015
Number of Units Collected	62,154	86,056	87,888	86,120
Number of Autologous Donors	9	116	0	123
Percentage type of allogeneic donors				
Voluntary, altruistic donors	11.48	9.20	9.13	10.25
Family/Replacement donors	88.51	90.8	90.87	89.75
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	98.99	100	100	100
HBsAg	98.99	100	100	100
HCV	98.99	100	100	100
Syphilis	98.99	100	100	100
T. cruzi	98.99	100	100	100
HTLV I-II	98.99	100	100	100
Anti-HBc	98.99	100	100	100
Percentage of units reactive/positive				
HIV	0.71	0.43	0.34	0.29
HBsAg	0.34	0.30	0.34	0.30
HCV	0.35	0.30	0.37	0.34
Syphilis	7.51	6.47	6.57	6
T. cruzi	2.48	2.33	2.33	2.37
HTLV I-II	0.16	0.28	0.21	0.32
Anti-HBc	2.67	3.03	2.90	2.75
Percentage of units separated into components				
Packed red blood cells	51.57	83.65	90.75	97.57
Fresh frozen plasma	41.5	70.73	67.99	75.71
Frozen plasma	8.08	30.87	13.68	9.92
Cryoprecipitate	0.91	6.38	7.94	8.54
Platelets	26.01	57.78	48.93	58.25
Percentage of units discarded				
Whole blood	13.65	7.88	1.67	1.44
Packed red blood cells	19.72	16.42	14.18	14.39
Fresh frozen plasma	34.60	15.5	25.38	28.22
Frozen plasma	38.06	14.53	NR	NR
Cryoprecipitate	28.87	4.27	9.70	8.14
Platelets	68	30.08	61.83	46.73

NR: Not Reported.

PERU (PER)	2012	2013	2014	2015
Number of Units Collected	166,049	204,871	NR	NR
Number of Autologous Donors	295	118	NR	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	5.66	4.56	NR	NR
Family/Replacement donors	94.34	95.43	NR	NR
Remunerated donors	0	0.005	NR	NR
Percentage of units screened				
HIV	100	100	NR	NR
HBsAg	100	100	NR	NR
HCV	100	100	NR	NR
Syphilis	100	100	NR	NR
T. cruzi	100	100	NR	NR
HTLV I-II	100	100	NR	NR
Anti-HBc	100	100	NR	NR
Percentage of units reactive/positive				
HIV	0.19	0.23	NR	NR
HBsAg	0.41	0.38	NR	NR
HCV	0.47	0.56	NR	NR
Syphilis	1.12	1.19	NR	NR
T. cruzi	0.61	0.5	NR	NR
HTLV I-II	0.98	0.88	NR	NR
Anti-HBc	4.31	4.19	NR	NR
Percentage of units separated into components				
Packed red blood cells	87.96	90.65	NR	NR
Fresh frozen plasma	62.65	67.53	NR	NR
Frozen plasma	15.51	14.22	NR	NR
Cryoprecipitate	6.39	8.82	NR	NR
Platelets	51.95	51.32	NR	NR
Percentage of units discarded				
Whole blood	10.17	11.33	NR	NR
Packed red blood cells	9.82	13.68	NR	NR
Fresh frozen plasma	21.14	30.92	NR	NR
Frozen plasma	50.89	92.46	NR	NR
Cryoprecipitate	18.67	7.78	NR	NR
Platelets	26.38	26.77	NR	NR

NR: Not Reported.

DOMINICAN REPUBLIC (DOM)	2012	2013	2014	2015
Number of Units Collected	106,291	110,780	93,949	78,533
Number of Autologous Donors	34	46	58	18
Percentage type of allogeneic donors				
Voluntary, altruistic donors	18.7	15.97	9.99	11.62
Family/Replacement donors	78.61	81.15	89.65	88.30
Remunerated donors	2.69	2.85	0.36	0.08
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	NR	NR	NR	NR
HTLV I-II	100	100	100	99.64
Anti-HBc	NR	NR	11.77	74.2
Percentage of units reactive/positive				
HIV	0.20	0.16	0.28	0.17
HBsAg	0.85	1.03	1.02	0.95
HCV	0.19	0.21	0.21	0.15
Syphilis	0.57	0.66	0.71	0.59
T. cruzi	NR	NR	NR	NR
HTLV I-II	0.24	0.23	0.16	0.21
Anti-HBc	NR	NR	4.70	1.18
Percentage of units separated into components				
Packed red blood cells	49.92	54.13	52.52	49.9
Fresh frozen plasma	5.64	6.50	4.39	1.43
Frozen plasma	4.14	4.61	5.47	2.34
Cryoprecipitate	0.08	0.05	NR	NR
Platelets	6.62	6.92	5.73	3.49
Percentage of units discarded				
Whole blood	8.15	12.12	11.42	13.61
Packed red blood cells	1.95	1.89	10.33	3.54
Fresh frozen plasma	79.02	67.93	29.92	7.10
Frozen plasma	NR	NR	11.13	0.05
Cryoprecipitate	1.16	0	NR	NR
Platelets	13.07	16.70	9.53	3.89

NR: Not Reported.

URUGUAY (URY)	2012	2013	2014	2015
Number of Units Collected	104,342	99,151	96,563	90,669
Number of Autologous Donors	358	604	305	198
Percentage type of allogeneic donors				
Voluntary, altruistic donors	NI	46.48	49.79	51.44
Family/Replacement donors	NI	53.52	50.21	48.56
Remunerated donors	NI	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
T. cruzi	100	100	100	100
HTLV I-II	100	100	100	100
Anti-HBc	100	100	100	100
Percentage of units reactive/positive				
HIV	0.11	0.13	0.09	0.11
HBsAg	0.13	0.10	0.10	0.11
HCV	0.34	0.36	0.32	0.31
Syphilis	0.45	0.49	0.51	0.41
T. cruzi	0.31	0.24	0.21	0.19
HTLV I-II	0.07	0.13	0.10	0.22
Anti-HBc	0.99	0.91	0.88	0.79
Percentage of units separated into components				
Packed red blood cells	NR	NR	NR	73.49
Fresh frozen plasma	NR	NR	NR	64.82
Frozen plasma	NR	NR	NR	4.02
Cryoprecipitate	NR	NR	NR	2.78
Platelets	NR	NR	NR	44.5
Percentage of units discarded				
Whole blood	NR	NR	NR	0.11
Packed red blood cells	NR	NR	NR	27.83
Fresh frozen plasma	NR	NR	NR	1.02
Frozen plasma	NR	NR	NR	1.51
Cryoprecipitate	NR	NR	NR	2.03
Platelets	NR	NR	NR	36.76

NR: Not Reported.

VENEZUELA (VEN)	2012	2013	2014	2015
Number of Units Collected	445,957	NR	312,048	299,879
Number of Autologous Donors	0	NR	0	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	6.62	NR	5.27	5.81
Family/Replacement donors	93.38	NR	94.73	94.19
Remunerated donors	0	NR	0	0
Percentage of units screened				
HIV	93.38	NR	100	100
HBsAg	93.38	NR	100	100
HCV	93.38	NR	100	100
Syphilis	93.38	NR	100	100
T. cruzi	93.38	NR	100	100
HTLV I-II	93.38	NR	100	100
Anti-HBc	93.38	NR	100	100
Percentage of units reactive/positive				
HIV	0.19	NR	0.25	0.25
HBsAg	0.43	NR	0.37	0.39
HCV	0.3	NR	0.28	0.34
Syphilis	1.69	NR	1.67	1.55
T. cruzi	0.27	NR	0.35	0.31
HTLV I-II	0.15	NR	0.14	0.18
Anti-HBc	2.85	NR	2.74	2.56
Percentage of units separated into components				
Packed red blood cells	88.27	NR	95.62	94.47
Fresh frozen plasma	73.11	NR	77.23	78.19
Frozen plasma	5.97	NR	NR	5.42
Cryoprecipitate	5.97	NR	4.89	5.42
Platelets	51.98	NR	55.98	58.45
Percentage of units discarded				
Whole blood	NR	NR	NR	NR
Packed red blood cells	4.47	NR	NR	12.78
Fresh frozen plasma	NR	NR	NR	NR
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	NR	NR	NR	NR
Platelets	NR	NR	NR	NR

NR: Not Reported.

CARIBBEAN COUNTRIES

ANGUILLA (AIA)	2012	2013	2014	2015
Number of Units Collected	115	140	121	97
Number of Autologous Donors	1	0	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	29.82	32.14	17.35	44.33
Family/Replacement donors	70.18	67.86	82.65	55.67
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	0	0	0	0
Percentage of units reactive/positive				
HIV	0	NR	NR	0
HBsAg	0.88	0.71	NR	0
HCV	0	0.71	NR	0
Syphilis	0	NR	NR	0
HTLV I-II	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	61.74	56.43	65.29	55.10
Fresh frozen plasma	NR	NR	NR	0
Frozen plasma	NR	NR	NR	0
Cryoprecipitate	NR	NR	NR	0
Platelets	NR	NR	NR	0
Percentage of units discarded				
Whole blood	22.72	14.75	8.26	10.20
Packed red blood cells	NR	NR	NR	0
Fresh frozen plasma	NR	NR	NR	NA
Frozen plasma	NR	NR	NR	NA
Cryoprecipitate	NR	NR	NR	NA
Platelets	NR	NR	NR	NA

NR: Not Reported.

ANTIGUA AND BARBUDA (ATG)	2012	2013	2014	2015
Number of Units Collected	NR	NR	NR	NR
Number of Autologous Donors	NR	NR	NR	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	NR	NR	NR	NR
Family/Replacement donors	NR	NR	NR	NR
Remunerated donors	NR	NR	NR	NR
Percentage of units screened				
HIV	NR	NR	NR	NR
HBsAg	NR	NR	NR	NR
HCV	NR	NR	NR	NR
Syphilis	NR	NR	NR	NR
HTLV I-II	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	NR	NR	NR	NR
HBsAg	NR	NR	NR	NR
HCV	NR	NR	NR	NR
Syphilis	NR	NR	NR	NR
HTLV I-II	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NR
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	NR	NR	NR	NR
Platelets	NR	NR	NR	NR
Percentage of units discarded				
Whole blood	NR	NR	NR	NR
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NR
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	NR	NR	NR	NR
Platelets	NR	NR	NR	NR

NR: Not Reported.

ARUBA (ABW)	2012	2013	2014	2015
Number of Units Collected	3,116	2,998	2,829	3,065
Number of Autologous Donors	5	4	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	100	100
Family/Replacement donors	0	0	0	0
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	100	100	100	100
Percentage of units reactive/positive				
HIV	0.03	0	0	0
HBsAg	0	0.03	0	0
HCV	0	0	0	0.03
Syphilis	0	0	0	0
HTLV I-II	0	0	0.04	0.03
Percentage of units separated into components				
Packed red blood cells	97.17	97.60	100	100
Fresh frozen plasma	15.10	18.55	14.70	17.13
Frozen plasma	NR	NR	0	0
Cryoprecipitate	NR	NR	0	0
Platelets	69.80	68.71	82.25	84.64
Percentage of units discarded				
Whole blood	NR	NR	0	0
Packed red blood cells	1.65	3.79	1.45	7.68
Fresh frozen plasma	15.35	26.26	9.86	13.84
Frozen plasma	NR	NR	NA	NA
Cryoprecipitate	NR	NR	NA	NA
Platelets	72	67.38	NR	65.27

NR: Not Reported.

BAHAMAS (BHS)	2012	2013	2014	2015
Number of Units Collected	7,638	7,214	4,563	5,747
Number of Autologous Donors	2	16	5	8
Percentage type of allogeneic donors				
Voluntary, altruistic donors	37.87	41.93	40.79	28.05
Family/Replacement donors	62.12	58.07	59.21	71.95
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	100	100	100	100
Percentage of units reactive/positive				
HIV	0.20	0.14	0	0.14
HBsAg	0.51	0.36	0.13	0.50
HCV	0.29	0.25	0.04	0.28
Syphilis	1.17	0.97	0.35	0.78
HTLV I-II	0.33	0.28	0.09	0.33
Percentage of units separated into components				
Packed red blood cells	71.16	69.64	100	99.87
Fresh frozen plasma	21.18	22.58	37.59	34.34
Frozen plasma	NR	33.50	0	0
Cryoprecipitate	NR	NR	0	0.39
Platelets	25.28	26.75	35.84	33.69
Percentage of units discarded				
Whole blood	NR	5.82	0	0
Packed red blood cells	6.49	11.43	6.21	6.59
Fresh frozen plasma	20.7	34.75	17.87	26.72
Frozen plasma	NR	NR	NA	NA
Cryoprecipitate	NR	NR	NA	NR
Platelets	23.77	48.70	25.26	52.83

NR: Not Reported.

BARBADOS (BRB)	2012	2013	2014	2015
Number of Units Collected	NR	NR	4,638	NR
Number of Autologous Donors	NR	NR	57	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	NR	NR	11.55	NR
Family/Replacement donors	NR	NR	88.45	NR
Remunerated donors	NR	NR	0	NR
Percentage of units screened				
HIV	NR	NR	100	NR
HBsAg	NR	NR	100	NR
HCV	NR	NR	100	NR
Syphilis	NR	NR	100	NR
HTLV I-II	NR	NR	100	NR
Percentage of units reactive/positive				
HIV	NR	NR	0.15	NR
HBsAg	NR	NR	0.32	NR
HCV	NR	NR	0.51	NR
Syphilis	NR	NR	1.22	NR
HTLV I-II	NR	NR	0.43	NR
Percentage of units separated into components				
Packed red blood cells	NR	NR	22.30	NR
Fresh frozen plasma	NR	NR	22.30	NR
Frozen plasma	NR	NR	0	NR
Cryoprecipitate	NR	NR	0.31	NR
Platelets	NR	NR	20.6	NR
Percentage of units discarded				
Whole blood	NR	NR	6.82	NR
Packed red blood cells	NR	NR	13.20	NR
Fresh frozen plasma	NR	NR	0	NR
Frozen plasma	NR	NR	NA	NR
Cryoprecipitate	NR	NR	0	NR
Platelets	NR	NR	0	NR

NR: Not Reported.

BELIZE (BLZ)	2012	2013	2014	2015
Number of Units Collected	4,795	5,120	4,329	5,564
Number of Autologous Donors	0	0	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	13.22	13.85	25.78	14.07
Family/Replacement donors	86.78	86.15	74.22	85.93
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	0.27	0.12	0.16	0.2
HBsAg	0.38	0.23	0.51	0.25
HCV	0.27	0.17	0.23	0.09
Syphilis	1.50	3.38	0.67	0.45
HTLV I-II	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	35.85	43.05	35.71	29.28
Fresh frozen plasma	15.66	21.11	12.2	16.55
Frozen plasma	20.19	21.86	23.52	12.37
Cryoprecipitate	NR	0.08	0.69	0.36
Platelets	15.62	12.79	11.60	13.17
Percentage of units discarded				
Whole blood	NI	29.49	17.88	10.44
Packed red blood cells	7.68	8.85	7.50	11.97
Fresh frozen plasma	14.25	13.5	15.72	16.61
Frozen plasma	75.41	30.92	12.87	18.46
Cryoprecipitate	NR	NR	0	NR
Platelets	37.52	81.22	54.18	46.25

NR: Not Reported.

BERMUDA (BMU)	2012	2013	2014	2015
Number of Units Collected	2,179	1,836	1,602	1,676
Number of Autologous Donors	11	2	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	100	100
Family/Replacement donors	0	0	0	0
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	100	100	100	100
Percentage of units reactive/positive				
HIV	0.05	0.05	0	0
HBsAg	0.05	0.05	0	0
HCV	0.05	0	0	0
Syphilis	0.18	0	0	0
HTLV I-II	0.05	0.50	0	0
Percentage of units separated into components				
Packed red blood cells	93.76	86.76	100	92.24
Fresh frozen plasma	19.60	16.72	22.35	10.80
Frozen plasma	NR	NR	0	0
Cryoprecipitate	NR	NR	0	0
Platelets	NR	NR	9.55	9.43
Percentage of units discarded				
Whole blood	NR	NR	2.19	1.73
Packed red blood cells	11.21	3.77	4.12	6.27
Fresh frozen plasma	17.10	18.24	13.69	21.55
Frozen plasma	NR	NR	NA	NA
Cryoprecipitate	NR	NR	NA	NA
Platelets	NR	NR	66.01	75.95

NR: Not Reported.

BRITISH VIRGIN ISLANDS (VGB)	2012	2013	2014	2015
Number of Units Collected	381	353	350	NR
Number of Autologous Donors	2	5	NR	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	0	0	NR	NR
Family/Replacement donors	100	100	NR	NR
Remunerated donors	0	0	NR	NR
Percentage of units screened				
HIV	100	100	100	NR
HBsAg	100	100	100	NR
HCV	100	100	100	NR
Syphilis	100	100	100	NR
HTLV I-II	100	100	100	NR
Percentage of units reactive/positive				
HIV	0	0	0	NR
HBsAg	1.05	0.85	0	NR
HCV	0.52	0	0.57	NR
Syphilis	1.05	1.42	0.86	NR
HTLV I-II	0.26	0.57	0.57	NR
Percentage of units separated into components				
Packed red blood cells	99.74	99.15	100	NR
Fresh frozen plasma	31.57	30.53	24	NR
Frozen plasma	68.24	68.56	76	NR
Cryoprecipitate	NR	0	0	NR
Platelets	NR	0	0	NR
Percentage of units discarded				
Whole blood	NR	NR	0	NR
Packed red blood cells	20.79	16.86	11.71	NR
Fresh frozen plasma	NR	13.89	16.67	NR
Frozen plasma	NR	100	0	NR
Cryoprecipitate	NR	NR	NA	NR
Platelets	NR	NR	NA	NR

NR: Not Reported.

CAYMAN ISLANDS (CYM)	2012	2013	2014	2015
Number of Units Collected	1,026	1,018	1,071	1,115
Number of Autologous Donors	0	0	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	100	100
Family/Replacement donors	0	0	0	0
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	100	100	100	100
Percentage of units reactive/positive				
HIV	0	0	0	0.18
HBsAg	0	0.30	0.37	0
HCV	0	0.10	0	0.18
Syphilis	0.10	0.10	0.28	0.09
HTLV I-II	0	1.18	1.21	0.36
Percentage of units separated into components				
Packed red blood cells	90.84	90.96	90.85	94.8
Fresh frozen plasma	48.25	51.77	38.94	53.81
Frozen plasma	NR	NR	0	0
Cryoprecipitate	NR	NR	0	0
Platelets	NR	NR	0	0
Percentage of units discarded				
Whole blood	57.45	50	4.11	4.84
Packed red blood cells	7.08	12.63	13.46	18.54
Fresh frozen plasma	39	26	27.10	28.17
Frozen plasma	NR	NR	NA	NA
Cryoprecipitate	NR	NR	NA	NA
Platelets	NR	NR	NA	NA

NR: Not Reported.

CURACAO (CUW)	2012	2013	2014	2015
Number of Units Collected	6,401	5,559	6,628	5,844
Number of Autologous Donors	3	2	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	100	100
Family/Replacement donors	0	0	0	0
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	100	100	100	100
Percentage of units reactive/positive				
HIV	0	0	0	0
HBsAg	0	0	0	0
HCV	0	0	0	0
Syphilis	0	0	0	0
HTLV I-II	0	0	0.02	0
Percentage of units separated into components				
Packed red blood cells	99	99.05	100	100
Fresh frozen plasma	20.81	19.81	76.95	NR
Frozen plasma	NR	NR	0	20.53
Cryoprecipitate	NR	NR	0	NR
Platelets	53.84	53.77	18.11	23.10
Percentage of units discarded				
Whole blood	NR	NR	0	0
Packed red blood cells	4.46	4.87	0.92	2.82
Fresh frozen plasma	4.73	4.63	1.20	NR
Frozen plasma	NR	NR	NA	NR
Cryoprecipitate	NR	NR	NA	NR
Platelets	63.61	71.17	0	13.26

NR: Not Reported.

DOMINICA (DMA)	2012	2013	2014	2015
Number of Units Collected	946	1,071	1,006	NR
Number of Autologous Donors	0	0	0	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	10.57	8.68	6.56	NR
Family/Replacement donors	89.43	91.32	93.44	NR
Remunerated donors	0	0	0	NR
Percentage of units screened				
HIV	100	100	100	NR
HBsAg	100	100	100	NR
HCV	NR	0	NR	NR
Syphilis	100	100	100	NR
HTLV I-II	100	100	100	NR
Percentage of units reactive/positive				
HIV	0	0	0	NR
HBsAg	0.21	0.19	0.20	NR
HCV	NR	NR	NR	NR
Syphilis	1.16	1.21	1.89	NR
HTLV I-II	0.95	1.49	0.80	NR
Percentage of units separated into components				
Packed red blood cells	95.35	96.26	50.70	NR
Fresh frozen plasma	54.33	63.77	50.70	NR
Frozen plasma	NR	NR	0	NR
Cryoprecipitate	3.81	2.15	0	NR
Platelets	49.68	43.32	47.22	NR
Percentage of units discarded				
Whole blood	NR	NI	4.87	NR
Packed red blood cells	12.86	9.12	10.39	NR
Fresh frozen plasma	NR	56.37	27.06	NR
Frozen plasma	NR	NR	NA	NR
Cryoprecipitate	NR	13.04	NA	NR
Platelets	NR	50.22	60.84	NR

NR: Not Reported.

GRENADA (GRD)	2012	2013	2014	2015
Number of Units Collected	1,365	NR	1,267	NR
Number of Autologous Donors	NR	NR	1	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	38.83	NR	40.20	NR
Family/Replacement donors	61.17	NR	59.8	NR
Remunerated donors	0	NR	0	NR
Percentage of units screened				
HIV	NR	NR	100	NR
HBsAg	NR	NR	100	NR
HCV	NR	NR	100	NR
Syphilis	NR	NR	100	NR
HTLV I-II	NR	NR	100	NR
Percentage of units reactive/positive				
HIV	NR	NR	0.32	NR
HBsAg	NR	NR	0.71	NR
HCV	NR	NR	0.24	NR
Syphilis	NR	NR	0.24	NR
HTLV I-II	NR	NR	0	NR
Percentage of units separated into components				
Packed red blood cells	NR	NR	99.05	NR
Fresh frozen plasma	NR	NR	3.95	NR
Frozen plasma	NR	NR	1.58	NR
Cryoprecipitate	NR	NR	0	NR
Platelets	NR	NR	11.21	NR
Percentage of units discarded				
Whole blood	NR	NR	0.95	NR
Packed red blood cells	NR	NR	9.88	NR
Fresh frozen plasma	NR	NR	2	NR
Frozen plasma	NR	NR	NA	NR
Cryoprecipitate	NR	NR	NA	NR
Platelets	NR	NR	0	NR

NR: Not Reported.

GUADELOUPE (GLP)	2012	2013	2014	2015
Number of Units Collected	6,788	10,508	NR	7,891
Number of Autologous Donors	0	0	NR	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	NR	100
Family/Replacement donors	0	0	NR	0
Remunerated donors	0	0	NR	0
Percentage of units screened				
HIV	100	100	NR	100
HBsAg	100	100	NR	100
HCV	100	100	NR	100
Syphilis	100	100	NR	100
HTLV I-II	100	100	NR	100
Percentage of units reactive/positive				
HIV	0.12	0.13	NR	0.03
HBsAg	0.13	0.11	NR	0.04
HCV	0	0.1	NR	0.01
Syphilis	0.37	0.54	NR	0.22
HTLV I-II	0.09	0.17	NR	0.01
Percentage of units separated into components				
Packed red blood cells	NR	NR	NR	98.01
Fresh frozen plasma	NR	NR	NR	0
Frozen plasma	NR	NR	NR	0
Cryoprecipitate	NR	NR	NR	0
Platelets	NR	NR	NR	8.09
Percentage of units discarded				
Whole blood	NR	NR	NR	NR
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NA
Frozen plasma	NR	NR	NR	NA
Cryoprecipitate	NR	NR	NR	NA
Platelets	NR	NR	NR	NR

NR: Not Reported.

GUYANA (GUY)	2012	2013	2014	2015
Number of Units Collected	7,712	11,148	NR	9,702
Number of Autologous Donors	0	0	NR	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	95.79	NR	100
Family/Replacement donors	0	4.21	NR	0
Remunerated donors	0	0	NR	0
Percentage of units screened				
HIV	100	100	NR	100
HBsAg	100	100	NR	100
HCV	100	100	NR	100
Syphilis	100	100	NR	100
HTLV I-II	100	100	NR	100
Percentage of units reactive/positive				
HIV	0.27	0.34	NR	0.98
HBsAg	0.96	0.88	NR	1.41
HCV	0.45	0.46	NR	1.07
Syphilis	0.66	0.37	NR	0.85
HTLV I-II	0.43	0.83	NR	1.01
Percentage of units separated into components				
Packed red blood cells	63.78	98.82	NR	100
Fresh frozen plasma	15.81	59.17	NR	66.05
Frozen plasma	NR	NR	NR	0
Cryoprecipitate	1.12	6.01	NR	2.16
Platelets	13	31.67	NR	20.95
Percentage of units discarded				
Whole blood	73.43	NR	NR	0
Packed red blood cells	NR	10	NR	10.48
Fresh frozen plasma	NR	1.49	NR	2.50
Frozen plasma	NR	NR	NR	NA
Cryoprecipitate	NR	0.75	NR	2.87
Platelets	NR	7.53	NR	14.72

NR: Not Reported.

HAITI (HTI)	2012	2013	2014	2015
Number of Units Collected	25,608	27,478	28,867	27,752
Number of Autologous Donors	0	0	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	71.75	59.16	53.71	47.70
Family/Replacement donors	28.25	40.84	46.29	52.3
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	100	100	100	100
Percentage of units reactive/positive				
HIV	0.93	1.10	0.98	0.79
HBsAg	3.44	3.52	3.42	3.68
HCV	0.44	1.03	0.86	0.85
Syphilis	1.99	2.45	2.57	3.50
HTLV I-II	0.62	0.71	0.69	0.78
Percentage of units separated into components				
Packed red blood cells	46.16	22.12	62.48	81.22
Fresh frozen plasma	NR	0.65	62.48	1.85
Frozen plasma	NR	NR	0	NR
Cryoprecipitate	NR	NR	0	0.04
Platelets	NR	4.51	1.72	6.03
Percentage of units discarded				
Whole blood	13.38	10.87	8.06	9.90
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NR
Frozen plasma	NR	NR	NA	NR
Cryoprecipitate	NR	NR	NA	NR
Platelets	NR	NR	NR	NR

NR: Not Reported.

JAMAICA (JAM)	2012	2013	2014	2015
Number of Units Collected	30,947	30,679	29,390	31,554
Number of Autologous Donors	75	78	112	183
Percentage type of allogeneic donors				
Voluntary, altruistic donors	23.8	16.48	21.9	35.85
Family/Replacement donors	76.2	83.52	78.10	64.15
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	98.27	100	100
HBsAg	100	98.27	100	100
HCV	100	98.27	100	100
Syphilis	100	98.27	100	100
HTLV I-II	100	98.27	100	100
Percentage of units reactive/positive				
HIV	1.09	0.40	0.44	0.30
HBsAg	0.80	0.60	0.75	0.64
HCV	0.69	0.70	0.27	0.50
Syphilis	2.20	1.50	1.73	2.01
HTLV I-II	1.57	2.60	1.51	1.52
Percentage of units separated into components				
Packed red blood cells	98.79	NR	68.31	73.01
Fresh frozen plasma	NR	9.66	49.84	51.9
Frozen plasma	NR	1.07	6.71	9.33
Cryoprecipitate	NR	1.34	6.96	7.30
Platelets	NR	4.67	21.49	20.63
Percentage of units discarded				
Whole blood	NR	NR	0	NR
Packed red blood cells	NR	NR	6.21	11.29
Fresh frozen plasma	NR	NR	3.60	2.68
Frozen plasma	NR	NR	0.56	NR
Cryoprecipitate	NR	NR	3.03	1
Platelets	NR	NR	4.40	7.86

NR: Not Reported.

MARTINIQUE (MTQ)	2012	2013	2014	2015
Number of Units Collected	NR	NR	NR	11,217
Number of Autologous Donors	NR	NR	NR	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	NR	NR	NR	100
Family/Replacement donors	NR	NR	NR	0
Remunerated donors	NR	NR	NR	0
Percentage of units screened				
HIV	NR	NR	NR	100
HBsAg	NR	NR	NR	100
HCV	NR	NR	NR	100
Syphilis	NR	NR	NR	100
HTLV I-II	NR	NR	NR	100
Percentage of units reactive/positive				
HIV	NR	NR	NR	0
HBsAg	NR	NR	NR	0.02
HCV	NR	NR	NR	0
Syphilis	NR	NR	NR	0.12
HTLV I-II	NR	NR	NR	0.02
Percentage of units separated into components				
Packed red blood cells	NR	NR	NR	91.51
Fresh frozen plasma	NR	NR	NR	0
Frozen plasma	NR	NR	NR	0
Cryoprecipitate	NR	NR	NR	0
Platelets	NR	NR	NR	15.94
Percentage of units discarded				
Whole blood	NR	NR	NR	NR
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NA
Frozen plasma	NR	NR	NR	NA
Cryoprecipitate	NR	NR	NR	NA
Platelets	NR	NR	NR	NR

NR: Not Reported.

MONTSERRAT (MSR)	2012	2013	2014	2015
Number of Units Collected	NR	NR	NR	NR
Number of Autologous Donors	NR	NR	NR	NR
Percentage type of allogeneic donors				
Voluntary, altruistic donors	NR	NR	NR	NR
Family/Replacement donors	NR	NR	NR	NR
Remunerated donors	NR	NR	NR	NR
Percentage of units screened				
HIV	NR	NR	NR	NR
HBsAg	NR	NR	NR	NR
HCV	NR	NR	NR	NR
Syphilis	NR	NR	NR	NR
HTLV I-II	NR	NR	NR	NR
Percentage of units reactive/positive				
HIV	NR	NR	NR	NR
HBsAg	NR	NR	NR	NR
HCV	NR	NR	NR	NR
Syphilis	NR	NR	NR	NR
HTLV I-II	NR	NR	NR	NR
Percentage of units separated into components				
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NR
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	NR	NR	NR	NR
Platelets	NR	NR	NR	NR
Percentage of units discarded				
Whole blood	NR	NR	NR	NR
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NR
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	NR	NR	NR	NR
Platelets	NR	NR	NR	NR

NR: Not Reported.

ST. KITTS AND NEVIS (KNA)	2012	2013	2014	2015
Number of Units Collected	NR	331	NR	408
Number of Autologous Donors	NR	0	NR	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	NR	21.45	NR	10.29
Family/Replacement donors	NR	78.55	NR	89.71
Remunerated donors	NR	0	NR	0
Percentage of units screened				
HIV	NR	100	NR	100
HBsAg	NR	100	NR	100
HCV	NR	100	NR	100
Syphilis	NR	100	NR	100
HTLV I-II	NR	76.13	NR	100
Percentage of units reactive/positive				
HIV	NR	0	NR	0
HBsAg	NR	3.63	NR	2.94
HCV	NR	0	NR	0.25
Syphilis	NR	0	NR	1.72
HTLV I-II	NR	0	NR	1.47
Percentage of units separated into components				
Packed red blood cells	NR	9.10	NR	4.90
Fresh frozen plasma	NR	9.10	NR	4.90
Frozen plasma	NR	NR	NR	0
Cryoprecipitate	NR	NR	NR	0
Platelets	NR	NR	NR	0
Percentage of units discarded				
Whole blood	NR	NR	NR	14.46
Packed red blood cells	NR	23.33	NR	60
Fresh frozen plasma	NR	23.33	NR	0
Frozen plasma	NR	NR	NR	NA
Cryoprecipitate	NR	NR	NR	NA
Platelets	NR	NR	NR	NA

NR: Not Reported.

ST. LUCIA (LCA)	2012	2013	2014	2015
Number of Units Collected	2,276	2,174	2,448	2,463
Number of Autologous Donors	9	7	8	2
Percentage type of allogeneic donors				
Voluntary, altruistic donors	67.76	62.11	57.46	63.51
Family/Replacement donors	32.24	37.97	42.54	36.49
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	100	100	100
HBsAg	100	100	100	100
HCV	100	100	100	100
Syphilis	100	100	100	100
HTLV I-II	100	100	100	100
Percentage of units reactive/positive				
HIV	0	0.09	0.08	0.16
HBsAg	0.83	0.64	1.26	0.89
HCV	0.08	0.05	0.12	0.04
Syphilis	0.78	1.10	1.75	1.38
HTLV I-II	0.57	0.87	0.61	0.85
Percentage of units separated into components				
Packed red blood cells	NR	95.54	99.76	96.14
Fresh frozen plasma	NR	18.03	33.10	32.11
Frozen plasma	NR	5.93	0	1.06
Cryoprecipitate	NR	NR	0	0.08
Platelets	NR	35.97	43.97	44.86
Percentage of units discarded				
Whole blood	NR	69.07	4.72	0.89
Packed red blood cells	NR	8.57	3.63	7.94
Fresh frozen plasma	NR	8.93	0	18.46
Frozen plasma	NR	0.78	NA	NR
Cryoprecipitate	NR	NR	NA	NR
Platelets	NR	61	51.85	46.97

NR: Not Reported.

ST. VINCENT AND THE GRENADINES (VCT)	2012	2013	2014	2015
Number of Units Collected	1,195	1,161	1,081	1,043
Number of Autologous Donors	23	16	17	15
Percentage type of allogeneic donors				
Voluntary, altruistic donors	6.14	13.8	7.24	14.01
Family/Replacement donors	93.86	86.2	92.76	85.99
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	99.5	100	85.70	98.56
HBsAg	99.5	100	85.70	98.56
HCV	99.5	100	85.70	98.56
Syphilis	99.5	100	85.70	98.56
HTLV I-II	99.5	100	85.70	98.56
Percentage of units reactive/positive				
HIV	0.17	0.17	0.10	0.10
HBsAg	1	0.43	0.80	0.49
HCV	0.42	0.52	0.30	0.20
Syphilis	1.51	2.8	2.70	2.24
HTLV I-II	2.18	2.33	2.21	2.14
Percentage of units separated into components				
Packed red blood cells	99	98.62	98.30	98.56
Fresh frozen plasma	18.08	22.14	19.12	28.38
Frozen plasma	NR	NR	0	0
Cryoprecipitate	NR	NR	0	0
Platelets	18.01	21.62	19.12	28.38
Percentage of units discarded				
Whole blood	NI	43.75	0.30	0.58
Packed red blood cells	6.68	16	11.41	9.14
Fresh frozen plasma	NR	10.51	5.76	3.04
Frozen plasma	NR	NR	NA	NA
Cryoprecipitate	NR	NR	NA	NA
Platelets	72.22	83.67	65.45	69.26

NR: Not Reported.

SURINAME (SUR)	2012	2013	2014	2015
Number of Units Collected	9,848	10,105	10,521	10,296
Number of Autologous Donors	2	2	0	6
Percentage type of allogeneic donors				
Voluntary, altruistic donors	100	100	100	100
Family/Replacement donors	0	0	0	0
Remunerated donors	0	0	0	0
Percentage of units screened				
HIV	100	98.39	100	100
HBsAg	100	98.39	100	100
HCV	100	98.39	100	100
Syphilis	100	98.39	100	100
HTLV I-II	100	98.39	100	100
Percentage of units reactive/positive				
HIV	0.03	0.01	0.01	0
HBsAg	0.02	0.05	0.09	0.06
HCV	0.01	0.03	0.03	0.01
Syphilis	0	0.03	0.03	0.02
HTLV I-II	0.03	0.01	0.02	0
Percentage of units separated into components				
Packed red blood cells	100	98.39	98.39	99.7
Fresh frozen plasma	20.33	19.08	20.49	19.22
Frozen plasma	NR	NR	0	0
Cryoprecipitate	NR	NR	0	0
Platelets	22.68	21.03	24.64	28.52
Percentage of units discarded				
Whole blood	NR	NR	0	0
Packed red blood cells	0.66	0.52	0.72	0.94
Fresh frozen plasma	0.65	0.31	1.19	1.42
Frozen plasma	NR	NR	NA	NA
Cryoprecipitate	NR	NR	NA	NA
Platelets	15.98	20.2	18.07	19.86

NR: Not Reported.

TURKS AND CAICOS (TCA)	2012	2013	2014	2015
Number of Units Collected	674	NR	354	437
Number of Autologous Donors	0	NR	0	0
Percentage type of allogeneic donors				
Voluntary, altruistic donors	57.57	NR	38.14	54.23
Family/Replacement donors	42.43	NR	61.86	45.77
Remunerated donors	0	NR	0	0
Percentage of units screened				
HIV	100	NR	100	100
HBsAg	100	NR	100	100
HCV	100	NR	100	100
Syphilis	100	NR	100	100
HTLV I-II	100	NR	100	100
Percentage of units reactive/positive				
HIV	0	NR	0.28	0
HBsAg	0	NR	0.85	0
HCV	0	NR	0	0.23
Syphilis	0.15	NR	0.85	1.60
HTLV I-II	0	NR	0.28	0
Percentage of units separated into components				
Packed red blood cells	23	NR	64.12	100
Fresh frozen plasma	4.30	NR	61.86	81.24
Frozen plasma	18.69	NR	0.57	0.46
Cryoprecipitate	0	NR	0	0
Platelets	0.74	NR	1.70	1.37
Percentage of units discarded				
Whole blood	NR	NR	7.91	0
Packed red blood cells	NR	NR	80.18	32.49
Fresh frozen plasma	NR	NR	0	0
Frozen plasma	NR	NR	0	0
Cryoprecipitate	NR	NR	NA	NA
Platelets	NR	NR	0	0

NR: Not Reported.

TRINIDAD AND TOBAGO (TTO)	2012	2013	2014	2015
Number of Units Collected	20,345	21,300	21,249	21,121
Number of Autologous Donors	55	NR	77	123
Percentage type of allogeneic donors				
Voluntary, altruistic donors	0	NR	17.73	18.41
Family/Replacement donors	100	NR	82.27	81.59
Remunerated donors	0	NR	0	0
Percentage of units screened				
HIV	100	100	NR	NR
HBsAg	100	100	NR	NR
HCV	100	100	NR	NR
Syphilis	100	100	NR	NR
HTLV I-II	100	100	NR	NR
Percentage of units reactive/positive				
HIV	0.20	0.19	NR	NR
HBsAg	0.33	0.23	NR	NR
HCV	0.31	0.20	NR	NR
Syphilis	1.41	1.40	NR	NR
HTLV I-II	0.62	0.19	NR	NR
Percentage of units separated into components				
Packed red blood cells	33.06	36.41	NR	NR
Fresh frozen plasma	21.59	24.66	NR	NR
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	1.71	6.71	NR	NR
Platelets	17.10	19.82	NR	NR
Percentage of units discarded				
Whole blood	NR	NR	NR	NR
Packed red blood cells	NR	NR	NR	NR
Fresh frozen plasma	NR	NR	NR	NR
Frozen plasma	NR	NR	NR	NR
Cryoprecipitate	NR	NR	NR	NR
Platelets	NR	NR	NR	NR

NR: Not Reported.

ANNEX

Pan American Health Organization
World Health Organization
REGIONAL OFFICE FOR THE Americas

53rd DIRECTING COUNCIL

66th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS

Washington, D.C., USA, 29 September-3 October 2014

Provisional Agenda Item 4.4

CD53/6
22 July 2014
Original: español

PLAN OF ACTION FOR UNIVERSAL ACCESS TO SAFE BLOOD

Introduction

1. This document is presented with a two-fold purpose: for the countries of the Region to use this Plan as a reference when drafting their national plans and strategies, tailoring it to their own needs; and for them to monitor and evaluate its implementation in order to reach the targets set for 2019.

2. The countries of the Region reaffirmed their commitment to universal health coverage at the last PAHO/WHO Directing Council in 2013. The commitment of the Member States is also expressed in the targets of the PAHO/WHO Strategic Plan 2014-2019, in which universal health coverage is one of the main unifying elements. Universal access to blood transfusions and safe blood products is an essential service for universal health coverage, helping to save millions of lives and improving the health of people who need them. Blood transfusions have been identified as one of the eight key life-saving interventions in health centers that offer emergency obstetric services *(1)*.

3. Transfusions are also necessary for the care of: *a)* children with severe anemia; *b)* patients with hemoglobin disorders such as thalassemia and sickle cell anemia; *c)* people injured in accidents; *d)* cancer patients; *e)* people who undergo major surgery and other surgical interventions such as transplants; and *f)* patients with chronic age-related diseases such as bleeding resulting from vascular problems or orthopedic surgery, among other causes. These groups are particularly vulnerable to blood scarcity and unsafe blood, since they are exposed to transfusion-transmitted infections such as HIV and hepatitis B and C.

4. In light of the above, this Plan of Action seeks to promote universal, timely access to safe blood in order to save lives and improve the health conditions of all patients who need it.

5. In this regard, the Plan is the result of: *a)* the systematization of the priorities and recommendations of the WHO Global Strategic Plan for Universal Access to Safe Blood Transfusion *(2)*; *b)* the work done in the Region for over a decade *(3)*; *c)* the results of the evaluation of the Regional Plan of Action for Transfusion Safety 2006-2010 *(4)*; *d)* the contributions made by the PAHO/WHO expert group and external experts; and *e)* the contributions received from the national blood programs in the Region.

Background

6. Every year, over 500,000 women die worldwide during pregnancy, childbirth, or the postpartum period, and 99% of these deaths occur in the developing world. An estimated 25% of these deaths are due to hemorrhage during delivery, the most common cause of maternal mortality, accounting for 21% of maternal deaths in Latin America and the Caribbean. If not addressed, this problem could compromise both the achievement of the Millennium Development Goal (MDG) 5 target of reducing maternal mortality and the enjoyment of the right to life, personal integrity, and the highest attainable standard of health, among other human rights. Maternal mortality from hemorrhage and the subsequent lack of blood for transfusion can be considered a human rights violation *(5)*. An inversely proportional relationship is observed between the maternal mortality ratio and the availability of blood; in countries where the availability of blood is low, maternal mortality is higher (Figures 1 and 2 available at: www.paho.org/figures-tables-regional-blood-plan).

7. To achieve universal access to safe blood for transfusions key strategies must be strengthened, among them: ensuring self-sufficiency in blood and blood products through voluntary non-remunerated blood donation; improving the quality of donated blood (from the donor's arm to the recipient's arm); maximizing appropriate blood use; strengthening human resources; adopting new advances; and establishing strategic partnerships with the different sectors involved in the area.

8. Since 1975, the World Health Assembly (WHA) and the WHO Executive Board have considered various documents and adopted numerous resolutions related to blood safety: WHA28.72 [1975], EB79.R1 [1987], WHA40.26 [1987], WHA45.35 [1992], WHA48.27 [1995], WHA53.14 [2000], WHA55.18 [2002], WHA56.30 [2003], WHA58.13 [2005], WHA63.12 [2010], WHA63.18 [2010], and WHA63.20 [2010] *(6 to 17)*.

9. Several resolutions on this matter have also been adopted in the Region of the Americas: CD41.R15 (1999), CD46.R5 (2005), CE142.R5 (2008), and CD48.R7 (2008). This issue is also related to the Strategy and Plan of Action for Chagas Disease Prevention, Control and Care (CD50/16 [2010]); the Plan of Action to Accelerate the Reduction of Maternal Mortality and Severe Maternal Morbidity [CE148/16 (2011)]; and the PAHO Regional Strategic Plan for HIV/AIDS/STI, 2006-2015 *(18-24)*.

10. Finally, in 2011, a group of external experts in transfusion medicine from different countries and organizations evaluated the Regional Plan of Action for Transfusion Safety 2006-2010. Their evaluation was presented to the 51st Directing Council in document CD51/INF/5 *(25)*, with the following recommendations: *a)* to continue the strengthening of blood collection, screening, and processing; *b)* to achieve the goal of 100% voluntary donation (mainly repeat donations); and *c)* to establish quality control systems. If these basic recommendations are followed, it will be possible for the Region to obtain sufficient quantities of safe blood in a timely fashion *(25-27)*.

Situation Analysis

11. In 2012 every country in Latin America had specific national blood legislation, but only four Caribbean countries did (Belize, Curaçao, Guyana, and Suriname). In that same year, 15 of the 41 countries and territories in Latin America and the Caribbean had an integrated, intersectoral, national strategic blood plan with resources for its implementation, monitoring, and evaluation. In 27 of the 41 countries and territories, a specific health ministry entity was responsible for planning, monitoring, and evaluating the national blood system; national intersectoral blood commissions were operating in only 14 countries *(28)*.

12. Furthermore, despite the demonstrated benefits of reducing the number of services that process blood—in terms of quality, safety, and lowering costs—the number of processing centers rose from 1,763 in 2010 to 1,772 in 2011. These benefits are demonstrated by considering the number of units produced per blood bank/year: Brazil, Colombia, Cuba, Ecuador, Nicaragua, and Paraguay have a higher production per bank, resulting from the reorganization of blood services and certain blood-related processes, and consolidation of blood banks. Production in the other countries is less than 5,000 units/bank/year, a figure that some studies have shown not to be cost-effective and that can compromise blood quality and safety *(29, 30)* (Table 1, available at: www.paho.org/figures-tables-regional-blood-plan). For the Caribbean countries, the number of units processed per blood bank/year shows that Curaçao, Guyana, Haiti, Jamaica, Suriname, and Trinidad and Tobago have the highest production, while the other countries are below 3,000 units/bank/year (Table 2, available at: www.paho.org/figures-tables-regional-blood-plan).

13. When reorganizing blood services networks, each country should give particular consideration to its specific needs, including its geographic and demographic characteristics, communication channels, and regional needs to ensure that blood is available and accessible where it is needed *(30)*. By 2011, only nine of the 19 countries in Latin America had reorganized their blood services networks *(28)*.

14. In 2011, 9,275,914 units of blood were collected in Latin America and the Caribbean, representing a 3.2% increase in the Region over 2010, with a more significant increase in the Caribbean countries (31%) than in Latin America (2.8%). This increase put the 2011 blood donation rate at 15 per 1000 population in Latin America and 18 per 1000 in the Caribbean (Table 3, available at: www.paho.org/figures-tables-regional-

blood-plan). When compared with global data, these figures put the Region at about average for middle-income countries and at the lower end for high-income countries *(30).*

15. The first studies estimating blood needs in Latin America and the Caribbean were conducted in 2010; to date, only four Latin American and two Caribbean countries have reported calculating these needs.[1]

16. The percentage of volunteer blood donors in Latin America and the Caribbean remained at around 41.4% in 2010-2011, meaning that the number of volunteer donors has not increased (Table 3, available at: www.paho.org/figures-tables-regional-blood-plan).

17. Thirty of 41 countries and territories in Latin America and the Caribbean reported having implemented some components of quality systems. However, certain aspects require greater development, for example, achieving 100% screening for transfusion-transmitted infections such as the human immunodeficiency virus (HIV), hepatitis B HBsAg, hepatitis C (HCV), and syphilis. In 2011, 99.7% of blood was screened in Latin America and the Caribbean, which indicates that 107,702 blood units are not being screened for some of these infectious agents. With regard to *T. cruzi,* 202,610 units were not screened for this marker in Latin America in 2011. (Table 3, available at: www.paho.org/figures-tables-regional-blood-plan). In that same year, the average prevalence of infectious markers in Latin America and the Caribbean did not differ significantly from 2010. (Table 4, available at: www.paho.org/figures-tables-regional-blood-plan). This situation can perhaps be explained by low growth in the number of repeat volunteer donors *(28).*

18. It should be pointed out that there is insufficient evidence in the Region to support the regulation of hepatitis E screening in high-risk groups, such as patients who undergo transplants and similar surgical interventions, patients on dialysis, and pregnant women who need surgery. As a result, research should be conducted in order to reach timely conclusions on this subject.

19. With regard to the separation of blood units into components, a figure of 92.9% was achieved for red blood cell concentrates in 2011 in Latin America and 67.04% in the Caribbean. As a result, Latin America and the Caribbean did not achieve 95% separation of units (the Plan 2006-2010 target).

20. When the increased availability of red blood cells is compared with the number of units of red blood cells discarded due to expiration, it is observed that (in 27 of 41 countries and territories in Latin America and the Caribbean) 10.3% was discarded in 2011—a slight improvement in this indicator over the 14.1% in 2009. This indicates that 799,738 units of red blood cells were no longer available for transfusion to patients because they had passed their expiration date (Tables 5 and 6, available at: www.paho.org/figures-tables-regional-blood-plan) *(28).* In 2011, discarded blood

[1] Information provided directly by the national blood programs to PAHO Headquarters in 2013.

represented a loss of US$44,785,328[2] (at an average cost of $56/unit), in addition to the cost in terms of blood availability, timely transfusions to patients, and the social value that this represents. This finding could reflect poor planning that does not allow for correlations between needs and the blood supply. This underscores the importance of prioritizing better management of the blood supply through organized networks and estimates of blood needs (Tables 5 and 6, available at: www.paho.org/figures-tables-regional-blood-plan) *(28).*

21. Concerning the rational use of blood and blood products, 20 of the 41 countries and territories in Latin America and the Caribbean reported having guidelines for the clinical use of blood, while only seven have transfusion committees in 75% of hospitals at the national level. From the information available in the countries, it is not possible to characterize blood recipients by age, sex, and pathology or determine the epidemiological factors that affect needs or the estimated number of units transfused by event.

22. Concerning the public health functions involved in health surveillance and hemovigilance, 20 of the 41 countries and territories (12 in Latin America and eight in the Caribbean) have programs for the inspection, monitoring, and oversight of blood services. Concerning the monitoring of adverse transfusion-related events, only two countries reported having information, research, and analysis mechanisms for timely decision-making *(28)* (Tables 7 and 8, available at: www.paho.org/figures-tables-regional-blood-plan). This situation underscores the need to integrate and harmonize blood and other public health indicators to improve hemovigilance and health surveillance. This would make it possible to determine whether the blood supply is self-sufficient, accessible, timely, and safe, and how it is affecting national morbidity and mortality. It would also make it possible to design risk management plans aimed at identifying and managing the risks associated with the transfusion chain in terms of blood safety and adverse events in donation and transfusion, which are related to blood supply, access, and availability, as well as emergencies and disasters *(30).*

Plan of Action (2014-2019)

Goal

23. The goal of this Plan is to promote universal access to safe blood through voluntary non-remunerated donations to help save lives and improve the health of patients who need them.

24. This Plan advocates appropriate blood use and greater leadership by health authorities, urging them to implement quality management programs in the transfusion chain (from promoting blood donation to monitoring patients) and to integrate the blood system into the national health system. Ultimately, this Plan calls for the restructuring of blood services, based on efficient and sustainable models.

[2] Unless otherwise indicated, all monetary figures in this report are expressed in United States dollars.

Strategic Lines of Action

25. Given this background and consistent with the progress made in the Region toward maintaining achievements and tackling new challenges, the regional Plan 2014-2019 focuses on the following critical areas:

a) effective and sustainable integration of national blood programs and services into the national health system to achieve blood self-sufficiency, safety, efficiency, availability, and universal access to blood and blood products;

b) self-sufficiency in safe blood and blood products through 100% voluntary non remunerated donations;

c) Quality management in the national blood system and screening for transfusion-transmitted infections;

d) Health surveillance, hemovigilance, risk management, monitoring, and evaluation.

Strategic Line of Action 1: Effective and sustainable integration of national blood programs and services into the national health system to achieve blood self-sufficiency, safety, efficiency, availability, and universal access to blood and blood products.

26. The intention is to guarantee, through greater political will and the participation of the ministries of health and other sectors, the countries' commitment to making it a national priority to achieve blood self-sufficiency, safety, availability, and universal access to blood and blood products, given that blood for transfusions is an indispensable cross-cutting health intervention and a basic requirement for guaranteeing the right to the enjoyment of the highest attainable standard of health and other related human rights.

Objective 1.1. Strengthen planning, implementation, monitoring, and evaluation processes in national blood programs.

Indicators:

1.1.1 Number of countries that have a specific functioning entity in the ministry of health that is responsible for planning, monitoring, and evaluation of the national blood system.
(Baseline: 27/41. Target: 36 countries)

1.1.2 Number of countries that have a functioning intersectoral national blood commission or advisory mechanism.
(Baseline: 14/41. Target: 21 countries)

1.1.3. Number of countries whose blood policy includes self-sufficiency, availability, and universal access to safe blood and blood products.
(Baseline: 18/41. Target: 26 countries)

Objective 1.2. Include the issue of safe blood in national health plans in order to ensure resources and intersectoral support.

Indicator:

1.2.1 Number of countries that have an integrated intersectoral national strategic blood plan that includes human resources training, monitoring and evaluation of the plan, and guaranteed resources for its implementation.
(Baseline: 13/41. Target: 21 countries)

Objective 1.3. Organize and consolidate an integrated blood services network within the health services network, tailored to the needs of each country.

Indicator:

1.3.1. Number of countries with more than one processing center that have increased the average number of units processed per blood bank/year (including screening) to over 5,000 units as a result of the restructuring of the blood services network.
(Baseline: 12/25. Target: 17 countries)

Strategic Line of Action 2: Self-sufficiency in safe blood and blood products through 100% voluntary non-remunerated donations.

27. The supply of blood and blood products should be based on voluntary non-remunerated donations to ensure blood self-sufficiency, availability, and safety; and on the promotion of healthy lifestyles, participation, and public solidarity.

Objective 2.1. Calculate the country's need for blood and blood products to achieve self-sufficiency in safe blood.

Indicator:

2.1.1 Number of countries that have calculated their blood needs at the national and regional level.
(Baseline: 6/41. Target: 12 countries)

Objective 2.2. Reach blood self-sufficiency through non-remunerated voluntary blood donations.

Indicator:

2.2.1 Number of countries that reach 100% non-remunerated voluntary blood donations.
(Baseline: 8/41. Target: 16 countries).

Strategic Line of Action 3: Quality management in the national blood system and screening for transfusion-transmitted infections.

28. This is aimed at fostering the countries' commitment to ensuring that their national blood system operates under a quality management framework and achieves 100% screening for the infections listed in PAHO/WHO recommendations, with a view to achieving blood self-sufficiency, safety, and availability, and universal access to blood and blood products.

Objective 3.1. Establish, monitor, and evaluate the quality management system in the blood services network, which includes screening for HIV, HBV, HCV, syphilis, and *T. cruzi* (the latter in endemic areas).

Indicators:

3.1.1 Number of countries that screen 100% of blood units for transfusion for HIV, HBV, HCV, syphilis, and *T. cruzi.*
(Baseline: 39/41. Target: 41 countries)

3.1.2 Number of countries that have a national program for external serology performance evaluations.
(Baseline: 22/41. Target: 27 countries)

3.1.3 Number of countries that have a national program for external immunohematology performance evaluations.
(Baseline: 12/41. Target: 18 countries)

Objective 3.2. Adopt the necessary mechanisms to increase the availability and appropriate use of blood and blood products.

Indicators:

3.2.1 Number of countries that have functioning transfusion committees in at least 75% of hospitals that perform daily transfusions.
(Baseline: 7/41. Target: 12 countries)

3.2.2 Number of countries that have national guidelines in place for the appropriate use of blood and blood products.
(Baseline: 20/41. Target: 30 countries)

3.2.3 Five percent (5%) reduction, in the Region, in the number of red blood cell units discarded due to expiration.
(Baseline 10.3%. Target: 5.3%)

Strategic Line of Action 4: Health surveillance, hemovigilance, risk management, monitoring, and evaluation.

29. The purpose of this strategic line is to strengthen the surveillance, evaluation, and monitoring system in order to obtain information to identify and implement timely and

appropriate interventions that will ensure sufficient supply, safety, and availability of blood, and universal access to blood and blood products.

Objective 4.1. Strengthen the national blood system so that health surveillance is included in blood services.

Indicator:

4.1.1 Number of countries that have a national model for inspection, surveillance, and oversight in blood services.
(Baseline: 20/41. Target: 30 countries)

Objective 4.2. Strengthen the national blood system to integrate hemovigilance in blood services.

Indicator:

4.2.1 Number of countries that have a national hemovigilance system
(Baseline: 2/41. Target: 7 countries)

Objective 4.3. Establish a mechanism to enable countries to monitor the implementation of their national plan.

Indicator:

4.3.1 Number of countries that annually report the indicators of their national plan in response to the implementation of the regional Plan 2014-2019.
(Baseline: 0/41. Target: 41 countries)

Objective 4.4. Draft risk management plans based on the information generated by the haemovigilance system.

Indicator:

4.4.1 Number of countries that have drafted risk management plans based on hemovigilance information.
(Baseline: 0/41. Target: 7 countries)

Monitoring and Evaluation

30. This Plan of Action will help achieve Category 4 of the PAHO Strategic Plan 2014-2019 and is directly related to program area 4.3 and outcomes 4.3.1, 4.3.3, and 4.3.4. Within that same category, it will also help achieve program areas 4.1, 4.2, 4.4. Annex C lists other outcomes to which this Plan contributes at the level of the Organization.

31. This Plan of Action 2014-2019 will help meet the global priorities set in the WHO Global Strategic Plan for Universal Access to Safe Blood Transfusion 2008-2015.

32. Monitoring and evaluation of this Plan is consistent with the Organization's results-based management framework and its performance, monitoring, and evaluation processes. Accordingly, PAHO/WHO plans to conduct a mid-term and final evaluation, and the countries are expected to prepare annual progress reports on the achievement of the indicators.

Financial Implications for the Organization

33. The estimated cost to the Organization of implementing the proposal over the five-year period includes $8 million in expenditures on technical and administrative staff and on cooperation activities. With regard both to budgetary implications and implementation of the interventions, the commitment and support of the Member States, as well as the collaborating centers and partners in this area, are essential. Since this regional plan cannot be undertaken by the Pan American Sanitary Bureau alone, it will be necessary for the more economically developed countries in the Region to invest in the blood safety through multilateral or bilateral cooperation. That investment—in addition to the support provided by the Bureau through its technical capacity to promote cooperation among countries and the creation and strengthening of networks in the Region—would provide the financial coverage needed to meet the Plan's targets and goals. (The financial and administrative aspects are described in Annex B).

Action by the Directing Council

34. The Directing Council is requested to review the information in this document and consider adopting the proposed resolution in Annex A.

Annexes

References

1. World Health Organization. New initiative to improve mothers'access to safe blood [Internet]. Geneva: WHO; 12 June 2007 [consulted on 7 March 2014]. Available at: http://who.int/mediacentre/news/releases/2007/pr29/en/

2. World Health Organization. Universal access to safe blood transfusion: scaling up the implementation of the WHO Strategy for blood safety and availability for improving patient health and saving lives. WHO global strategic plan, 2008-2015 [Internet]. Geneva: WHO; 2008 [consulted on 7 March 2014]. Available at: http://www.who.int/bloodsafety/StrategicPlan2008-2015AccessSafeBloodTransfusion.pdf

3. Pan American Health Organization. Strategic and Programmatic Orientations for the Pan American Sanitary Bureau, 1999-2002 [Internet]. 25th Pan American Sanitary Conference, 50th session of the WHO Regional Committee for the

Americas; 21-25 September 1998, Washington, D.C. United States. Washington, D.C.; PAHO; 1998 [consulted on 7 March 2014]. Available at: http://www1.paho.org/english/gov/csp/csp25_8.pdf?ua=1

4. Pan American Health Organization. Progress Report on the Global Safe Blood Initiative and Plan of Action for 2005-2010 [Internet]. 46th PAHO Directing Council, 57th session of the WHO Regional Committee for the Americas; 26-30 September 2005; Washington, D.C., United States. Washington, D.C.: PAHO; 2005 (Resolution CD46.R5) [consulted on 7 March 2014]. Available at: http://www1.paho.org/english/gov/cd/CD46.r5-e.pdf

5. Graciela Freyermuth and Paola Sesia. La muerte materna. Acciones y estrategias hacia una maternidad segura [Internet]. México: Centro de Investigaciones y Estudios Superiores en Antropología Social: Comité Promotor por una Maternidad sin Riesgos en México; 2009 [consulted on 7 March 2014]. Available at: http://elrostrodelamortalidadmaterna.cimac.org.mx/sites/default/files/La_Muerte_Materna_2_Acciones_y_Estrategias_hacia_una_maternidad_Segura.pdf

6. World Health Organization. Utilization and supply of human blood and blood products. In: Official Records of the World Health Organization No. 226 [Internet]. 28th World Health Assembly, 13-30 May 1975; Geneva, Switzerland. Geneva: WHO; 1975 (Resolution WHA28.72, p. 40) [consulted on 7 March 2014]. Available at: http://www.who.int/bloodsafety/en/WHA28.72.pdf

7. World Health Organization. Blood and blood products [Internet]. 79th session of the WHO Executive Board; 12-23 January 1987; Geneva, Switzerland. Geneva: WHO; 1987 (Resolution EB79.R1) [consulted on 7 March 2014]. Available at: http://www.who.int/bloodsafety/en/EB79.R1.pdf

8. World Health Organization. Global strategy for the prevention and control of AIDS [Internet]. 40th World Health Assembly; 4-15 May 1987; Geneva, Switzerland. Geneva: WHO; 1987 (Resolution WHA40.26) [consulted on 7 March 2014]. Available at: http://www.who.int/bloodsafety/en/WHA40.26.pdf

9. World Health Organization. Global strategy for the prevention and control of AIDS [Internet]. 45th World Health Assembly; 4-14 May 1992; Geneva, Switzerland. Geneva: WHO; 1992 (Resolution WHA45.35) [consulted on 7 March 2014]. Available at: http://digicollection.org/hss/documents/s15420e/s15420e.pdf

10. World Health Organization. Paris AIDS Summit [Internet]. 48th World Health Assembly; 1-12 May 1995; Geneva, Switzerland. Geneva: WHO; 1995 (Resolution WHA48.27) [consulted on 7 March 2014]. Available at: http://whqlibdoc.who.int/wholis/3/WHA48_R27_eng.pdf

11. World Health Organization. HIV/AIDS: confronting the epidemic [Internet]. 53rd World Health Assembly; 15-20 May 2000; Geneva, Switzerland. Geneva: WHO; 2000 (Resolution WHA53.14) [consulted on 7 March 2014]. Available at: http://apps.who.int/gb/archive/pdf_files/WHA53/ResWHA53/14.pdf

12. World Health Organization. Quality of care: patient safety [Internet]. 55th World Health Assembly; 13-18 May 2002; Geneva, Switzerland. Geneva: WHO; 2002 (Resolution WHA55.18) [consulted on 7 March 2014]. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/ewha5518.pdf

13. World Health Organization. Global health-sector strategy for HIV/AIDS [Internet]. 56th World Health Assembly; 19-28 May 2003; Geneva, Switzerland. Geneva: WHO; 2003 (Resolution WHA56.30) [consulted on 7 March 2014]. Available at: http://apps.who.int/gb/archive/pdf_files/WHA56/ea56r30.pdf

14. World Health Organization. Blood safety: proposal to establish World Blood Donor Day [Internet]. 58th World Health Assembly; 16-25 May 2005; Geneva, Switzerland. Geneva: WHO; 2005 (Resolution WHA58.13, p. 80) [consulted on 7 March 2014]. Available at: http://www.who.int/bloodsafety/WHA58_13-en.pdf?ua=1

15. World Health Organization. Availability, safety and quality of blood products [Internet]. 63rd World Health Assembly; 17-21 May 2010; Geneva, Switzerland. Geneva: WHO; 2010 (Resolution WHA63.12) [consulted on 7 March 2014]. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf

16. World Health Organization. Viral hepatitis [Internet]. 63rd World Health Assembly; 17-21 May 2010; Geneva, Switzerland. Geneva: WHO; 2010 (Resolution WHA63.18) [consulted on 7 March 2014]. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R18-en.pdf

17. World Health Organization. Chagas disease: control and elimination [Internet]. 63rd World Health Assembly; 17-21 May 2010; Geneva, Switzerland. Geneva: WHO; 2010 (Resolution WHA63.20) [consulted on 7 March 2014]. Available at: http://www.who.int/neglected_diseases/mediacentre/WHA_63.20_Eng.pdf

18. Pan American Health Organization. Strengthening Blood Banks in the Region of the Americas [Internet]. 41st PAHO Directing Council, 51st session of the WHO Regional Committee for the Americas; 27 September to 1 October 1999; San

Juan, Puerto Rico. Washington, D.C.: PAHO 1999 (Resolution CD41.R15) [consulted on 7 March 2014]. Available at: http://iris.paho.org/xmlui/bitstream/handle/123456789/1409/CD41.R15en.pdf?sequence=1

19. Pan American Health Organization. Progress Report on the Global Safe Blood Initiative and Plan of Action 2005-2010 [Internet]. 46th PAHO Directing Council, 57th session of the WHO Regional Committee for the Americas; 26-30 September 2005, Washington, D.C., United States. Washington, D.C.: PAHO; 2005 (Resolution CD46.R5) [consulted on 7 March 2014]. Available at: http://www1.paho.org/english/gov/cd/cd46.r5-e.pdf

20. Pan American Health Organization. Blood Transfusion Safety: Progress Report [Internet]. 142nd session of the PAHO Executive Committee; 23-27 June 2008; Washington, D.C., United States. Washington, D.C.: PAHO 2008 (Resolution CE142.R5) [consulted on 7 March 2014]. Available at: http://www1.paho.org/english/gov/ce/ce142.r5-e.pdf

21. Pan American Health Organization. Improving Blood Availability and Transfusion Safety in the Americas [Internet]. 48th PAHO Directing Council, 60th session of the WHO Regional Committee for the Americas; 29 September to 3 October 2008, Washington, D.C., United States. Washington, D.C.: PAHO; 2008 (document CD48/11) [consulted on 7 March 2014]. Available at: http://www1.paho.org/english/gov/cd/cd48-11-e.pdf

22. Pan American Health Organization. Strategy and Plan of Action for Chagas Disease Prevention, Control and Care [Internet]. 50th PAHO Directing Council, 62nd session of the WHO Regional Committee for the Americas; 27 September to 1 October 2010; Washington, D.C., United States. Washington, D.C.: PAHO;

2010 (document CD50/16) [consulted on 7 March 2014]. Available at: http://www2.paho.org/hq/dmdocuments/2011/CD50-16-e.pdf

23. Pan American Health Organization. Plan of Action to Accelerate the Reduction of Maternal Mortality and Severe Maternal Morbidity [Internet]. 148th session of the PAHO Executive Committee; 20-24 June 2011; Washington, D.C., United States. Washington, D.C.: PAHO; 2011 (document CE148/16, Rev.1) [consulted on 7 March 2014]. Available at: http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=13444&Itemid=

24. Pan American Health Organization. Regional Strategic Plan for HIV/AIDS/STI, 2006-2015, of the Pan American Health Organization [Internet]. 46th PAHO Directing Council, 57th session of the WHO Regional Committee for the Americas; 26-30 September 2005; Washington, D.C., United States. Washington,

D.C.: PAHO; 2005 (document CD46/20, Add. I) [consulted on 7 March 2014]. Available at: http://www1.paho.org/english/gov/cd/cd46-20a-e.pdf

25. Pan American Health Organization. Regional Initiative and Plan of Action for Transfusion Safety 2006-2010: Final Evaluation [Internet]. 51st PAHO Directing Council, 63rd session of the WHO Regional Committee for the Americas; 26-30 September 2011; Washington, D.C., United States. Washington, D.C.: PAHO; (document CD51/INF/5-G) [consulted on 7 March 2014]. Available at: file:///C:/Users/loomerd/Downloads/CD51-INF-5-G-e%20(1).pdf

26. Pan American Health Organization. Evaluation of the PAHO Regional Plan for Transfusion Safety 2006-2010, Washington, D.C.: PAHO; 11 June 2011. (internal document, available on request).

27. Pan American Health Organization. Supply of Blood for Transfusion in the Caribbean and Latin American Countries in 2006, 2007, 2008, and 2009: Progress since 2005 of the Regional Plan of Action for Transfusion Safety [Internet]. Washington, D.C.: PAHO; 2010 (Technical Documents, Monitoring and Evaluation Series [HSS/MT/2010/01ESP]). Washington, D.C., 2010. Available at: http://www2.paho.org/hq/dmdocuments/2011/BloodEnweb.pdf

28. Pan American Health Organization. Supply of Blood for Transfusion in Latin American and Caribbean Countries 2010 and 2011 [Internet]. Washington, D.C.: PAHO; 2013 [consulted on 7 March 2014]. Available at: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=22468&Itemid==

29. Beltrán Durán M, Ayala Guzmán M. Evaluación externa de los resultados serológicos en los bancos de sangre de Colombia. *Rev Panam Salud Pública* 2003;13(2-3):138-142.

30. World Health Organization. Towards self-sufficiency in safe blood and blood products based on voluntary non-remunerated donation: global status 2013 [Internet]. Geneva: WHO; 2013 [consulted on 7 March 2014]. Available at: http://www.who.int/bloodsafety/transfusion_services/WHO_GlobalStatusReportSelf-SufficiencyinBloodBloodProducts.pdf

Pan American Health Organization
World Health Organization
REGIONAL OFFICE FOR THE Americas

53rd DIRECTING COUNCIL

66th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS

Washington, D.C., USA, 29 September-3 October 2014

CD53/6
Annex A
Original: Spanish

PROPOSED RESOLUTION

PLAN OF ACTION FOR UNIVERSAL ACCESS TO SAFE BLOOD

THE 53rd DIRECTING COUNCIL,

Having reviewed the *Plan of Action for Universal Access to Safe Blood* (Document CD53/6);

Observing the importance of effectively and sustainably integrating national blood programs and services into national health systems to achieve blood self-sufficiency, safety, efficiency, and availability, and universal access to blood and blood products, when and where these are needed to help save lives and improve the health condition of all people who need them, including children with severe anemia, the chronically ill, patients with hemoglobin disorders, injuries, or cancer; pregnant women, and patients who undergo major surgery;

Considering blood transfusion to be one of the eight key interventions in emergency obstetric care;

Aware of the efforts made by the Pan American Sanitary Bureau and the national blood programs of the Member States to strengthen national blood systems to improve access to blood, and its availability and safety;

Taking into account the joint evaluation of the implementation of the Plan of Action for Transfusion Safety 2006-2010, conducted in 2011 and presented to the 51st PAHO Directing Council in Document CD51/INF/5; and the achievements and challenges identified in the evaluation, which serve as a starting point for drafting the Plan of Action for Universal Access to Safe Blood 2014-2019;

Recognizing the need to adjust current national approaches to achieve sufficient blood supply, appropriate quality, and safe transfusion;

Concerned that in order to achieve self-sufficiency in blood and blood products, it will be necessary to increase the number of volunteer donors in the Region of the Americas, and considering that the collected blood is routinely processed to be transformed into blood components;

Motivated by the spirit of Pan-Americanism, the internationally agreed development goals stated in the U.N. Millennium Declaration, binding universal and regional human rights instruments, and the challenge of achieving universal access to safe blood and blood products,

RESOLVES:

1. To approve the *Plan of Action for Universal Access to Safe Blood* and its implementation in the context of the particular conditions of each country.

2. To urge the Member States, taking into account their national context and priorities to:

a) renew their commitment to supporting the establishment of well-organized, nationally coordinated, and sustainable blood programs and services that are integrated into the health system with appropriate legal and regulatory framework necessary to advance toward ensuring universal access to blood and blood products through sufficient supply, quality and safety, and the appropriate use of blood and blood products;

b) allocate the necessary resources for the proper functioning and development of the system, including:

   i. financial resources to ensure the viability and transparent management of the system to prevent the sale of blood and resulting profiteering, except where national law so allows,

   ii. ensuring the availability of trained human resources by supporting educational efforts and measures to avoid high staff rotation in blood services;

c) promote only non-remunerated, preferably repeated, voluntary blood donations; and discourage remunerated and family/replacement donations, except where protected by the national regulatory system;

d) set up quality management systems that ensure: universal screening of blood for the markers that PAHO/WHO has stipulated for the Region; the implementation of national programs for external performance evaluation; and the appropriate use of blood and blood products to promote patient safety;

e) promote intersectoral participation (public and private sector, other ministries, civil society, among others) to strengthen resources and achieve synergies that benefit the national blood system;

f) establish a regulatory framework that strengthens the health surveillance system to ensure regulation and oversight of the transfusion chain;

g) ensure mechanisms to implement a non-punitive hemovigilance system in which transfusion reactions are reported in order to identify timely interventions and take corrective action to minimize risks;

h) allocate and use, as appropriate, resources to achieve the objectives of the Plan of Action for Universal Access to Safe Blood 2014-2019;

i) establish mechanisms to monitor and evaluate implementation of the Plan of Action for Universal Access to Safe Blood 2014-2019.

3. To request the Director to:

a) cooperate with the Member States, as needed, in the implementation of this Plan 2014-2019, taking a multidisciplinary approach and considering health promotion, human rights, gender equity, and the social determinants of health;

b) promote the implementation of this Plan of Action and guarantee its cross-cutting nature through the Organization's program areas and the different regional, subregional, and national contexts, and through collaboration with and among the countries in strategy design and the sharing of competencies and resources;

c) continue advocating for active resource mobilization and promote partnerships that support the implementation of this resolution;

d) monitor and evaluate the implementation of this Plan of Action and report periodically to the Governing Bodies on the progress made and the obstacles to the implementation of the Plan, and on any necessary adaptations to new contexts and needs.

Pan American Health Organization

World Health Organization
REGIONAL OFFICE FOR THE Americas

CD53/6
Annex B

Report on the Financial and Administrative Implications of the Proposed Resolution for PASB

1. Agenda item: 4.4 - Plan of Action for Universal Access to Safe Blood

2. Linkage to Program and Budget 2014-2015:

a) Category: 4. Health systems. Strengthening health systems based on primary care; focusing health governance and financing toward progressive realization of universal health coverage; organizing people-centered, integrated service delivery; promoting access to and rational use of health technologies; strengthening health information and research systems and the integration of evidence into health policies and health care; facilitating transfer of knowledge and technologies; and developing human resources for health (HSS).

Expected outcomes: Health Systems and Services/Medicines and Health Technologies (HSS/MT).

4.3. Improved access to and rational use of safe, effective, and quality medicines, medical products, and health technologies:

OPT:

4.3.1. Countries enabled to develop/update, implement, monitor, and evaluate national policies for better access to medicines and other health technologies.

4.3.3. Countries enabled to assess their national regulatory capacity for medicines and other health technologies.

4.3.4. Countries enabled to implement processes and mechanisms for health technologies assessment, incorporation, and management, and for rational use of medicines and other health technologies.

3. Financial implications:

a) Total estimated cost for implementation over the lifecycle of the resolution (estimated to the nearest US$ 10,000, including staff and activities):

For 2014-2019 quinquennium, approximately US$ 8 million would be needed, considering what has been invested in the past and what should be invested to achieve the proposed objectives.

b) Estimated cost for the 2014-2015 biennium (estimated to the nearest US$ 10,000, including staff and activities):

US$ 3.9 million.

c) Of the estimated cost noted in *b),* what can be subsumed under existing programmed activities?

All funds allocated for the present biennium (2014-2015) are to support products and services linked to the achievement of the Plan's objectives.

4. Administrative implications:

a) Indicate the levels of the Organization at which the work will be undertaken:
Since this regional plan cannot be implemented by the Pan American Sanitary Bureau alone, it will be necessary for the more economically developed countries of the Region to invest in the area of blood safety through multilateral or bilateral cooperation. That investment—in addition to the support provided by the Bureau through its technical capacity to promote cooperation among countries, as well as the creation and strengthening of networks in the Region—will provide the financial coverage needed to meet the Plan's targets and goals. (The financial and administrative aspects are described in Annex B).

The work will be undertaken with the countries and focus on the priority countries, based on the situation analysis. The same will be done at the subregional level and at Headquarters, with ongoing support from the collaborating centers and partners in the area.

There will be integration with other units of the Health Systems and Services department and with other departments, such as Family, Gender, and Life Course; Communicable Diseases and Health Analysis; Noncommunicable Diseases and Mental Health; and Emergency Preparedness and Disaster Relief.

b) Additional staffing requirements (indicate additional required staff full-time equivalents, noting necessary skills profile):

- One regional adviser for blood services
- Administrative support
- Four subregional advisers for blood services (one in the Caribbean, one in Central America, one in the Andean zone, and one in the Southern Cone).

c) Time frames (indicate broad time frames for the implementation and evaluation):

- 2014: Approval of Plan 2014-2019: Implementation of the Plan
- 2017-2018 Mid-term evaluation
- 2020 Final evaluation and presentation of results and recommendations

CD53/6
Annex C

ANALYTICAL FORM TO LINK AGENDA ITEM WITH ORGANIZATIONAL MANDATES

1. Agenda item: 4.4. Plan of Action for Universal Access to Safe Blood

2. Responsible unit: Health Systems and Services/Medicines and Health Technologies (HSS/MT)

3. Preparing officer: Dr. María Dolores Pérez-Rosales

4. List of collaborating centers and national institutions linked to this Agenda item:

- Advancing Transfusion and Cellular Therapies Worldwide (AABB)
- Health surveillance agencies of the member countries
- Spanish Association of Hematology and Hemotherapy
- National professional associations of the member countries
- Centers for Disease Control and Prevention (CDC)
- Blood Transfusion Center of Valencia (Spain)
- Blood Transfusion Center of Seville (Spain)
- International Federation of Red Cross and Red Crescent Societies
- World Federation of Hemophilia
- Thalassemia International Federation
- International Federation of Blood Donor Organizations (FIODS)
- Global Health Initiative (national health institutes of member countries)
- Ibero-American Collaborative Group on Transfusion Medicine (GCIAMT)
- ProSangue blood center/foundation, São Paulo, Brazil. PAHO/WHO Collaborating Center for Quality Control of Serology in Blood Banks
- International Hemovigilance Network
- International Society for Blood Transfusion (ISBT)
- National reference laboratories of member countries
- National programs of member countries
- National Red Cross societies of member countries

5. Link between Agenda item and Health Agenda for the Americas 2008-2017:

***Human rights, universal access, and inclusion*:** The Plan of Action for Universal Access to Safe Blood 2014-2019 seeks to guarantee the right to health and other related basic human rights through the availability of and access to blood for transfusions in the Region of the Americas, without distinction of age, gender, ethnicity, political ideology, economic or social condition, religion, or sexual orientation, or any other kind of discrimination that invalidates or undermines the enjoyment of the right to health or other related human rights (Resolution CD50.R8: "Health and Human Rights").

Pan American solidarity: The Plan promotes cooperation among countries in the Americas with the participation of PAHO collaborating centers and professional associations.

Equity in health: The Plan seeks to eliminate differences among and within countries in terms of availability, access, timeliness, and quality of blood for transfusions with a public health approach.

Social participation: An organized social network is essential for achieving 100% voluntary blood donations and blood self-sufficiency.

***Strengthening the health authority*:** The Plan of Action 2014-2019 includes four strategic lines. The first line directly refers to strengthening planning, implementation, monitoring, and evaluation processes in national blood programs, which requires strong leadership from the ministries of health.

***Health determinants approach: Reducing the risk and burden of disease*:** Blood safety depends mainly on the quality of the donated blood. National blood requirements depend on the overall health of the population. Health promotion, health education, and interventions to protect the population will result in safer blood donors and less need for blood products. Safe blood helps reduce HIV, HBV, HCV, *T. cruzi*, and other infections.

***Increasing social protection and access to quality health services; reducing health inequities among and within countries*:** Blood availability and access in the Region vary within and among countries. The overall objective of the Plan of Action 2014-2019 is to promote universal access to safe blood and blood products without distinction of age, gender, ethnicity, political ideology, economic or social condition, religion, or sexual orientation.

6. Link between Agenda item and the PAHO Strategic Plan 2014-2019:

This Plan of Action is directly linked to Category 4 (Health Systems) and outcome 4.3 (Improved access to and rational use of safe, effective, and quality medicines, medical products, and health technologies). Also within Category 4, it contributes to the achievement of outcomes 4.1, 4.2, 4.4, and 4.5. In categories 1, 2, and 3, it contributes to program areas and outcomes 1.1, 1.4, 2.3, 3.1, 3.2, 3.3, 3.4, and 3.5 of the PAHO Strategic Plan 2014-2019.

7. Best practices in this area and examples from countries within the Region of the Americas:

- Organization of blood services: Argentina, Bolivia, Brazil, Canada, Chile, Ecuador, Nicaragua.
- Blood self-sufficiency based on voluntary nonremunerated donation: Bermuda, Canada, Cayman Islands, Colombia, Monserrat, Netherlands Antilles, Nicaragua, Suriname, USA.
- Quality management: Brazil, Canada, Colombia, Netherlands Antilles, Nicaragua, USA.
- Health surveillance and hemovigilance: Brazil, Canada, and USA.

8. Financial implications of this Agenda item:

The estimated cost to the Organization of implementing the proposal over the five-year period includes $8 million in expenditures on technical and administrative staff and cooperation activities. With regard both to budgetary implications and the implementation of the interventions, it is essential that the member countries, as well as collaborating centers and partners in this area, provide their commitment and support. Since this regional plan cannot be undertaken by the Pan American Sanitary Bureau alone, it will be necessary for the more economically developed countries of the Region to invest in the area of blood safety through multilateral or bilateral cooperation. This investment—in addition to the support provided by the Bureau through its technical capacity to promote cooperation among countries and the creation and strengthening of networks in the Region—will provide the financial coverage needed to meet the Plan's targets and goals. (The financial and administrative aspects are described in Annex B).

- - -

Pan American Health Organization

World Health Organization
REGIONAL OFFICE FOR THE Americas

9 789275 119587